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Abstract 
 
Background: Diabetes is a debilitating metabolic condition with associated vascular complications 
that are a major cause of morbidity and mortality. Endothelial dysfunction is central to 
microvascular complications such as diabetic retinopathy (DR) and impaired wound healing in 
diabetes. Hyperbaric oxygen therapy (HBOT) is the administration of hyperbaric oxygen (HBO) 
which involves breathing ≥ 95% oxygen at elevated pressures. It is used for the treatment of 
recalcitrant ulcers in diabetes. However, the exact molecular mechanism is unclear, and there are 
questions about its safety, and what contribution the single components of hyperoxia and elevated 
pressure provide. The effect of HBO on human dermal microvascular endothelial cells (HDMEC) and 
porcine retinal vasculature is presented with three mechanistic pathways of transcriptional factors 
regulating the redox (nuclear factor type-2 (Nrf2)), pro-inflammation (Nuclear Factor kappa B; 
(NFᴋB)), and oxygen signalling (hypoxia inducible factor type 1 (HIF-1)).  
Method: HDMEC and porcine retinal explants (a novel explant model) were exposed to treatments 
simulating HBOT using a bespoke HBO chamber (≥95% oxygen at 2.2 absolute pressures (2.2ATA) 
for 105 mins), or hyperoxia alone (HYP) (≥95% oxygen) or hyperbaric pressure alone (HYB) (2.2ATA) 
for 90 mins in low (*LG) or high glucose (HG) concentration. HDMEC and explants were exposed to 
20 mM and 25 mM D-glucose concentrations respectively for HG treatment. Post treatments, 
samples were incubated for 2 h (explants), 4 h (HDMEC) and up to 24 h (explants and HDMEC). 
HDMEC morphology and metabolic activities were determined using image analysis and the 
Resazurin assay respectively. Targets of the aforementioned pathways; nrf2 (HO-1), NFĸB (IL-6 
mRNA), HIF-1α (VEGF) and PECAM-1 were examined. HIF-1α, nrf2, HO-1, PECAM-1, VEGF, and NFᴋB 
levels were detected by immunocytochemical/immunohistochemistry and/or by Western blotting 
(WB). Total RNA was isolated from HDMEC and cDNA prepared and amplified for each treatment 
with IL-6 mRNA specific primers with β2m as reference. 
Results: Porcine retinal explants were established as a viable explant model. HIF-1α 
immunoreactivity was increased in response to HG relative to LG in retinal explants. In addition, 
HIF-1α reactivity was augmented post treatments; HBO, HYP and HYB, and further exaggerated in 
the presence of HG relative to control, with a corresponding increase in PECAM-1. In retinal 
explants, HIF-1α expression post HBO was increased, including increased nuclear associated HIF-1α 
reactivity which was sustained for up to 24 h across all retinal layers relative to control. Whilst HG 
was associated with profound HIF-1α reactivity in retinal explants, HIF-1α expression in HDMEC 
appeared suppressed in response to HG, which may indicate cell type differences between retinal 
cells and HDMEC. Mean HDMEC size was significantly varied between samples (p < 0.0001, n = 8), 
and HDMEC in HYP were significantly larger relative to control or HBO (p < 0.05) and hyperbaric 
pressure (p < 0.01), but HBO was not associated with HDMEC morphology or size alteration relative 
to control (p > 0.05). Nrf2 was basal in control sample which was consistent with a homeostatic 
condition but, ironically nrf2 was acutely lower in HG relative to LG for HDMEC in control condition 
(p < 0.05). Increased nrf2 stabilisation and accumulation was seen following HBO, HYP and HYB 
relative to control. In addition, nrf2 distribution post HBO and to a lesser extent in HYB were nuclear 
and plasma membrane associated, whilst predominantly perinuclear associated post hyperoxia 
relative to control.   
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Total HO-1 protein in HDMEC appeared elevated in response to treatments; HBO and HYP relative 
to control possibly via nrf2 mediated mechanism(s). In addition, HO-1 appeared more elevated in 
HG relative to LG in control and HBO conditions but HO-1 elevation post HYP seemed independent 
of glucose concentration, alluding to a predominant hyperoxia mediated effect. More so, VEGF 
accumulation possibly linked to HO-1 increase appeared imminent post HYP relative to control. In 
HDMEC, concomitant HYP and HG at 24 h were associated with downregulation of PECAM-1 relative 
to control, although this response appeared lacking in the retinal explants. HBO, HYP and HYB, but 
more so HBO were associated with significant IL-6 mRNA downregulation relative to control (p < 
0.0001). IL-6 mRNA was significantly less suppressed post HBO (p < 0.01), whilst more suppressed 
post HYP (p < 0.0001) in HG relative to LG control. This shows a significantly higher level of IL-6 
mRNA was induced post HBO, whilst decreased post HYP in response to high glucose. NFĸB (p65) 
appeared basal post HBO, whilst elevated post HYP and HYB but more so post HYP relative to 
control which is suggestive of an acute pro-inflammatory response or endothelial cell activation.  
Conclusion: HDMEC and retinal cells appear to have different responses to HG, which highlights 
pertinent cell-type differences that may be fundamental in understanding dysfunctions in 
endothelial cells of retinal or dermal origin. Also, differential responses are evident in the 
expression of HIF-1α, nrf2 stabilisation and possibly its target protein HO-1, and IL-6 post 
treatments alone and in concert with HG. Fundamentally, this demonstrates the pivotal role of high 
glucose on HBO mediated effects. Taken together, HBO effects in HDMEC and retinal explants are 
distinct and may generate a greater protective environment in relation to redox, immune-response 
and HIF-1α expression. Further studies are needed to identify the exact mechanisms of redox (nrf2), 
inflammatory (NFĸB), and HIF-1α expression in HBO particularly in in-vivo setting. 
Key words: Diabetes, Hyperglycaemia, Endothelial dysfunction, Retinal explants, Nrf2, NFᴋB, HIF-
1α, HBO. Abbreviations; Diabetic retinopathy (DR), hyperbaric oxygen (HBO), Hyperoxia (HYP), 
Hyperbaric pressure (HYB). High glucose (HG), low glucose (LG). *The term low glucose (LG) is used 
to refer to basal physiological (5.5 mM) glucose level. 
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1.0 Introduction 
Diabetes is a debilitating metabolic syndrome whose prevalence has gained significant grounds in 
recent years. Diabetes is associated with vascular complications that are a major cause of morbidity 
and mortality. Endothelial dysfunction is central to microvascular complications such as diabetic 
retinopathy (DR) and impaired wound healing in diabetes. Hyperbaric oxygen therapy (HBOT) 
involves the use of hyperbaric oxygen (HBO) which entails breathing ≥95% oxygen at elevated 
pressures and is used for the treatment of recalcitrant ulcers in diabetes. However, the exact 
molecular mechanism is unclear, and there are questions about its safety, and what contribution the 
single components of hyperoxia and elevated pressure provide. The effect of HBO on human dermal 
microvascular endothelial cells (HDMEC) and porcine retinal vasculature is presented with three 
mechanistic pathways of pro-inflammation (Nuclear Factor kappa B; (NFᴋB)), redox (nuclear factor 
type-2 (Nrf2)), and oxygen signalling (hypoxia inducible factor type 1 (HIF-1)). 
 
 
1.1 Diabetes Mellitus 
Diabetes mellitus (DM) is a metabolic syndrome of multiple aetiology characterised by chronic 
elevated glucose (hyperglycaemia) (WHO 1999, ADA 2014). Diabetes was first described 3500 years 
ago by the Ancient Egyptians. Aretaeus (120 AD) described the condition as ‘fortunately rare’, but 
‘short will be the life of the man in whom the disease is fully developed’ (Reed 1954). The loss of 
normal hyperglycemic control in diabetes is attributed to deficiencies in insulin secretion, insulin 
action or a combination of both (ADA 2014, Herman 1999). Diabetes is generally divided into type 1 
diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM) and as well as Gestational diabetes (IDF 
2018a). The current diagnostic criteria for DM are a fasting plasma glucose ≥ 7.0mmol/l (126mg/dl) 
or 2h post prandial plasma glucose of 11.1mmol/l (200 mg/dl) (WHO 1999, Herman 1999). T1DM, 
also known as ‘juvenile’ diabetes, is characterized by autoimmune destruction of the insulin-
secreting β-cells of the islets of Langerhans in the pancreas (Solari et al 2009). In T2DM, there is 
varying degree of β-cell failure relative to insulin resistance that results in the loss of insulin action or 
an effect owing to metabolic exhaustion (Fotino et al 2010, Cnop et al 2005). T2DM is marked by 
increased insulin resistance, hyperinsulinemia, and pancreatic β-cell failure and alpha cell 
deregulation, immune deregulation, with pro-inflammation (reviewed in Chatterjee et al 2017).  
 
 
  
3 
 
Exogenous insulin is the mainstay of life-sustaining therapy in T1DM and late stage T2DM, in addition 
to oral drug therapy for management of blood glucose and micro- or macrovascular complication 
predominantly in T2DM. In our times, Aretaeus’ description about diabetes is far from true as the 
incidence of diabetes has doubled every 20 years since 1945 (Barnett 1998). About 425 million 
people world-wide are currently living with diabetes mellitus with two-thirds of those in the adult 
working population affected (IDF 2017b). This figure is expected to reach 700 million by 2045 owing 
to an aging population, increasing trends of sedentary lifestyle with inadequate physical activities 
and obesity-associated diets. There is a strong genetic constituent to T1DM and T2DM susceptibility 
that can be measured by single nucleotide polymorphism (SNP) genotyping (reviewed in Oram et al 
2016). Genome wide association studies (GWAS) have identified some commonly affected genes; 
HNF-1α, HNF-4α, and GCK (Thanabalasingham et al 2012) of glycemic traits in T2DM but these 
variants only account for 10% of total trait variance, suggesting that there are more rare 
(unidentified) variants which are important (Grarup et al 2014). Although the epidemiology of T2DM 
is affected by genetic and environment factors, genetic factors exert their effect more following 
exposure to environmental factors such as a sedentary lifestyle and excessive sugar and fat 
consumption (Chatterjee et al 2017). The financial burden of diabetes mellitus is high with a total 
global expenditure of $727 billion per annum (IDF 2017). In addition, the daily management of T1DM 
and T2DM is burdensome to patients and their families made worse by long-term complications such 
as microvascular (retinopathy, neuropathy and nephropathy) and macrovascular such as coronary 
heart disease (CHD), myocardial infarction (MI) and peripheral vascular diseases (PVD) which have 
caused the most morbidity and mortality in DM (NDDG 1985, Deckert et al 1978).  
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1.2 Diabetic complications 
Hyperglycaemia sufficient to cause tissue damage can be present without clinical symptoms for 
many years before diagnosis and this is particularly relevant in T2DM (Herman 1999). Severe 
hyperglycaemia (≥ 10 mM of chronic elevated glucose) causes excessive urination (polyuria) and 
thirst (polydipsia), weight loss, and blurred vision. Acute, life threatening hyperglycaemia causes 
ketoacidosis and non-ketotic hyperosmolar syndrome with increased vulnerability to certain 
infections. Long term, hyperglycaemia results in retinopathy (with potential blindness), nephropathy, 
peripheral neuropathy (increased risk of diabetic recalcitrant ulcers, amputation, and Charcot joints), 
autonomic neuropathy (with gastrointestinal, sexual, and bladder dysfunction), and greatly increased 
risk of atheroma in large vessels (Herman 1999).  
A link between developments of long-term complications (retinopathy, neuropathy and 
nephropathy) and cardiovascular complications and high glucose (hyperglycaemia) has long been 
documented resulting from studies in animal models and clinical observations showing a causal link 
between chronic hyperglycaemia in the pathogenesis of long-term complications with diabetes 
mellitus (NDDG 1985, Deckert 1978). Yet, clinical trial data did not demonstrate any consistent 
beneficial effect of intensive blood-glucose control on DM complications, until two pivotal clinical 
studies; the diabetes control and complication trial (DCCT 1993) and the United Kingdom prospective 
diabetes study (UKPDS1998) were carried out.  
The DCCT (1993) study was a clinical study conducted from 1983 to 1993 and funded by the National 
Institute of Diabetes and Digestive and Kidney Diseases (USA and Canada). This study showed that 
intensive control of blood glucose levels slows the onset and progression of retinopathy, 
nephropathy, and neuropathy in diabetes for T1DM. The follow-up study, Epidemiology of Diabetes 
Interventions and Complications (EDIC) study (2005) also showed intensive blood glucose control has 
long-term beneficial effects on lowering the risk of cardiovascular disease in patients with T1DM. In 
addition, the Kumamoto study (1995) showed intensive blood glucose control in insulin treated 
T2DM over six years lowered relative risks of retinopathy, nephropathy, and neuropathy. Similarly, 
the Stockholm diabetes Intervention Study demonstrated a beneficial effect of intensive blood 
glucose control in patients with established microvascular complications, although there was 
crossover of conventional control group patients to intensive therapy during the trial (Reichard et al 
1999). 
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The United Kingdom Prospective Diabetes Study (UKPDS) was the largest and longest study ever 
undertaken in diabetes; median follow-up was 10 years (UKPDS1991). The study demonstrated that 
intensive therapy effectively delays the onset and slows the progression of DR, nephropathy, and 
neuropathy in patients with IDDM (UKPDS1998a). In addition, the group determined that intensive 
blood-glucose control by either sulphonylureas or insulin substantially decreases the risk of 
microvascular complications, but not macrovascular disease, in patients with T2DM (UKPDS 1998b). 
Furthermore, the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release 
Controlled Evaluation (ADVANCE 2008), and the Veterans Association Diabetes Trial (VADT) 
(Duckworth et al 2009) are other large randomised control trials like the UKPDS which have helped 
to establish the benefits of intensive glucose management on microvascular complications, such as 
retinopathy, nephropathy, and neuropathy. In effect, what these large randomised clinical trials 
(RCTs) showed was that improved glycaemic control prevents/reduces diabetic complications, 
especially microvascular complications.  
 
 
1.2.1 Macrovascular complications 
Macrovascular complications in diabetes are coronary heart disease (CHD), myocardial infarction and 
peripheral vascular diseases (PVD). The Framingham study first identified CHD as a macrovascular 
diabetes complication (Kannel and McGee 1979). Studies have shown the risk of myocardial 
infarction (MI) in people with diabetes is equivalent to the risk in nondiabetic patients with a history 
of previous MI (Haffner et al 1998). This culminated in the classification of diabetes as coronary 
artery disease by the American diabetes association (ADA) and the American Heart Association (Buse 
et al 2007). The process of atherosclerosis in arterial macro vessels is central in diabetes associated 
macrovascular dysfunction. Atherosclerosis results from chronic inflammation in the endothelium 
and insults in arterial vessels of the peripheral or coronary vascular system.  
As a result of endothelial barrier dysfunction, oxidized lipids from low density lipoproteins (LDL) 
particles infiltrate and accumulate in the endothelial wall of arteries. Inflammatory cells such as 
monocytes extravasations into the arterial wall and differentiate into macrophages which produce 
foam cells from accumulated oxidized lipids. Once formed, foam cells stimulate macrophage 
proliferation and increased recruitment of T-lymphocytes. Recruited T-lymphocytes induce smooth 
muscle proliferation in the arterial walls and collagen accumulation. Consequently, a lipid rich 
atherosclerotic plaque with a fibrous cap is formed in the arterial wall and the rupture of this lesion 
may precipitate an acute vascular infarction (Boyle 2007).  
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In T2DM, there is impaired nitric oxide generation and increased free radicals (reactive oxygen 
species) (ROS) generation in platelets with altered calcium regulation which promotes platelet 
aggregation and hypercoagulability. Elevated levels of plasminogen activator inhibitor type 1 (PAI-1) 
in diabetic patients further impairs fibrinolysis. This combined incidence of increased coagulation 
and impaired fibrinolysis increases the risk of vascular occlusion and cardiovascular events in T2DM 
(Beckman et al 2002). 
 
1.2.2 Microvascular complications 
Microvascular complications in diabetes relates to diabetes specific damage to microvessels in the 
retina of the eye, the glomerulus of the kidney, and vasa nervorum of the peripheral nerves which 
share similar pathophysiologic characteristics and hyperglycaemia is the central instigator and driver 
in all types of diabetic microvascular disease (reviewed in Brownlee et al 2016). In addition, there is 
also a genetic determinant of susceptibility to microvascular complication due to polymorphisms 
that have been observed in several protein-coding genes. Furthermore, the involvement of regulator 
non-coding microRNAs (miRNAs) on different biological and cellular pathways in diabetic 
complications is now increasingly evident. In the whole retina, diabetes has been associated with 
increased levels of NFᴋB responsive miRNAs such as miR-21, miR-132, miRNA-155, and miRNA-146, 
while a specific downregulation of miRNA-146a in retinal microvessels endothelial expression due to 
high glucose has been reported (Kato et al 2013). These aspects shed light on the complexity of 
diabetes and its complications. In the following paragraphs, pathophysiologic features of DR, 
nephropathy and neuropathy are reviewed with detailed attention to retinopathy. In section 1.4, the 
mechanisms associated with high glucose mediated toxicity and damage are reviewed. 
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1.2.2.1 Diabetic Retinopathy 
Diabetic retinopathy (DR) is initiated from injury and insults to the retinal microvasculature and it is 
one of the commonest microvascular complications with a frequency of 75%, and a common cause 
of blindness in those aged 25-74 years (reviewed in Klein et al 1989). Poor glycaemic control is a 
strong risk factor for the development and progression of DR which affects all three parts of the 
retinal vessel (reviewed in Knott and Forrester 2003). Retinal damage appears to precede clinical 
manifestations of diabetes in T2DM, and retinopathy may already be in existence as early as 7 years 
in patients with T2DM before clinical diagnosis is made (Fong et al 2004).Several mechanisms have 
been put forward for the development of diabetes associated retinopathy. Increased flux of the 
polyol pathway and activation of the enzyme Aldose reductase (AR), which catalyses the initial step 
in glucose conversion to sorbitol, is the most implicated pathway in the development of retinopathy 
(mechanism is covered in section 1.4). The polyol pathway is attendant with increased free radical 
formation due to depletion of the two major non-enzymatic anti-oxidants; ascorbate and 
glutathione.  
In animal models of retinopathy, sugar alcohols such as sorbitol accumulation were linked to 
microaneurysm formation, thickening of the basement membranes, and loss of pericytes (Fong et al 
2004, Gabbay 1975 and 2004). In view of that, anti-oxidant treatments were found to be associated 
with decrease of polyol-pathway induced deleterious effects on the retina (Knott and Forrester 2003, 
Obrosova et al 2005). In-vitro evidence also corroborated this positive role of anti-oxidant treatment 
on amelioration of polyol-induced effects on the retina with the observation of decreased retinal 
capillary cell apoptosis in high glucose in the presence of vitamin D3 (Lu et al 2018). Sorbitol 
accumulation in cells through the polyol pathway precipitates osmotic stress, and this may also 
contribute to onset and development of retinopathy. AR inhibitors were expected to have excellent 
outcomes in retinopathy, but treatment studies with AR have so far not been successful (Fong et al 
2004, Gabbay et al 1975 and 2004, reviewed in Brownlee 2016), although interest remains. DR is 
associated with pericytes coverage loss in retinal capillaries leading to acellular capillaries due to 
hyperglycaemia induced apoptotic pericytes and endothelial cell death (Cogan et al 1961, Kuwabara 
et al 1960and 1963, Shepro and Morel 1993, Robison et al 1983and 1986, Frank et al 1983, Das et al 
1990). Consequently, microvasculature autoregulation, which is essential for regulation of nutrient 
and oxygen, and modulation of vascular tone in the microvasculature, is lost. 
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Glycoproteins are injurious to endothelial cells and elevated high glucose concentrations in the 
retinal microvasculature can promote non-enzymatic formation of advanced glycosylated end 
products (AGEs). AGEs associated microaneurysm and pericyte loss resulting in retinal blood retinal 
barrier (BRB) have been demonstrated in animal models and drug targets of AGEs are effective to 
some degree. Aminoguanidine, the first known AGE inhibitor was effective but it is now overtaken by 
second generation derivatives such as algebrium (ALT-711), an aminoguanidine and thiazolum 
derived compound but clinical developments of algebrium was discontinued due to safety and/or a 
lack of efficacy concerns (Freedman et al 1999, reviewed in Furlani et al 2015). A lead compound, bis-
2 Aminoguanidine has been developed and it is expected to exhibit superior AGE inhibition, although 
it is yet to make it into clinical trials (Furlani et al 2015).  
In diabetic retina, sustained elevated high glucose instigates protein kinase C (PKC) activation which 
drives vascular endothelial growth factor (VEGF) expression and raised levels of the vasoconstrictor, 
endothelin-1 (ET-1), both of which culminates in retinal vessel vasoconstriction and ischaemia (Park 
et al 2000, Matsuo et al 2009, reviewed in Zhongwei and Khalil  2018). In addition, due to hypoxia 
stemming from retinal ischaemia in the diabetic retina, VEGF is over-expressed leading to 
uncontrolled angiogenesis, which is common cause of blindness in DR (Semenza 2008, Nussenbaum 
and Herman 2010). In animal models of DR, suppressed VEGF production is associated with reduced 
progressive retinopathy (Keenan et al 1995, Fong et al 2004). VEGF is a classical mediator of BRB 
breakdown in DR because it increases retinal neovascularisation and increased retinal vessel 
permeability (Keck et al 1989). In addition to VEGF, increase in levels of several growth factors 
including transforming growth factor β (TGFβ), and angiostatic factors such as Tie 2 play important 
roles in the development of DR (Hammes et al 2011). 
The successful use of anti-VEGF agents for age-related macular degeneration helped to showcase the 
important role of anti-VEGF in the treatment of ocular treatments (Lim et al 2012). Anti-VEGF 
indications have since been expanded to encompass diabetic macular oedema (DME) and 
proliferative DR (PDR). Among the four anti-VEGF agents (ranibizumab, bevacizumab, pegaptanib, 
and aflibercept), ranibizumab has been most thoroughly tested in clinical trials (Cheung et al 2014). A 
novel in-vitro candidate (RC28-E), with VEGF and fibroblast growth factor 2 (FGF2) blockade activity 
has recently been reported to decrease retinal cell apoptosis, nonspecific reactive change of glial 
cells  (gliosis), leakage and pro-inflammatory microenvironment in early DR (Yang et al 2018), and it 
is still undergoing development.  
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Hyperglycaemia induced oxidative stress plays a key role in cellular injury in DR because high glucose 
stimulates free radical production and ROS formation. The concept of hyperglycaemia induced 
oxidative damage in diabetes is supported by several in-vivo and in-vitro evidences. Vitamin E and C 
administration were associated with amelioration of oxidative stress in diabetes (reviewed in 
Kastelan et al 2013). In addition, in-vivo administration of vitamin E is associated with decline of 
macro-vascular dysfunctions in diabetes, but not on the development and progression of 
microvascular complications including retinopathy (Kunisaki et al 1995, Fong et al 2004).An in-vitro 
example is the inhibition of oxidative stress, nitrotyrosine formation, NFᴋB activation, and apoptosis 
in retinal capillary cells with antioxidants (N-acetyl cysteine and α-lipoic acid) (Kowluru 2005).  
Inflammatory processes have a considerable role in the pathogenesis of DR with multiple studies 
showing associations between increased levels of systemic and local (vitreous and aqueous fluid) 
inflammatory factors and the progression of DR. Inflammation is key in retinal vessel permeability 
and neovascularisation (PDR), both of which leads to vision loss in diabetes (reviewed in Kastelan et 
al 2013). Raised levels of tumour necrosis factor –alpha (TNF-α) in vitreous, serum, and ocular 
fibrovascular membranes of patients with DR in comparison to non-DR subjects have been found 
(Limb et al 1996, Joussen et al 2002). Consequently, TNF-α is now regarded as a novel biomarker to 
assess the degree of DR (Costagliola et al 2013). Furthermore, increased interleukin-6 (IL-6) level in 
the vitreous has been shown to significantly correlate with DR severity and progression (Funatsu et al 
2003, Mocan et al 2006, and Feng et al 2018). Therefore, the use of anti-inflammatory agents such as 
steroidal corticosteroids; triamcinolone, fluocinolone and dexamethasone and non-steroidal anti-
inflammatory (NSAIDs) drugs in experimental research and in the clinic in DR has strong molecular 
basis (reviewed in Kastelan et al 2013).  
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1.2.2.2 Diabetic Nephropathy 
Diabetic nephropathy is the main cause of renal dysfunction in the United States and is predominant 
in both T1DM and T2DM. It is defined by proteinuria > 500 mg in 24 h in the setting of diabetes, 
preceded by lower degrees of proteinuria, or microalbuminuria a state characterized by albumin 
excretion of 30-299 mg/24 h (Fowler 2008).Microalbuminuria is correlated with increased glomerular 
extracellular matrix in both T1DM and T2DM and it is present in 7% of T2DMpatients at diagnosis 
(Osterby 1992, Osterby et al 1993 and Gross et al 2005).High glucose (hyperglycaemia) is dominant 
in the pathogenesis of diabetic nephropathy since the development of diabetic nephropathy is faster 
in patients with poor metabolic control (Ayo et al 1990, Schleicher and Nerlich 1996), and significant 
structural changes particularly the thickening of glomerular basement membrane and mesangial 
expansion occurs only after several years of diabetes. Diabetic nephropathy affects both the 
glomerulus and the tubular interstitium of the kidney. Non-enzymatic pathways are set off by high 
glucose which results in glycation end-products (Brownlee et al 1988), oxidative stress activation via 
AGE/RAGE pathway (Bierhaus et al 1998). Moreover, hyperglycaemia-induced formation of ROS 
leading to increased apoptosis has been shown with cultured renal endothelial cells (Du et al 1998). 
The biochemical mechanisms of high glucose mediated toxicity are discussed further in section 1.4. 
 
 
1.2.2.3 Diabetic Neuropathy 
Diabetic neuropathy (DN) has a high prevalence (45–50%) in diabetes (Shaw and Zimmet 1999). 
Several studies have shown the presence of neurological involvement in impaired glucose tolerance 
(IGT). Neurological symptom such as small fibre neuropathy characterised by intra-dermal nerve 
fibre loss is found in IGT (Sumner et al 2003, Polydefkis et al 2003). In DN, microangiopathies such as 
increased capillary density, decreased capillary luminal area and increased basement membrane are 
precipitated by IGT and exist in parallel with nerve fibre loss and endothelial cell swelling 
(Thrainsdottir et al 2003).This scenario is compounded in diabetes because vascular supply of 
peripheral nerves is sparse and lacks autoregulation which makes peripheral nerves vulnerable to 
IGT associated vascular hypoxia and ischaemia(Smith et al 1977, Yagihashi et al 2011). In addition, 
sustained elevated blood glucose triggers pathways; polyol pathway, AGE, oxidative stress, PKC 
activity and the activation of polyADP-ribose polymerase (PARP) enzyme, all which contribute to the 
initiation and progression of neuropathy (Yagihashi et al 2011), as outlined in the glucotoxicity 
pathways in section 1.4. 
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Hyperglycaemia driven polyol pathway activation causes NADPH depletion resulting in impaired 
nitric oxide (NO) synthesis or reduced glutathione regeneration. Impaired NO synthesis and 
decreased glutathione can precipitate vascular insufficiency and over-production of free radicals 
respectively. Consequently, the treatment of streptozotocin-induced diabetic rats with butylated 
hydroxytoluene, a lipophilic radical scavenger and trientine, a heavy metal chelator was found to 
significantly reduce nerve denervation highlighting the role of free radical in neural/neurovascular 
deficits (Love et al 1996). Furthermore, the distribution of AR enzyme in Schwann cells supports the 
role of hyperglycaemia induced polyol pathway activation in nerve damage in DN. Ischaemia/poor 
reperfusion in distal peripheral nerves of diabetic patients’ cause polyol activation which exacerbates 
DN (reviewed in Yagihashi et al 2011). Moreover, the mitogen-activated protein kinase (MAPK) 
pathway causes functional and structural deregulation of peripheral nervous system in DN (Sima and 
Sugimoto 1999, Tomlinson 1999). Thus, the flavonoid baicalcein was reported to alleviate DN in 
C57B16/J mice models through the inhibition of the polyol-sorbitol accumulation which culminated 
with the reduction of the p38 MAPK and oxidative nitrosative stress pathways (Stavniichuk et al 
2011). 
 
 
1.2.2.4 Impaired wound healing of diabetes 
Diabetes is the commonest cause of non-traumatic lower limb amputation and 15–20% of all foot 
ulcers will ultimately require amputation (Mulder et al 1994). Diabetic foot ulcers (DFUs) are 
common and serious complications of diabetes due to its high prevalence and impairment of wound 
healing. The risk factors for DFUs are peripheral neuropathy, peripheral arterial disease and trauma 
but, impaired wound healing is the main complication that results in the development of chronic 
wounds, which often lead to amputations. Wound healing is a dynamic complex process that begins 
when tissue integrity is disrupted and can be divided into four partly overlapping phases: 
coagulation, inflammation, migration-proliferation (including matrix deposition) and remodelling 
(reviewed in Falanga 2005, Guo and Dipietro 2010). Acute wounds go through the linear progression 
of overlapping biological and molecular events as outlined in table 1.1 below. Although, in reality, 
even in normal wound healing process, complications such as infection, thrombosis and ischaemia 
can occur and this can confound the linear progression outlined.  
 
 
 
  
12 
 
Table 1. 1 Phases of wound healing Major cells types involved in each phase with selected 
specific events of wound healing (Adapted from Falanga 2005). 
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Inflammation with subsequent coagulation sets in early after an acute wound for haemostasis and 
wound protection (a and b), giving rise to fibrin plugs around the wound site which aids to ward off 
bacteria. Platelets within the fibrin plug release pro-inflammatory cytokines and growth factors such 
as platelet derived growth factor (PDGF) and transforming growth factor (TGF) β1. Endothelial cells 
express selectins, and leucocytes are slowed down in the bloodstream and are able to extravasate 
through endothelial gaps via binding to integrins into the extracellular space (diapedesis) (Martin 
1997). In non-diabetic wounds, these recruited inflammatory cells (especially neutrophils and 
macrophages) aid wound debridement and recruited neutrophils secrete tissue growth factors that 
drives wound repair process (Singer and Clark 1999).  
The local vessels in the vicinity of acute wounds are acutely hypoxic as a result of damage to blood 
vessel. This temporary hypoxia drives the third stage of wound healing; migration and proliferation 
(C). Hypoxia increases keratinocyte migration, early angiogenesis, and fibroblasts proliferation, in 
addition to increased production of PDGF and TGFβ1 (Falanga 2004). Matrix metalloproteinase 
(MMPs) and other enzymes (tissue plasminogen activator, tPA and urokinase plasminogen activator, 
uPA) break down the stable structures around cells so they are free to migrate. For instance, the 
hemidesmosomes, a highly organized structure which provide anchorage of the basal keratinocytes 
to the underlying basement membrane are broken down by MMPs for the purpose of keratinocyte 
cell migration. Recruited monocytes which are now differentiated as macrophages, fibroblasts and 
endothelial cells forms the early granulation tissue that initiates wound contraction process, 
overlapping with the fourth stage (Remodelling) (D). Within weeks to months of an acute wound, 
inflammatory responses are resolved. This aspect distinguishes an acute from a chronic wound as in 
diabetes ulcers where there is low-grade chronic inflammation which drives aberrant gene 
expression (Tang et al 2013).  
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Angiogenesis, contraction and extra-cellular matrix (ECM) deposition are critical for this last phase of 
acute wound healing. ECM proteins such as collagen, fibronectin, and vitronectin are laid down to 
provide substrate for cell attachment via integrins to enable cell-cell communication and migration 
(Falanga 2002, Santoro and Gaudino 2005). In addition, wound contraction which is vital for wound 
closure is made possible by the newly formed ECM, granulation tissue and newly formed 
myofibroblasts. Integrins are essential in wound healing because they support cell-cell, cell-ECM 
communication and migration. Diabetic wounds do not follow the wound progression and resolution 
outline in table 1.1 (Loots et al 1998 and 2002), due to Intrinsic factors and extrinsic factors which 
complicates wound healing in diabetes (reviewed in Falanga 2005).In diabetic wounds, the basement 
membrane is thickened so migrating leucocytes cannot extravasate into extracellular spaces (i.e. 
diapedesis is slowed down) which contributes to infection (Martin 1997). Also due to endothelial 
dysfunction, endothelial nitric oxide synthetase (eNOS) expression is reduced which contributes to 
blood flow maldistribution although true luminal occlusion of small vessels does not occur (LoGerfo 
and Coffman 1984). As a consequence, microvessels autoregulatory capacity required for meeting 
local needs of cells in response to cellular demands are impaired (Dinh and Veves 2005, Zong et al 
2017). 
In diabetic wounds, wound contraction and closure is impaired and the impairment is worsened by 
the presence of infection in diabetic wounds. More so, excessive collagen and fibronectin (ECMs) 
deposition has been identified in diabetic wounds, which causes ECM stiffening, and hampering cell 
movement (Falanga 2004).As stated previously, acute local hypoxia in wound vicinity is necessary for 
early angiogenic response, however, there is chronic hypoxia in diabetic wounds due to vascular 
inefficiencies that are often characteristic of diabetes (Catrina et al 2004). Oxygen is critical in tissue 
healing and oxygen tension is a major controlling factor in bacterial killing, resistance to infection, 
collagen synthesis, angiogenesis, and epithelisation. Oxygen tension in diabetic wounds are low and 
ranges from 5 to 20 mM Hg (1.1% - 4.2%), which limits the leukocyte's function, which requires an 
optimal oxygen tension of 45 to 80 mm Hg (9.5% - 17%) relative to sea level conditions for bacterial 
lethality (Hodges et al 2003).  
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Furthermore, fibroblasts mediated matrix deposition e.g. in collagen synthesis required for 
angiogenesis and tissue remodelling are impaired in chronic hypoxia (Niinikoski 1972, Hunt and Pai 
1972, Hunt et al 1974, Siddiqui et al 1996). In wound healing the signalling activity of the hypoxia 
inducible factor -1 alpha (HIF-1α) is necessary for expression of multiple angiogenic growth factors, 
and recruitment of endothelial progenitor cells (Kelly et al 2003, Catrina et al 2004). But the stability 
of HIF-1α, the regulated subunit of HIF-1 is impaired by hyperglycaemia with very low levels of HIF-
1α expression in ulcerated diabetic foot biopsies (Catrina et al 2004, Fadini et al 2006, and Gao et al 
2006). Accordingly, HIF-1α stabilization and consequently HIF-1 activation and signalling have been 
shown to reverse pathological processes in hyperglycaemia associated diabetic wound impairment 
(Botusan et al 2008). 
Low-grade chronic inflammation in diabetes and diabetic wound also drives aberrant gene 
expression in diabetic wounds (Tang et al 2013). The activation of the Poly (ADP-ribose) polymerase 
(PARP), a nuclear enzyme which is activated by hyperglycaemia induced ROS which causes oxidative 
DNA damage leads to cell necrosis and changes in microcirculatory reactivity (reviewed in Falanga 
2005). This suggested a role for anti-oxidant therapy in diabetic wound healing. A recent study 
demonstrated the beneficial effect of the nuclear factor-E2- related factor (nrf2)-mediated 
antioxidant response in treating diabetic skin ulcer (Long et al 2016), which supported the implied 
role of ROS in cell necrosis and changes in microcirculatory reactivity.  
Taken together, hyperglycaemia, hypoxia, oxidative stress and impairment of neutrophil and 
macrophage function can result in endothelial dysfunction and are some of the key drivers in 
diabetic wound impairment (Catrina et al 2004, Patel et al 2005, reviewed in Falanga 2005, Long et al 
2016).  
Infection is an important cause of morbidity and hospitalisation, amputation, and impaired healing in 
DFUs, although it is unclear whether it plays a role in DFUs development. The combination of stress 
and pressure sites is said to favour overgrowth of bacteria (Ctercteko et al 1981). In addition, 
decreased macrophage and neutrophil function in diabetic wounds encourages infection because 
these cells produce ROS using oxygen derived radicals to kill bacteria (Knighton et al 1984, Naghibi et 
al 1987, Alien et al 1997 and Zykova et al 2000).  
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1.3 Endothelial Perturbations 
The thin single layered specialized squamous epithelial cells lining the luminal surfaces of blood and 
lymphatic vessels are referred to as the endothelium or endothelial cells. Endothelial cells also line 
the heart cavity. They form an interface separating circulating lymph or blood in the vessel from the 
rest of the vessel wall. The endothelium is involved in the maintenance of vessel wall permeability 
and regulation of blood flow (Fishman et al 1982). Glucotoxicity induced endothelial dysfunction is 
present in the earliest stages of diabetic metabolic syndrome and insulin resistance, and may be 
established prior to any clinical diagnosis of T2DM by several years (Ruderman et al 1992, Brownlee 
et al 1989, reviewed in Sena et al 2013). Acute, transient and sustained hyperglycaemia impairs 
endothelial function of both micro and macro vascular beds (Ceriello 2010). Endothelial dysfunction 
in diabetes worsens diabetes-associated vasoconstriction, inflammation, and thrombosis (Beckman 
et al 2002, Nesto 2004).  
Insulin dependent stimulation of NO in endothelial cells via activation of the endothelial NO synthase 
(eNOS) PI-3K dependent pathway is impaired by insulin resistance, and consequently NO is 
diminished while insulin resistance drives MAPK signalling (Kim et al 2006). This culminate in 
increased production of endothelin -1 (ET-1), and the plasminogen activator inhibitor (PAI-1), which 
increases endothelial platelet adhesion expression (Muniyappa and Sowers et al 2013). Ultimately, 
hyperglycaemia driven insulin resistance culminates in chronic low-grade inflammation with 
persistent elevated serum levels of IL-6, PAI-1, ET-1, and sensitive C-reactive protein (CRP) (Kim et al 
2006). Enhanced cytokine mediated endothelial dysfunction in diabetes is well known (Aoki et al 
1989, Kim et al 2006). Heightened NFᴋB signalling occurs early in vascular dysfunction via cytokine 
mediated signal transduction, including interleukin -6 (IL-6) (Castell et al 1988, Pober 1999). 
Moreover, endothelial contraction and impaired microvascular function due to the presence of 
vasoconstrictors such as ET-1 and Ang II are linked to increased levels of IL-6 and TNFα in the 
endothelium (Iversen et al 1999, Weis et al 1999, Peng et al 2018).  
Blood flow is regulated, in part, through secretion and uptake of vasoactive substances by the 
endothelium that act in a paracrine manner to constrict and dilate specific vascular beds in response 
to vasoconstriction stimuli such as Ang II, endotoxin, and ET-I or vasodilators such as NO and 
prostacyclin (reviewed in Cines et al 1998, Cameron and Cotter 1999). In normal circumstance in-
vivo, Ang II regulates capillary perfusion in retinal capillaries by inducing abluminal retinal pericytes 
contraction and thereby constricts microvessels lumen (Zhang et al 2011, Kawamura et al 2004). This 
response is also seen in-vitro where Ang II induced stimulation of pericytes in cultured retinal 
microvessels resulted in vessel  depolarisation and constriction, an effect that was vessel-type/site 
dependent (Kawamura et al 2004).  
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In diabetes, vascular tone modulation by Ang II is lost because of glucotoxicity induced cell death of 
retinal endothelial cells and pericytes (Nakaizumi et al 2012). In view of that, high glucose was shown 
to inhibit contractile response in cultured bovine retinal capillary pericytes (Gillies and Su 1993). 
Polyunsaturated fatty acids are a major target for ROS. Hence in diabetes, there is reduced 
availability of essential fatty acids and this is worsened in the presence of hyperglycaemia associated 
increased ROS production. ROS causes vascular endothelium dysfunction via impairment of NO-
mediated vasodilatation which is made worse in the presence of reduced synthesis of prostanoids 
such as the vasodilator, prostacyclin while Ang II and ET-1 production are enhanced (Cameron and 
Cotter 1999).  
In the diabetic endothelium, uncontrolled angiogenesis is potentiated by VEGF, FGF, PDGF and TGF-β 
(Mackay 2001, Jackson et al 1997, Naldini et al 2003, Carmeliet 2000). High glucose (15mM) induced 
upregulation of TGF-β1 in human retinal endothelial cells (HREC) has been documented highlighting 
that glucose may regulate TGF-β1 and play a role in the growth and proliferation of HREC in a similar 
manner as DR (Pascal et al 1999). In endothelial cells, chronic high glucose results in pseudohypoxia 
which is characterised by increased cellular cytosolic ratio of free NAD+ to NADH and is distinct from 
true hypoxia because it is initiated under non-hypoxic condition in the absence of any vascular 
compromise (Williamson et al 1993, reviewed in Catrina et al 2004). Subsequently, hyperglycaemia 
driven pseudohypoxia in diabetes may lead to enhanced TGF-β and VEGF expression and collagen 
synthesis (Williamson et al 1993, Marfella et al 2002). Thus, pseudohypoxia is a likely driver of 
endothelial dysfunction (Williamson et al 1993).  
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Theoretically a hyperglycaemic microenvironment should be stimulatory for VEGF production 
because of pseudohypoxia but this effect appears to be selective (Kim et al 2002). For instance, 
vascular endothelial cells are renewed by angiogenesis and this is dysfunctional in diabetes with 
reduced revascularisation and impaired wound healing (Martin et al 2003). However, in the retina 
there is over-expression of VEGF and uncontrolled angiogenesis in the later stages of DR (Aiello 
2005). Thus, pseudohypoxia driven VEGF expression is a cell-type dependent response.  
Hyperglycaemia is also associated with true cellular hypoxia in the endothelium via increased 
production of mitochondrial ROS (Brownlee 2005, Nishikawa et al 2000, Cameron and Cotter 1999), 
and subsequent to aquaporin-1 suppression (Sada et al 2016). ROS is produced by all layers of the 
endothelium. The mitochondrial electron transport chain (ETC) (Chance et al 1979, Jezek and Hlavata 
2005, Turrens 2003), NADPH oxidase (Griendling et al 1997, Ray and Shah 2005, Soccio et al (2005), 
xanthine oxidase (Cai and Harrison 2000, Suzuki et al 1995) are all sources of ROS in the 
endothelium, in addition to the ROS generated by uncoupled eNOS (Cai and Harrison 2000). NADPH 
oxidases produce ROS in response to cytokines, and mechanical stimuli (shear stress and stretch), 
and in response to Ang II and ET-1 (De Keulenaer et al 1998, Schramm et al 2012). ROS production is 
further augmented in the diabetic endothelium due to insulin resistance (INRS), which impairs 
protein tyrosine phosphatase non-receptor type 1 (PTPN1/PTP1B) (Tiganis 2011) and nuclear factor-
erythroid derived 2-like (NFE2L2/NRF2) redox function (KEAP 1) (Kobayashi and Yamamoto 2006). 
Consequently, oxidative stress impairment of endothelium-dependent vasodilatation is the earliest 
consequence of hyperglycaemia (Cai and Harrison 2000). Several mitochondrial antioxidant systems 
are in place to protect against ROS-induced damage in the endothelium. Nonetheless, anti-oxidant 
systems can be overwhelmed leading to ROS deleterious effect, as is the case in the diabetic 
endothelium (reviewed in Sena et al 2013).  
The heme oxygenase is an example of endothelial anti-oxidant defence protein with an indirect 
antioxidant function through its action of free heme breakdown to carbon monoxide, biliverdin and 
bilirubin metabolites (Perrella and Yet 2003). Also, its HO-1 isoform is involved in an adaptive 
cytoprotective role in endothelial cells in response to oxidative stress (Hoekstra et al 2004).  
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In the early stages of vascular development, junction formation initially involves rather weak 
adhesion complexes required for cell-cell recognition. Endothelial cell-cell adhesion molecules are 
expressed by the endothelium and are necessary for vessel sprouting and extension. A classic 
example of cell-cell mediator molecule in endothelial cells is the platelet endothelial cell adhesion 
molecule -1 (PECAM-1), also referred to as the cluster of differentiation 31 (CD31) (Albelda et al 
1991). ECs express two isoforms of PECAM that mediate cell adhesion that differ in their 
requirement for divalent cations and sulphated proteoglycans. The VE-cadherin isoform (cadherin-5) 
of PECAM, is found almost exclusively on ECs, and promotes endothelial cell adhesion via a calcium-
dependent homotypic mechanism (Dejana 1996). Hence, in the presence of calcium, VE cadherin 
from one endothelial cell binds to the VE-cadherin expressed on an adjacent cell. As vessel matures, 
stronger connections such as tight junctions and gap junctions are formed depending on the vessel 
type (reviewed in Cines et al 1998). In addition to cell adhesion functions, PECAM-1 undergoes 
phosphorylation and activation on tyrosine residues following mechanical or biochemical stimulation 
(reviewed in Ilan et al 2000, Fleming et al 2005). Furthermore, PECAM-1 presence in endothelial cells 
is associated with decreased/absence of endothelial-mesenchymal transition (EMT) and MMP-2 
expression (Enciso et al 2003). Moreover, PECAM-1 is involved in maintenance of endothelial cell 
junctional integrity (Privratsky and Newman 2014).  
High glucose disturbs endothelial integrity via disruption of tight junction proteins such as Occludin 
and Zona Occludin protein -1 (ZO-1) (Yan et al 2012). In addition, high glucose disrupts endothelial 
VE-cadherin junctions causing increased endothelial junction paracellular permeability, and 
consequently blood-retinal barrier (BRB) breakdown in DR (Gillies et al 1997, Peng et al 2016). Direct 
in vitro evidence shows high glucose induced toxicity and BRB breakdown in DR. Incidentally; these 
high glucose mediated effects were ameliorated in diabetic mice with vitamin D3 administration, 
suggesting a role of glucose induced oxidative damage on BRB breakdown (Lu et al 2018).  
 
 
 
 
 
 
 
 
 
  
20 
 
In addition to junctional compromise, endothelial morphology (size/shape) is affected by 
hyperglycaemia. Diabetes associated hyperglycaemia and ROS are associated with endothelial cell 
phenotype (shape/size) transformation in-vivo and in-vitro (Bowden and Adamson, 1974, Crapo et al 
1980, Attaye et al 2017, Hempel et al 1997, and Peng et al 2016). In addition, diabetes associated 
dysregulation of vascular flow and shear stress, altered pro-inflammatory cytokine activity, and 
endothelial derived factors such as endothelin-1 (ET-1) are associated with alterations in endothelial 
cell size and shape (Barbee et al 1994, Malek and Izumo 1996, Chung et al 2000). Moreover, high 
glucose is linked with endothelial switch to mesenchymal phenotype (spindle shaped) in the 
endothelial mesenchymal transition (EndMT). The physiological consequence of EndMT and 
alterations in endothelial cell morphology is increased endothelial paracellular permeability via 
disruption of VE-cadherin, and consequently blood retinal-barrier breakdown (Gillies et al 1997, Peng 
et al 2016). Therefore, hyperglycaemia associated glucotoxicity and interaction with various other 
factors fosters the development and progression of endothelial dysfunction. In the following 
paragraphs the four biochemical pathways implicated in the various diabetes induced 
hyperglycaemia driven deregulations/complications are outlined. 
 
 
1.4 Mechanisms of diabetic complications 
Diabetes mellitus initiates retinopathy, neuropathy and nephropathy (DCCT 1993, UKPDS 1998). 
Hyperglycaemic injury is meted on endothelial cells in vascular walls including microvascular walls of 
the retina (reviewed in Rask-Masden and King 2013), renal glomerular endothelium (reviewed in 
Arora and Singh 2013), and in neurons and Schwann cells of peripheral nerves (Cameron and Cotter 
1999, reviewed in Yagihashi et al 2011). All diabetic cells are exposed to high plasma glucose levels 
but high glucose damage to the endothelial, mesangial, neurons and Schwann cells is selective 
(Brownlee et al 2016). Non-insulin dependent glucose transporter-1 (GLUT-1) mediated facilitated 
diffusion is the mechanism by which glucose enters endothelial and smooth muscle cells (Takata et al 
1997). However, glucose transport into endothelial cells is not auto-regulated as in smooth muscle 
cells, and unlike smooth muscle cells, endothelial cells cannot downregulate glucose transport when 
exposed to extracellular high glucose. Instead, GLUT1 in retinal endothelial cell operates at near 
saturation levels at normal physiological blood glucose concentration. Consequently, it is not 
positively regulated by glucose (Brownlee 2001 and Brownlee et al 2016).  
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Therefore, diabetes induced hyperglycaemia drives increase in intracellular glucose in cells which 
produce harmful effects in cells via the following four biochemical pathways. 
 
a) Increased flux of glucose via the polyol pathway 
b) Increased intracellular production of AGEs 
c) Protein kinase C (PKC) activation 
d) The hexosamine pathway 
 
 
The polyol pathway is regulated by the enzyme aldose reductase (AR) which converts glucose to 
sorbitol. Under normal condition AR converts the toxic aldehydes into non-toxic alcohol. But in 
hyperglycaemia, there is persistent elevated intracellular glucose, and glucose is diverted into the 
polyol pathway. Increased intracellular glucose is reduced by AR to sorbitol using nicotinamide 
adenine dinucleotide phosphate (NADPH) as a co-factor. Sorbitol is further converted to fructose by 
the enzyme sorbitol dehydrogenase (SDH) which utilises nicotinamide adenine dinucleotide (NADH) 
as a reducing intermediate. Therefore, the polyol pathway when activated disturbs cellular redox 
balance because NADPH and NADH which are required for glutathione regeneration, a key 
antioxidant needed for counteracting ROS in the cell are made unavailable (reviewed in Sena et al 
2013). Thus the normal endogenous protection offered by glutathione is limited by the competing 
requirement of NADPH for AR activity in diabetes induced polyol pathway activation.  
This underlines the role of anti-oxidant mechanism in ameliorating hyperglycaemia derangement in 
polyol pathway associated cellular redox imbalance. Lead inhibitors of AR pathway; Sorlini, Kinostat, 
ARI-809 and Ranirestat have been developed and are proposed for use in the prevention of 
microvascular complications (Zhu 2013). Recent animal studies conducted in dogs showed that AR 
activity inhibition had more profound effect on prevention of DN, but the inhibition of this enzyme 
was not as effective in preventing retinopathy or capillary basement thickening in the retina 
(reviewed in Brownlee et al 2016).  
Hyperglycaemia causes damage via increased production of advanced glycation end-product (AGEs). 
AGEs are a diverse group of metabolites resulting from the intracellular auto-oxidation of glucose to 
three reactive dicarbonyl intermediates; glyoxal, methylglyoxal and 3Deoxyglucosone (Taguchi and 
Brownlee 2003), which subsequently react with amino groups of both intra/extracellular proteins 
and other macromolecules such as nucleic acids to form AGEs (Degenhardt et al 1998, Wells-Knecht 
et al 1995, Thornalley 1990).  
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AGEs modifies intracellular and extracellular protein, and growth factors including basic fibroblast 
growth factor (bFGF) in bovine endothelial cells (Giardino et al 1994). In addition, extracellular (ECM) 
matrix proteins such as collagen I, IV and laminin are modified by AGEs, resulting in alteration of ECM 
structures which are critical for endothelial cell adhesion and migration (Falanga 2004). More so, the 
methylglyoxal detoxifying enzyme glyoxalase I, an enzyme necessary for macromolecule endocytosis 
is also altered by AGEs (Shinohara et al 1998). Furthermore, AGEs modifies cell associated receptors 
culminating in the upregulation of receptors for AGEs (RAGE) leading to increased gene expression of 
cytokines, growth factors, pro-inflammatory and pro-coagulatory molecules. Moreover, RAGE 
activation results in increased production of ROS by stimulating specific signalling cascades such as 
NFĸB (Daffu et al 2013). Due to the complex nature of the receptor and multiple intersecting 
pathways, the AGE/RAGE signalling mechanism is still not well understood (reviewed in Kay et al 
2016).  
The protein kinase C (PKC) family members (α, β, δ, ε, ζ) are activated by hyperglycaemia and PKC 
signalling activity is upregulated in diabetic vascular tissues including the retina (Suzuma et al 2002, 
Geraldes et al 2009). Hyperglycaemia stimulates PKC signalling via de novo synthesis of diacylglycerol 
(DAG) from glyceraldehyde 3-phosphate and phosphatidic acid or from non-esterified fatty acids. 
DAG is also accumulated via the glycolytic pathway due to the inhibition of GAPDH by PARP in high 
glucose concentrations (Du et al 2003). Hyperglycaemia indirectly stimulates PKC-β via the binding of 
AGE receptors (e.g. RAGE) and by increased polyol pathway flux, apparently by increasing ROS 
(Portilla et al 2000, Keough et al 1997). PKCβ activation leads to inhibition of NO (Ishii et al 1996), 
increased ET-1 (Yokota et al 2003), and vascular permeability which were associated with altered 
retinal blood flow and increased vascular permeability (Behzadian et al 2000), and angiogenesis via 
upregulation of VEGF expression (Rask-Masden and King 2013).  
Further hyperglycaemia induced PKC activation drives pro-inflammatory and redox imbalance 
response via upregulation of NFᴋB and ROS overproduction (reviewed in Evcimen and King 2007). 
More so, PKC activation drives increased matrix protein e.g. fibronectin, collagen IV, and TGF-β 
accumulation in retinal vessels leading to basement membrane thickening and capillary occlusion 
(Studer et al 1993, Craven et al 1997, Pieper and Riaz-ul-Haq 1997, Kuboki et al 2000, Ganz and Seftel 
2000). Activation of PKC signalling causes vascular occlusion via upregulation of the fibrinolytic 
inhibitor PAI-1 (Ahn et al 2001). In that respect, human studies with Ruboxistaurin, a PKC inhibitor 
demonstrated beneficial clinical effect by limiting the progression of macular oedema and 
albuminuria levels in patients with T2D (Aiello et al 2005). However, Ruboxistaurin has not made it to 
the market yet (NICE 2018).  
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Glycolytic conversion of glucose first to glucose-6-phoshate, fructose-6-phosphate and subsequently 
into metabolic intermediates of the glycolytic pathways is the norm for glucose metabolism. Some of 
the fructose -6- phosphate is diverted into the signalling pathway in which glutamine: fructose-6 
phosphate amidotransferase (GFAT) catalyses the conversion of fructose-6 phosphate to 
glucosamine-6 phosphate and finally to uridine diphosphate (UDP) N-acetyl glucosamine. 
Consequently, N-acetyl glucosamine is incorporated into serine and threonine residues of 
transcription factors. In hyperglycaemia driven high intracellular glucose flux, glucose enters 
endothelial, mesangial, neuron and Schwann cells indiscriminately. Fructose-6-phosphate conversion 
is shunted to N-acetyl glucosamine resulting in over-modification of glucosamine which causes 
pathologically aberrant changes in gene expression, lesions and pathological damage, and increased 
endothelial cell protein modification (Kolm-Litty et al 1998, Sayeski and Kudlow et al 1996, Wells and 
Hart 2003, Clark et al 2003, Federici et al 2002). A single unifying hypothesis of ROS overproduction 
as the unifying instigator for the four biochemical pathways of glucotoxicity in diabetes was 
proposed (Brownlee 2005, Nishikawa et al 2000). In support of this hypothesis, Brownlee and co 
(2005) showed that the four hyperglycaemia driven glucotoxicity pathways were blocked by 
mitochondrial superoxide blockade via (UCP-1 and SOD2 over-expression (Nishikawa et al 2000).  
The unifying mechanism of hyperglycaemia mediated complications as hypothesised by Brownlee et 
al (2005) is illustrated in a simplified diagram below (fig 1.1). According to this theory, 
hyperglycaemia associated inhibition of GAPDH results in increased intracellular glucose (which 
drives the four biochemical pathways already outlined). This results in the overproduction of 
superoxide (ROS) and increased intracellular ROS in the mitochondria which induces DNA strand 
breaks, consequently leading to the activation of poly ADP (ribose) polymerase (PARP) enzyme 
(Brownlee 2001). Activated PARP catalyses NAD+ breakdown into nicotinic acid and ADP-ribose and 
subsequently PARP induced polymerisation of GAPDH with ADP-ribose, thereby inactivating GAPDH 
and other nuclear proteins (Du et al 2003). Thus, glycolytic intermediates accumulate which drives 
increased polyol flux, PKC pathway, AGEs and RAGE production with increased ROS and oxidative 
stress in the cells. 
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Figure 1.1 Simple diagram of the unifying mechanism 
Persistent high glucose in diabetes drives uncontrolled glucose entry into selectively susceptible cells such as endothelial 
cells. Increased intracellular glucose exerts oxidative stress in the mitochondria via increased mitochondrial ROS. ROS drives 
the four damaging pathway; polyol, AGEs, PKC, and hexosamine flux pathway via PARP-dependent inhibition of GAPDH. 
Increased ROS initiates DNA strand breaks which activates PARP enzyme in the nucleus. PARP makes ADP-ribose polymers 
which are added unto GAPDH inactivating the enzyme, and glycolytic intermediates accumulates leading to more activation 
of polyol pathway flux, PKC activation, hexosamine pathway flux, and inflammation via NFᴋB activation.  
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An inflammatory theme is proposed as the instigator for the derangement seen in DR (Adamis 2008). 
Microscopic manifestations of inflammation in retinal vessels are vessel dilatation, altered flow, fluid 
exudation, leukocyte accumulation and migration (Gallin and Snyderman 1999, reviewed in 
Chatterjee et al 2017). A causal link between CD18/ICAM-1 mediated leukocyte adhesion and blood-
retinal barrier (BRB) breakdown have been shown (Adamis 2008, Joussen et al 2004). Hallmark 
features of DR such as acellular capillaries and leukocyte adhesion were inhibited in CD18/ICAM-1-/- 
knockout mice with ameliorated pericytes loss (Joussen et al 2004).  
Various mechanisms have been put forward to explain the damaging effects of inflammatory 
leukocytes in the pathogenesis of DR. Leukocytes may exert a direct damage to endothelial cells, 
leading to endothelial cell death. They are likely to exert an indirect effect on endothelial cells by 
damaging endothelial supportive cells such as pericytes. Leukocytes are known to induce tight 
junction opening and endothelial fenestrae via leukocyte mediated release of permeability factor 
such as VEGF, thereby impairing endothelial barrier (Adamis 2002, Joussen et al 2004). In addition, 
leukocytes adhesion may promote receptor mediated endothelial apoptosis (Joussen et al 2004).  
The role of inflammation in DR is strengthened by the role of anti-inflammatory agents in ocular 
diseases. Administration of high dose aspirin, a non-steroidal anti-inflammatory (50mg/kg), 
meloxicam (a cyclooxygenase 2 inhibitor) and etanercept (a soluble tumour necrosis factor α 
receptor) significantly inhibited diabetic retinal ICAM-1 expression, leukocyte adhesion, and BRB 
breakdown through a mechanism involving TNF-α suppression (Joussen et al 2002). In addition, 
Ozurdex (dexamethasone) (NICE 2015) and Iluvien (fluocinolone acetonide) (NICE 2013), both 
corticosteroidal anti-inflammatory drugs are in clinical use for treatment of chronic diabetic macular 
oedema in adults.  
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1.5 Oxidative Stress, Inflammation and 
Angiogenesis 
Three cardinal themes; oxidative stress, inflammation and angiogenesis are evident from 
glucotoxicity of the endothelium. In normal physiological conditions, these events are under the 
control of three transcriptional factors; the nuclear factor (erythroid-derived 2)-like 2 (nrf2), the 
nuclear factor kappa-light-chain-enhancer of activated B cells (NFĸB), and the hypoxia inducible -1 
(HIF-1) respectively. Discussion of these transcription factors important in responses of endothelium 
to glucotoxicity is presented in the following paragraphs. 
 
 
1.5.1 Nuclear factor erythroid 2–related factor 2 (Nrf2) 
The nuclear factor erythroid 2-related factor (Nrf2) is a cytoprotective transcription factor which 
regulates the expression of genes coding for anti-oxidant, anti-inflammatory and detoxifying 
proteins, in addition to modulation of species longevity and in cellular metabolism (Kansanen et al 
2013, Mitsuishi et al 2012,Negi et al 2011, and Siewart et al 2013, Heiss et al 2013). The vertebrate 
nrf2 belongs to Cap ‘n’ Collar (Cnc) bZIP family of transcription factors and shares a high homology 
with SKN-1 from Caenorhabditis elegans or Cnc found in Drosophila melanogaster (reviewed in Hu et 
al 2011). Nrf2 has seven functional domains (Neh1-7) which are important for its stability and its 
transcriptional activity (fig 1.2).  
The N-terminal domain is the interaction site for nrf2 and Kelch-like ECH associated protein 1 (Keap 
1) (Chen et al 2012). The Neh5 domain regulates nrf2 cellular localisation (Namani et al 2014, Krajka-
Kuźniak et al 2017), while the Neh6 domain controls Keap 1-independent nrf2 degradation. Nrf2 
binds to its target antioxidant response elements (AREs) sequences via the Neh1 domain which 
represents a platform for modulation of nrf2 protein stability (Keum and Choi 2014). The nuclear 
localisation signal required for nrf2 nuclear translocation is located on the Neh1 domain and is 
unmasked after Keap 1 dissociation. Co-activators of the ARE-dependent gene transcription complex 
such as chromo-ATPase/helicase DNA-binding protein (CHD6) interact with nrf2 via the Neh3 domain 
(Namani et al 2014, Krajka-Kuźniak et al 2017, and Xiang et al 2014).  
Similarly, Neh4 and Neh5 are domains for targets that facilitate nrf2 transcription by binding to the 
co-activator cyclic adenosine monophosphate –responsive element-binding protein (CBP/P300) such 
as NFᴋB (Xiang et al 2014). Nrf2 nuclear cofactor, Ras-related C3 botulinum toxin substrate 3 protein 
(RAC3) interacts with Neh4 and Neh5 domains resulting in the enhancement of nrf2-targeted ARE 
gene expression (Namani et al 2014, Krajka-Kuźniak et al 2017, and Xiang et al 2014).  
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The repression of nrf2 activity by retinoic acid receptor alpha takes place in the Neh7 domain (Bai et 
al 2016). The Nfe2/2 gene promoter also contains ARE-like sequences providing a positive feedback 
mechanism which amplifies nrf2 when bound to AREs (Kwak et al 2002).The adaptor molecule, beta-
transducin repeat containing E3 ubiquitin protein ligase (Β-TrCP), regulates nrf2 in a Keap 1-
independent manner via glycogen synthase kinase 3 (GSK-3β)-mediated phosphorylation of the Neh6 
domain (Rada et al 2011 and 2012). PKC activity promotes nrf2 activation via phosphorylation of the 
serine residue (Ser40) in Neh2 domain of nrf2 (Steinberg 2015), highlighting a possible link by which 
nrf2 activity may be induced by signals that induce PKC, such as high glucose or ROS induced 
oxidative stress. The phosphoinositide-3 kinase (PI3K), PKC, MAPK, and the extracellular signal 
regulated kinase (ERK) also enhance nrf2 activity through inhibition of GSK-3β, in addition to the 
Notch signalling pathways (Kaidanovich-Beilin et al 2011, Wakabayashi et al 2010).  
Another potential regulator for nrf2 is the musculoaponeurotic fibrosarcoma oncogene homolog 
small Maf (sMaf) proteins which are co-transcription activators for nrf2with capacity to dimerize 
with nrf2 or self-dimerize. Ironically, over-expression and self-dimerization of sMaf is associated with 
impairment of nrf2 transactivation because sMaf dimers are incapable of mediating transcriptional 
activation with nrf2 (Motohashi et al 2010). The nrf2 functional domains are shown in fig 1.2.  
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Figure 1. 2 Schematic representative structure of Nrf2 
Nrf2 has seven functional domains (Neh1-7). Neh1 (N-terminal) is nrf2-Keap 1 interaction domain and represents the 
platform for Keap 1 mediated nrf2 degradation via ubiquitination. Nuclear localisation site for nrf2 on Neh1 domain is 
unmasked after Keap 1 dissociation. Neh5 regulates nrf2 cellular localisation and Neh6 is the site for Keap 1-independent 
nrf2 degradation. Nrf2 interacts with co-activators that transactivate ARE-dependent genes after chromatin remodelling, 
while CBP binding co-activators such as NFĸB interacts with nrf2 via Neh4 and Neh5 domains. Nrf2 is repressed by retinoic 
acid receptor via Neh7 domain. (Reproduced with permission from Bellezza et al 2018). 
 
 
Nrf2 protein is distributed in the cytosol and translocate to the nucleus upon its stabilisation and 
activation, and there is small evidence that nrf2 might be distributed in the plasma membrane (HPA, 
2018). Owing to its global role in the activation of vast arrays of genes, nrf2 level is well regulated in 
cells. During cell homeostasis, although nrf2 is constitutively expressed in the cytoplasm, it is isolated 
via two molecules of Kelch-like ECH associated protein 1 (Keap 1) under normal conditions (Chen et 
al 2012). Keap 1 promotes ubiquitination and degradation of nrf2, thus Keap 1 modulates nrf2 
protein stability, maintaining basal levels in unstressed cell states. However, nrf2 is constitutively 
expressed in some disease states such as in acute myeloid leukaemia (AML) (Fuse and Kobayashi 
2017). The half-life of nrf2 in the cytosol in normal condition is approximately 20 min (Kobayashi and 
Yamamoto 2006). In conditions of excess oxidants or electrophiles e.g. ROS, nrf2-dependent cellular 
defence response is activated, and Keap 1 is oxidised at its cysteine thiol groups. Both nrf2 and Keap 
1 undergo post-translational modification and the oxidation of Keap 1 cysteine group allows for nrf2 
dissociation from Keap 1 and its subsequent stabilisation.  
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In human cell lines, Keap 1 knock down is associated with nrf2 accumulation (Wakabayashi et al 
2003, Devling et al 2005), and stabilisation of nrf2 protein is reported to increase its half-life to 200 
mins (Canning et al 2015). With increased residence time, nrf2 translocate to the nucleus where it 
binds with specific DNA-recognition sequence antioxidant response elements (AREs) as a 
heterodimer with sMaf resulting in activation of transcription to induce anti-oxidant and metabolic 
gene expression (Katsuoka et al 2005, Bellezza et al 2018).Nrf2 regulation in normal and stress 
condition is illustrated in figure 1.3. 
 
 
 
Figure 1. 3 Nrf2 regulation in normal and stress condition 
In normal (homeostatic) condition, nrf2 (light blue) is bound tightly by Keap 1 via F-actin cytoskeleton (Velichkova and 
Hasson 2005, Bellezza et al 2010). In homeostatic condition nrf2 levels are kept very low via proteasomal (red) mediated 
ubiquitination (yellow) and degradation. Stress signals such as oxidative stress causes nrf2 to separate from Keap 1 and 
translocate to the nucleus where it heterodimerizes with sMaf proteins (blue) and the nrf2-Maf heterodimer binds to AREs 
(black) to induce anti-oxidant and metabolic gene expression (Reproduced with permission from Bellezza et al 2018). 
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Nrf2 is a mechanosensitive transcription regulator in endothelial cells (ECs) (reviewed in McSweeney 
et al 2015). Increased shear stress in ECs is accompanied by ROS generation and increased 
expression of adhesion molecules which may explain the activation of nrf2 during increased shear 
stress in ECs presumably to mediate the expression of anti-oxidant response genes and proteins 
(reviewed in McSweeney et al 2015). Mechanical stress associated ROS enhancement also indirectly 
mediates nrf2 activation via ROS activation of the p38 and c-Jun N-terminal (JNK) activity leading to 
NFᴋB activation. Activated NFᴋB cross-talks with nrf2 via guanosine triphosphatases (GTPase) Rac1 
(Ras-related C3 botulinum toxin substrate 1) resulting in nrf2 activation and the inducement of nrf2 
cytoprotective genes and protein such as the heme oxygenase -1 (HO-1) (Bellezza et al 2012, Minelli 
et al 2009, and Cuardrado et al 2014) (fig 1.4 and 1.6).  
The effect of nrf2 in cells is predominantly protective. Recently, the over-expression of nrf2in 
endothelial progenitor cells (EPCs) of diabetic mice was shown to be associated with increased 
protection against oxidative stress (Wang et al 2018). Although, hyperglycaemia induced endothelial 
dysfunction is associated with ROS production and oxidative stress and several of the glucotoxicity 
effects are driven from the build-up of glycolytic intermediates, the activation of the pentose 
phosphate pathway (PPP) is reported to counter hyperglycaemia induced metabolic dysfunction 
(Babaei-Jadidi et al 2003, Hammes et al 2003, and Berrone et al 2006). What was not evident at the 
time was the link between the PPP and nrf2 redox system because several of the PPP enzymes 
including glucose-6 phosphate dehydrogenase (G6PD) are under the control of nrf2. Accordingly, 
Nrf2 activation has been shown to prevent metabolic dysfunction in endothelial cells via increased 
expression of transketolase (Xue et al 2008). Recently, vitamin D3, was shown to downregulate 
intracellular ROS and inhibited TRX-interacting protein (TXNIP)/NOD-like receptor family, pyrin 
domain-containing 3 (NLRP3) inflammasome pathway activation in diabetic mice and human retinal 
microvascular endothelial cells, which strengthens the association of the redox system controlled by 
the transcriptional factor, nrf2 (Lu et al 2018).  
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Nrf2 is also involved in cell membrane homeostasis. High glucose also increases PMRS activity but 
PMRS activity is not observed in low glucose (Leiser and Miller 2010).Activation of the nrf2 is 
associated with up-regulation of plasma membrane redox system (PMRS) activity which is linked 
with cell survival under stress conditions (Hyun et al 2006, Saraswat and Rizvi 2017). In dwarf cells, 
elevated nrf2 protein levels with increased PMRS resulted in decreased stress-induced lipid 
peroxidation (Leiser and Miller 2010).There are not many studies that have examined plasma 
membrane associated nrf2 activation in endothelial cells.  
Nrf2 pathway signalling activates over 200 antioxidant and cytoprotective genes (Godman et al 
2010). Nrf2 regulated pathway regulates the expression of cytoprotective genes including anti-
oxidant genes e.g. heme oxygenase -1 (HO-1), ferritin, and SOD, genes encoding enzymes that 
participate in glutathione synthesis and regeneration such as G6PD, glutathione peroxidase(GPx), 
glutathione S transferase (GST), glutathione reductase (GR) and γ-glutamylcysteine ligase, in addition 
to the xenobiotic detoxifying pathway. A list of examples of genes/pathways regulated by nrf2/Keap 
1 pathway is presented in table 1.2 (reviewed in Loboda et al 2015).  
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Table 1.2 Nrf2 dependent genes. Examples of the cytoprotective 
genes regulated by nrf2 (adapted from Loboda et al 2015) 
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1.5.1.1 Nrf2- NFᴋB Crosstalk 
Nrf2 pathway performs a pro-survival role via its cross-talks with the nuclear factor kappa-light-
chain-enhancer of activated B cells (NFĸB) pathway which ameliorates the pro-death ROS-mediated 
JNK activation signalling pathway (Bellezza et al 2018) (fig 1.4). This interaction between nrf2 and 
NFᴋB is made possible by the presence of an NFᴋB binding site on the promoter region of nrf2 Neh4 
and Neh5 domains via CBP (Xiang et al 2010). Hence, this cross-talk allows the influence of 
inflammatory or redox stimuli to be co-operatively regulated by the nrf2/NFᴋB system (Rushworth et 
al 2012). During cellular oxidative stress/injury, nrf2 migrates into the nucleus and binds to AREs 
upon dimerization with sMaf to drive expression of target genes including HO-1.Both nrf2 and NFᴋB 
compete for CBP/300 binding in the nucleus, dependent on the relative amounts of NFᴋB or nrf2 as 
shown in fig 1.4 (A), and in the presence of simultaneous nuclear increases in these two transcription 
factors, NFĸB (p65) antagonizes nrf2-induced gene transcription (Bellezza et al 2018).  
 
 
Figure 1. 4 Nrf2 and NFᴋB cross-talk 
Nrf2 and NFĸB compete for CBP/P300 binding in the nucleus (A). When NFᴋB is more in abundance, it upsets nrf2 gene 
transcription. But if NFᴋB activity is suppressed by anti-inflammatory molecules, then nrf2 activity is activated (B). When 
NFᴋB is activated it binds on ᴋB response elements (ᴋBRE) on nrf2 promoter region, causing nrf2 induction (C). 
Rac1activates NFᴋB which stimulates nrf2 and upregulates HO-1 (D). HO-1 goes back and inhibits NFᴋB. (Reproduced with 
permission from Bellezza et al 2018). 
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On the other hand, compounds with anti-inflammatory properties indirectly activate nrf2 by 
suppressing NFᴋB activity, which relieves NFᴋB competition for CBP/P300 with nrf2 (Grottelli et al 
2016, Li et al 2008, Kim et al 2013, and Minelli et al 2012). Ironically, NFᴋB also shows protective anti-
inflammatory activity by activating nrf2 activity via GTPase Rac1 (C) (Cuardrado et al 2014). Activated 
nrf2 induces HO-1 which inhibits further NFᴋB activity (Bellezza et al 2012, Minelli et al 2009, and 
Cuardrado et al 2014). NFĸB mediates this effect on ROS via its effect on the expression of several 
antioxidant proteins including nrf2.Secreted cytokines are also able to stimulate nrf2. Kharazmi et al 
(1989) showed that secretory cytokines including IL-6 and TNFα are able to auto-activate (prime) 
macrophages and increase their production of superoxide anion, and TNFα cell lethality is in part due 
to TNFα induced oxidative free radical damage.  
In-vivo studies have evidenced the role of nrf2 in mediating inflammatory signals. In nrf2-deficient 
(Nrf2-/-) mice, increased plasma TNFα and decreased levels of glutathione in the retina were 
documented versus their wild-type (Nr2f+/+) diabetic equivalents at 8 weeks of diabetes (Xu et al 
2014). Consequently, these Nrf2 knockout mice exhibited early onset of blood–retina barrier 
dysfunction and exacerbation of neuronal dysfunction in diabetes demonstrating nrf2 has a 
protective transcription factor in DR and suggests enhancement of the nrf2 pathway as a potential 
therapeutic strategy (Xu et al 2014).   
 
 
1.5.1.2 Heme Oxygenase isoform 1 
Nrf2 regulated pathway regulates the expression of cytoprotective genes including anti-oxidant 
heme oxygenase -1 (HO-1) (reviewed in Loboda et al 2015). The heme oxygenase-1 (HO-1, HMOX1) is 
regulated by nrf2 (Alam et al 1999, Kansanen et al 2013). HO-1 is an inducible 32-kDa protein found 
in mammals and it is distinct from the constitutive HO-2 isoform of heme oxygenase (HO). HO-1 
functions as an anti-oxidant, anti-inflammatory and anti-apoptotic microsomal stress response 
protein (Otterbein et al 1999, Chen et al 2012). It is expressed as an integral protein of the smooth 
endoplasmic reticulum but localises to caveolae, mitochondrion and the nucleus (Yoshida and Sato 
1989), Yoshida et al 1991, Jung et al 2003, Slebos et al 2007, and Sacca et al 2007). HO-1 is 
upregulated by a number of stimuli including heme, nitric oxide, heavy metals, growth factor, 
cytokines, and NFᴋB in response to oxidative stress (ROS) (reviewed in Loboda et al 2008, Bellezza et 
al 2018). 
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Figure 1. 5 Heme oxygenase -1 pathway 
Nrf2 stabilisation, accumulation and activation may result in the induction of HO-1 protein. HO-1 enzyme when induced co-
operates with NADPH cytochrome P450 to degrade heme, to three bioactive intermediates; iron ions, carbon monoxide 
and biliverdin. Biliverdin is rapidly converted to bilirubin by biliverdin reductase (BVR). All three metabolites of HO-1 elicit 
functions that are pro-angiogenic, anti-oxidant or anti-inflammatory (Adapted from Loboda et al 2015). 
 
 
 
 
HO-1 catalyses the breakdown of heme to; iron, carbon monoxide (CO) and biliverdin in a catalytic 
reaction aided by NADPH cytochrome P450. The enzyme, biliverdin reductase (BVR) reduces 
biliverdin to bilirubin, which confers anti-oxidant and anti-inflammatory protection. In addition, free 
iron released as a by-product of heme breakdown induces and enhances ferritin, an iron scavenger 
in endothelial cells (Balla et al 1992). Therefore, enhanced ferritin levels reduces availability of redox-
active iron from participating in the Fenton reaction, thereby preventing the generation of highly 
reactive and DNA-damaging hydroxyl radical (Tenhunen et al 1968, Choi et al 1996, Elbirt and 
Bonkovsky 1999, and Otterbein et al 1999). Moreover, ferritin elevation also confers anti-apoptotic 
protection to endothelial cells (reviewed in Loboda et al 2015). Furthermore, carbon monoxide, 
another heme metabolite is associated with anti-inflammatory and anti-proliferative and protective 
effects especially in vascular dysfunction (Loboda et al 2015). 
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In addition to Keap 1, nrf2 is regulated via GSK-3β mediated phosphorylation. GSK-3β 
phosphorylation is associated with increased proteasomal degradation of nrf2 (Biswas et al 
2014).Initial studies identified the translocation of a truncated (28-kDa) enzymatically inactive HO-1 
with nrf2 into the nucleus during times of oxidative injury (Otterbein et al 1999). Later studies 
suggested the truncated HO-1 interacts with activator protein 1 (AP-1) consensus sequences on nrf2 
during oxidative stress consequently stabilising nrf2 against GSK-3β mediated phosphorylation and 
that HO-1/nrf2 interaction in the nucleus prolongs nrf2 nuclear residence and provides sustained 
tolerance against oxidative injury, thus increasing cell survival (Dennery 2013). The importance of 
HO-1 enzyme is demonstrated by some of the effects of HO-1-deficiencies which include marked 
systemic inflammation, abnormalities of the coagulation/fibrinolysis system, developmental failure, 
and iron-deficiency anaemia, intravascular haemolysis with fragmented erythrocytes, nephropathy, 
and vascular endothelial injury (Yachie et al 1999).  
 
 
1.5.2 Nuclear factor kappa-light-chain-enhancer of 
activated B cells 
The nuclear factor kappa-light chain-enhancer of activated B cells (NFĸB) and its activating receptors 
were first described in immune cells. They are a five member family of transcription factors with a 
Rel-homology (RHD) domain that is critical for DNA binding and dimerization. Three of the five NFᴋB 
members; Rel A, (also known as p65), Rel B and cRel, have a C-terminal transcription activation 
domain (TADs) that serves to positively regulate gene expression, while the P105 and p100 members  
are synthesised as inactive precursor proteins that are cleaved to the smaller p50 and p52 subunits 
which lack TADs. Unlike the Rels with transactivational C-terminals, the C-terminals of P105 and p100 
subunits have inhibitory ankyrin repeats. However, they are able to associate with the Rel proteins 
to form transcriptionally active heterodimers.  
In normal conditions, NFĸB is sequestered in the cytoplasm by inhibitors of kB (IKB). IκB possesses 
potent nuclear export signal (NES), hence their capability to export nuclear NFĸB. In addition, IκB 
inhibits NFĸB by binding to NFĸB DNA binding, thereby excluding any NFĸB target gene binding and 
gene expression. Phosphorylation of IκB by upstream IκB kinases (IKKs) targets it for ubiquitination 
and proteasomal degradation, thus unmasking the DNA binding activity of the p50/Rel A 
heterodimer. NFᴋB is regulated via canonical (fig 1.6) and non-canonical pathways but canonical 
NFᴋB regulation is more relevant physiologically versus non-canonical pathway.  
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Figure 1. 6 Canonical (classical) NFᴋB signalling pathways 
Ligands such as IL-6 or ROS bind to cytokine and TLR receptors on NFᴋB respectively. IKK alpha and/or IKK beta catalytic 
subunits and two molecules of NFᴋB essential modulator (NEMO) are recruited forming the IKK complex.  The IKK complex 
phosphorylates IκB leading to degradation by the proteasome. NFĸB heterodimer (Rel A (p65)/c-Rel/p50) complex 
translocate to the nucleus to activate target genes. Source: Abcam- https://www.abcam.com/research-areas/overview-of-
NFᴋB-signaling 11.45pm/ 13th September 2018. 
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The canonical and non-canonical NFᴋB pathways share a common regulatory step of activation of an 
IκB kinase (IKK) complex consisting of catalytic kinase subunits (IKKα and/or IKKβ) and the regulatory 
non-enzymatic scaffold protein, NFᴋB essential modulator (NEMO)also known as IKKγ. In the 
canonical route, Rel A/c-Rel/p50 NFĸB complex translocate to the nucleus where it activates the 
transcription of its target genes (Hayden and Ghosh 2008, Karin and Ben-Neriah 2000).In the non-
canonical pathway, p100 is degraded to p52, allowing a Rel B/p52 complex to translocate from the 
cytoplasm to the nucleus (Xiao et al 2001). 
NFĸB is important for regulation of inflammatory responses. In addition to mediating induction of 
various pro-inflammatory genes in innate immune cells, NFĸB regulates the activation, 
differentiation and effector function of inflammatory T cells (Tak and Firestein 2001, Lawrence 
2009).  NFĸB also has a role in regulating the activation of inflammasome (Sutterwala et al 
2014). Furthermore, NFĸB exerts a protective role in oxidative stress by suppressing ROS 
accumulation via nrf2 activation and directs host response to environmental stress (Hayden et al 
2004 and Bellezza et al 2018). For instance, NFĸB is a mediator of mechanotransduction in several 
cell types including endothelial cells (Barkett and Gilmore 1999, Dolcet et al 2005). Mechano-
transduced signals at focal endothelial cell adhesion stimulates NFᴋB in response to shear stress via 
Rac1 and cell division control protein 42 homolog (Cdc42) activation (Khachigian et al 1995, Chien et 
al 1998, and Tong and Tergaonkar 2014). 
Thus, basal NFᴋB activity is critical for the regulation of inflammatory response, cellular growth, 
permeability and apoptosis in endothelial cells (Barkett and Gilmore 1999, Dolcet et al 2005). More 
so acute Inflammation is a protective response of the host to infections and tissue damages, 
necessary for cell response to infection or tissue injury. Hence, inflammation can be beneficial to the 
host if resolved in a timely manner; however, deregulated inflammatory responses can cause 
excessive or long-lasting tissue damages, contributing to the development of acute or chronic 
inflammatory diseases. Indeed chronic deregulated NFĸB activation is a hallmark of chronic 
inflammatory diseases including diabetes.  In the diabetic endothelium, chronic NFᴋB expression is 
promoted and augmented due to hyperglycaemia induced PKC activation which drives pro-
inflammatory and redox imbalance response via chronic upregulation of NFᴋB and ROS 
overproduction (reviewed in Evcimen and King 2007).   
 
 
 
 
 
  
39 
 
Endothelial cells (ECs) direct leukocyte traffic through regulation of adhesion molecules, chemokines, 
and cytokines (Galley and Webster 2004, Zhang and Frei 2001, Aoki et al 2001, and Badrichani et al 
1999).Pro- inflammatory cytokines have profound effect on endothelial function, including their 
regulation of vascular tone, permeability, and leukocyte diapedesis (Aoki et al 1989, Galley and 
Webster 2004, Lush et al 2000). The pro-inflammatory cytokine, interleukin 6 (IL-6) and ROS activate 
canonical pro-inflammatory NFᴋB (p65) activation in endothelial cells via cytokine receptors and toll-
like receptors (TLRs) respectively (Castell et al 1988, Pober 1999, Morgan and Liu 2011).  
 
 
1.5.2.1 Endothelial interleukin-6 (IL-6) 
Interleukin-6 (IL-6) is a pleiotropic cytokine with functions in acute phase protein response, 
autoimmunity in addition to driving chronic inflammation and endothelial dysfunction. IL-6 was 
molecularly cloned in 1986 as a B-cell stimulatory factor by the group of (Hirano et al 1986). Human 
IL-6 is made up of 212 amino acids, including a 28-amino-acid signal peptide, and its gene has been 
mapped to chromosome 7p21 (Kobayashi et al 2012). It is also associated with factors including 
myeloid blood cell differentiation-inducing protein indicating its other roles in addition to immune 
response (reviewed in Schaper and Rose-John 2015, and Barnes et al 2011).IL-6 is synthesized and 
secreted by several cell types including endothelial cells (ECs), monocytes, T-cells and fibroblasts 
(Schaper and Rose-John 2015).Accordingly, IL-6 mRNA and protein were shown to be upregulated in 
endothelial cells (HUVECs) independent of LPS or contamination (Kobayashi et al 2012).  
The vascular endothelium, particularly the lymphatics constitutively synthesize IL-6 which offers 
immune surveillance and protection in readiness for acute phase protein activation (Castell 1988, 
reviewed in Gabbay 2006). IL-6 signalling takes place via classic (a membrane bound receptor) or 
soluble receptor (trans) signalling mechanisms and the biological effects of these two mechanisms 
are separate (reviewed in Schaper and Rose-John 2015). Membrane bound IL-6 receptors (IL-6R) are 
not expressed in ECs hence IL-6 signalling in ECs occurs via trans signalling has been observed 
(Romano et al 1997). IL-6 trans signalling is associated with pro-inflammatory and stress response to 
restore homeostasis (Schaper and Rose-John 2015). In addition, IL-6 promotes endothelial tube 
formation and proliferation (Sato et al 2016), and neoangiogenesis (Tartour et al 2011). However, IL-
6 overstimulation in the endothelium is linked to increase in the expression of adhesion molecules 
such as ICAM-1 and VCAM-1 and endothelial cell dysfunction(reviewed in Barnes et al 2011).IL-6 was 
recently shown to increase migration and proliferation of human dermal microvascular endothelial 
cells (HDMECs) without inducing endothelial-mesenchymal transition (EndMT) (Kevin et al 2018).  
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IL-6 has been shown to exhibit both pro-inflammatory and anti-inflammatory functions mediated 
predominantly via NFᴋB in cells (reviewed in Scheller et al 2011, Sato et al 2016). NFᴋB binding sites 
are found on functional cis-regulatory elements in human IL-6 gene 5′ flanking region demonstrating 
the regulation of the IL-6 gene transcription by NFᴋB (Tanaka et al 2014). Stretch induced IL-6 
responses in ECs are dependent on sequential IKKs and NFᴋB activation in a ROS dependent manner 
(Kobayashi et al 2003).  
IL-6 is regulated predominantly at the transcriptional level (Castell et al 1988).In vivo IL-6 mRNA is 
unstable and has a half-life of 30 mins due to AU-rich instability elements in its 3' untranslated region 
and serum IL-6 is rapidly cleared (Paschoud 2006, Saitoh et al 2000, and Ramakers et al 2009). 
However, in in-vitro experiments using human pulmonary artery endothelial cells (HPAECs) and 
HUVECs, IL-6wasstable (> 2 h) indicating serum IL-6 and IL-6 mRNA may be cleared in-vivo by 
mechanisms which may be lacking in-vitro (Kobayashi et al 2012). Non-coding regulatory microRNAs 
(miRNA) are suggested to be associated with IL-6 mRNA instability in-vivo. MiRNA are small non-
coding regulatory RNA, 22-24 nucleotide long that silences gene expression at post-transcriptional 
level by base pairing with the 3’-untranslated region (3’-UTR) of complementary sequences within 
coding mRNA molecules, thereby suppressing gene expression (Bartel 2004, Xu et al 2011). Base-
pairing silences the target mRNA either by destabilization of the  mRNA through shortening of its 
poly(A) tail, cleavage, or decreased translation of the mRNA into proteins by ribosomes. Interaction 
of miRNA-146a/b and -223 was shown to indirectly suppress transcription of IL-6 by respectively 
targeting IL-1 receptor–associated kinase 1 and signal transducer and activator of transcription 3 
(STAT3) (Chen et al 2012, Zilahi et al 2012). 
 
 
1.5.3 Hypoxia inducible factor -1 alpha (HIF-1α) 
Hypoxia-inducible factor -1 (HIF-1) is the major transcription factor regulating genes that facilitate 
adaptation and survival of cells and the whole organism from normoxia (~ 21% oxygen) to hypoxia (~ 
1% O2) (Wang et al 1995, Semenza 1998). HIF-1 was discovered by the identification of a hypoxia 
response element (HRE; 5’-RCGTG-3’) in the 3’ enhancer of the gene that codes for erythropoietin 
(EPO) hormone (Goldberg et al 1988, Semenza et al 1991). HIF-1 is a heterodimer complex consisting 
of a regulated subunit, HIF-1α and a constitutively expressed subunit, HIF-1β,also known as the aryl 
hydrocarbon nuclear translocator (ARNT) (fig 1.7) (Semenza et al 1991, Wang and Semenza 1993). 
HIF-1α isoforms; HIF-2α and HIF-3α and splice variant inhibitory PAS (IPAS) have been described 
(Semenza et al 1991, Wang and Semenza 1993). The human HIF-1 gene is found on chromosome 14 
(14q21-q24), while HIF-1β gene is located on chromosome 1 (1q21).  
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HIF-1α and HIF-1β are large proteins composed of 826 basic helix-loop-helix motifs (bHLH) and the 
bHLH and PAS motifs are requisite for HIF-1α and HIF-1β heterodimer formation (Semenza et al 
1991, and 1993).The downstream basic region is required for binding to the HRE DNA sequence 
(Wang et al 1995, Crews 1998). HIF-1α (HIF-1α, HIF-2α, HIF-3α, and inhibitory Per-ARNT-Sim (IPAS) 
and HIF-1β belong to the Per-ARNT-Sim (bHLH-PAS) protein family (Wang et al 1995).The HIF-1α 
subunit has two transactivation domains (TAD); the N- and C-terminal transactivation domains: 
NTAD and CTAD, found between residues 531-575 and 813-826 respectively (Ruas et al 2002). The 
NTAD motif overlaps with a larger O2-dependent degradation domain (ODDD), which confers control 
on HIF-1α in response to O2 concentration (Pugh et al 1997). The main function of CTAD is to recruit 
transcriptional co-activators; CBP/P300, SRC-1 and TIF-2 (Kung et al 2000, Lando et al 2002b, and 
Hirota and Semenza 2006).  
 
 
 
 
 
Figure 1. 7 Domain structure of human HI 1α and HIF-1β 
HIF-1α and HIF-1β belong to the bHLH (purple) and PAS (green) protein family. HIF-1α contains an ODDD that mediates HIF-
1α regulation based on O2 concentration via hydroxylation of two proline residues which is absent in HIF-1β. HIF-1α 
contains two transactivation domains; C-TAD and N-TAD, whereas HIF-1β has only one TAD. HIF-1α has a total of 826 amino 
acids (AA), whilst there are 789 AAs in HIF-1β (Adapted from Ke and Costa 2006).  
 
 
 
 
 
HIF-1β is constitutively expressed and its mRNA and protein levels are maintained at a constant level 
regardless of oxygen availability (Kallio et al 1997). The transcription and synthesis of HIF-1α is 
constitutive and unaffected by oxygen levels (Wang et al 1995, Kallio et al 1997). However, in 
normoxia de novo synthesized cytoplasmic HIF-1α is degraded within a half-life of (t1/2 of ~ 5 min) 
resulting in very low levels of HIF-1α protein (Wang et al 1995). In converse, HIF-1α is stabilized in 
hypoxia or other relevant stimuli, and translocate to the nucleus where it dimerizes with HIF-1β 
forming a transcriptionally active complex. HIF-1α and HIF-1β heterodimer bind to hypoxia response 
elements (HREs) in the regulatory regions of target genes. Transcriptional co-activators such as the 
CBP/P300 are recruited to the HIF-HRE complex which activates transcription (Ruas et al 2002).  
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HIF-1α stability and the subsequent transactivational function of HIF-1 are controlled mainly via post-
translational modifications including hydroxylation, ubiquitination, acetylation, and phosphorylation. 
Translation modification of HIF-1α is also known. In normal oxygen tension (normoxia), two proline; 
Pro402 and Pro564 residues at the ODDD undergo hydroxylation which promotes HIF-1α association 
with the tumour suppressor protein von Hippel–Lindau (pVHL) ubiquitin E3 ligase complex. The VHL 
tumour suppressor protein is a substrate recognition element of the E3 ubiquitin ligase complex 
proteasomal pathway and pVHL labels HIF-1α with ubiquitin tag marking HIF-1α for degradation via 
the ubiquitin-proteasomal degradation pathway (Srinivas et al 1999). Mutation of both proline 402 
and 564 disrupts HIF-1α interactions with pVHL, resulting in increased HIF-1α protein stability in 
normoxia (Masson et al 2001).  
HIF-1α activity is also controlled via modulation of HIF-1α transactivation domains, NTAD and CTAD. 
Transactivation domains function to recruit co-activators such as with cyclic adenosine 
monophosphate –responsive element-binding protein (CBP/P300) for example (Arany et al 1996).  
In normoxia, the factor inhibiting HIF-1α (FIH) hydroxylates asparagine (Asn) residue 803 (Asn803) in 
C-TAD of HIF-1α, thereby preventing HIF-1α interaction with CBP/300 (Lando et al 2002). But hypoxia 
abrogates FIH mediated Asn803 hydroxylation in a reaction requiring 2-oxoglutarate dependent 
dioxygenase, iron and ascorbate as coactivators (Lando et al 2002a). The distribution of FIH-1 is 
mainly cytoplasmic, but a nuclear fraction is documented (Metzen et al 2003). Hence, FIH is able to 
disrupt HIF-1α transactivation domains in both nuclear and cytoplasmic compartments.  
In regards to post-translational regulation, HIF-1α protein levels are maintained low by prolyl 
hydroxylases (PHDs), more so by PHD2 in comparison to PHD3 and PHD1 (Huang et al 2002). PHD2 is 
primarily located in the cytoplasm but also shuttles between the cytoplasm and the nuclear 
compartment, thus regulating HIF-1α in both compartments, suggesting HIF-1α may still be degraded 
in the nucleus by PHD2 unless HIF-1α is stabilized. In addition to sub-cellular distribution, PHDs also 
differ in their tissue distribution which may enable a graded or tissue-specific response to hypoxia, 
thereby promoting the O2-dependent degradation of HIF-1α (Baek et al 2005).  
The name ‘hypoxia inducible factor’ sometimes seems at odds for studies involving the use of 
physiologically higher than normal oxygen levels (hyperoxia). This conundrum has long been 
addressed by the understanding that HIF-1 is also stimulated by oxygen independent mechanisms 
including ROS (Haddad et al 2001 and 2002), growth factors via PI3K, serine/threonine kinase AKT 
(protein kinase B), and FKBP-rapamycin associated protein (FRAP) (Zhong et al 1998). The 
PI3K/AKT/mTOR pathways play important roles in the regulation of angiogenesis in normal and 
cancerous tissues as well as in endothelial cells, thus linking HIF-1α with regulation of angiogenesis in 
endothelial cells (Karar and Maity 2011).  
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HIF-1αexpressions in hyperbaric oxygen (HBO) are regulated by a PHD-VHL independent, HSP70, or 
RAC1 mediated mechanisms (Catrina et al 2008). Physiological activation of HIF-1α is observed 
during embryogenesis and in wound-healing processes. However, HIF-1α activation in cancer is 
associated with malignancy and poor prognosis.  
There are more than 100 HIF-1 downstream target genes. HIF-1 regulates the expressions of these 
genes by binding to a 50 base pair (bp) cis-acting HIF-1 response element (HRE) located in their 
enhancer and promoter regions (Semenza et al 1991). The table below (table 1.3) adapted from Ke 
and Costa (2006) outlines some relevant HIF-1 target genes. HIF-1 activity increases virtually all 
glycolytic enzymes and glucose transporters. Several of these intermediate if not all e.g. hexokinase 
and the GAPDH for instance are implicated in the four biochemical pathways leading to diabetic 
complications (Brownlee 2005). Consequently, HIF-1 signalling is implicated in high glucose-induced 
blood-retinal barrier breakdown (Yan et al 2012). In DR, hypoxia and over-expression of VEGF 
precipitates vessel-overgrowth and blood-retinal barrier breakdown resulting in vision loss. This 
posits the indirect role of HIF-1 signalling mediated VEGF accumulation in DR. Accordingly, activation 
of PHD2 prevented high glucose (30mM)-induced BRB breakdown in human retinal microvascular 
endothelial cells (HRMECs) and in retina of STZ-induced DR rats via increased PHD2-mediated HIF-1α 
degradation and consequently, the downregulation of HIF-1α-VEGF signalling pathway (Liang 2015). 
This aspect highlights the likelihood for a HIF-1 targeted therapy in the treatment of BRB in DR.  
HIF-1 regulates erythropoiesis and iron metabolism via its regulation of the erythropoietin (EPO) 
gene required for the formation of blood cells and HIF-1 was first discovered by the identification of 
HREs in the enhancer region of EPO (Goldberg et al 1988, Semenza et al 1991). As a result, HIF-1 
regulates not only vascular integrity but also vascular function since HIF-1 acts in concert with 
hypoxia to stimulate EPO (Semenza et al 1991).  
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Table 1.3 HIF-1 target genes. Examples of relevant target genes regulated by HIF-1 and the 
references (Adapted from Ke and Costa 2006) 
 
 
 
 
 
 
 
 
 
 
  
45 
 
1.5.3.1 Vascular endothelial growth factor 
The vascular endothelial growth factor (VEGF) is a diffusible endothelial cell-specific mitogen that 
potently stimulates angiogenesis, vasodilatation, and microvascular hyperpermeability (Hood et al 
1998). VEGF is a 46 KD dimer of two identical disulphide-linked subunits (Kagsbrun and Soker 1999), 
with at least six isoforms produced through alternative splicing (Ferrara et al 2003). VEGF directly 
participates in angiogenesis by recruiting endothelial cells and endothelial progenitor cells (EPCs) 
into hypoxic and avascular area and stimulating endothelial proliferation (Rafii and Lyden 2003). 
VEGF signalling in endothelial cells is activated after VEGF binds to the receptor via activation of 
phospholipase C-gamma which results in increased activity PKC and entry of intracellular calcium, 
activation of the PI3K-dependent Akt/ protein kinase beta (PKB) and inducing MAPK via Ras/Raf 
stimulation.  
VEGF functions to induce endothelial proliferation, differentiation, permeability, vascular tone, 
sprouting, migration and tube formation (Kroll and Waltenberger 1999, Ferrara et al 2003). It is also 
a potent survival factor for endothelial cells during physiological angiogenesis by inducing the 
expression of anti-apoptotic proteins including B-cell lymphoma 2 (Bcl-2) and Bcl-2 related protein 
(Gerber et al 1998). Hypoxia is not the only mechanism for VEGF upregulation in wound, hyperoxia 
as used in HBO also stimulates VEGF expression (Sheikh et al 2000). In addition, endothelial cytokine 
molecules such as the platelet derived growth factor (PDGF), epidermal growth factor (EGF), basic 
fibroblast growth factor (bFGF), and the transforming growth factors (TGF) also induce VEGF 
expression (Ferrara et al 2004). Moreover, VEGF and PECAM-1 are induced in response to 
mechanical stimulus (Fujiwara 2006, Tzima et al 2005) via VEGF receptor-2 (VEGFR-2) (Mahajan et al 
2017).  
Endothelial cells renewal by angiogenesis is dysfunctional in hyperglycaemia and diabetes, possibly 
via VEGF downregulation (Enciso et al 2003). In diabetic wounds, HIF-1α stability is impaired due to 
hyperglycaemia with very low levels of HIF-1 activity in ulcerated diabetic foot biopsies leading to 
VEGF downregulation, decreased angiogenesis and impaired wound healing (Catrina et al 2004, 
Fadini et al 2006, and Gao et al 2006). But HIF-1α stabilization reverses diabetic wound impairment 
possibly via HIF-1 induced VEGF upregulation (Botusan et al 2008). VEGF causes increased 
paracellular permeability in endothelial cells through the formation of intercellular gaps, vesico-
vascular organelles, vacuoles and fenestration (Bates et al 2002). In addition, VEGF exerts potent 
vasodilatation effects via induction of the endothelial nitric oxide synthase (eNOS), thereby 
increasing NO (Kroll and Waltenberger 1999).  
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Over-expression of VEGF is associated with uncontrolled signalling of cytokine growth molecules 
such as bFGF, PDGF, TGFβ in the diabetic endothelium which drives vascular complications (Mackay 
2001, Jackson et al 1997, Naldini et al 2003, Carmeliet 2000). This presents an aspect of VEGF in 
diabetes that is not desirable as in DR. Animal studies and observations in human patients provide 
convincing evidence of the role of VEGF in the development and progression of DR via several of 
these mechanisms involving cytokine growth factor molecules (Keck et al 1989, Hammes et al 2011, 
Mackay 2001, Jackson et al 1997, Naldini et al 2003, Carmeliet 2000). Accordingly, ocular anti- VEGF 
therapy represents one of the most significant advances in DR (Cheung et al 2014).  
 
 
1.6 Endothelial cell models 
 
1.6.1 Human dermal microvascular endothelial cells 
(HDMEC) 
Endothelial cells (ECs) form an interface separating circulating lymph or blood in the vessel from the 
rest of the vessel wall. Blood and lymphatic endothelium have cell‐cell contact at the capillary level, 
thus ECs express common lineage markers such as PECAM-1 (Podgrabinska et al 2002, Robichaux et 
al 2010). However, lymphatic endothelial cells (LECs) which originate from venous endothelial cells 
express lymphatic specific markers such as lymphatic vessel endothelial hyaluronan receptor 1 
(Lyve1), prospero homeobox 1 (Prox1), high levels of Neuropilin2 (Nrp2), VEGF receptor 3 (VEGFR3) 
and podoplanin, whilst blood endothelial cells (BECs) express blood lineage markers such as laminin 
and cluster of differentiation 34 (CD34). In mouse embryonic stage (E9.0 upwards), some venous ECs 
in the paired cardinal vein initiate Lyve1 and SRY-Box 18 (Sox18) expression culminating 
subsequently in the upregulation of Prox1 within a subset of venous ECs via SRY-Box 1 (Sox1) and 
COUP transcription factor 2 (Coup-TFII) activity. Prox1 positive cells migrate out of the cardinal vein 
to form the primary lymph sacs. Upon the appearance of LECs, the expression of VEGFR3 (the main 
growth factor receptor on LECs) thereafter is restricted to lymphatic vessels, and prior blood vascular 
makers such as CD34 and laminin on these progenitors decreases (reviewed in Neufeld et al 2014). 
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The constitutive phenotype of endothelial cells (ECs) is unstable and their behaviour change rapidly 
once explanted in-vitro. As a result, there is no resting endothelial cell model that perfectly replicates 
typical in-vivo endothelial behaviour (Grant et al 1989). For instance, in static in-vitro culture, ECs 
exhibit a non-aligned polygonal cobblestone appearance which is different from their in-vivo 
alignment with flow in vessels (Phillips et al 1988, Malek and Izumo 1996, Chung et al 2000, Leung et 
al 2002, and Potter et al 2011). Structurally, lymphatic capillaries are larger than the blood 
capillaries; they have an irregular or collapsed lumen with no red blood cells, a discontinuous basal 
lamina, overlapping intercellular junctional complexes and anchoring filaments that connect the 
lymphatic endothelial cells to the extracellular matrix (Witte et al 2001). In addition, lymphatic 
vessels lack pericytes coverage and hence may not play a role in hyperglycaemia induced pericytes 
loss in retinal capillaries in comparison to blood endothelial cells (Fong et al 2004, Gabbay 1975 and 
2004). The pro-inflammatory cytokine, IL-6 is expressed in all vascular endothelium, but lymphatic 
endothelium are more primed for IL-6 expression necessary for immune surveillance, antigen 
presentation and initiation of adaptive responses  in comparison to blood endothelial cells (Witte et 
al 2001, Förster et al 2008, Pflicke and Sixt 2009, Girard 2012, Ataie-Kachoie et al 2016). Interleukin 6 
is described as a lymphangiogenic inflammatory cytokine (McKimmie et al 2013). In-vitro observation 
also supports this view because the expression and effect of IL-6 in lymphatic cell lines such as the 
human dermal lymphatic endothelial cell (HDLECs) has been documented to be significantly higher 
versus blood endothelial cells (BECs) (Sato et al 2016). 
Ironically, a lot of the studies in vascular biology have used the umbilical endothelial cells (HUVECs) 
which have provided phenomenal insights into vascular biology, but they are derived from a type of 
vessel that is rarely affected by common human vascular disorders including diabetes (reviewed in 
Cines et al 1998). In-vivo, it is likely that EC heterogeneity may contribute to adaptive processes as 
well as the development of disorders restricted to specific vascular beds. Therefore, cell models that 
are more akin to in-vivo endothelial behaviour from vessel types related to what is being studied are 
advantageous (Oberringer et al 2007). Endothelial cells (ECs) of different lineage differ in some 
aspects of their function, gene expression profiles, markers and phenotypic characteristics 
(Podgrabinska et al 2002, Petrova et al 2002). 
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Primary human dermal microvascular endothelial cells (HDMECs), which are composed of 83% 
human dermal lymphatic endothelial cells (HDLECs) and 17% blood lineage (BECs) endothelial cell 
therefore represent a model of the microvascular bed that prototypes lymphatic and blood 
endothelial lineage characteristics (Oberringer et al 2007). Several targets; HIF-1, VEGF and PECAM-1 
(Podgrabinska et al 2002), inflammatory markers; NFᴋB (Hauser et al 2017), IL-6 (Sato et al 2016, 
Ataie-Kachoie et al 2016), nrf2 and HO-1 (Loboda et al 2016) are expressed by HDMEC. In addition, 
endothelial cells such as HDMEC do not inter-convert so they are a good model to understand how 
endothelial cells of different vascular beds respond, which may give information that is akin to that 
of blood and lymphatic endothelium cell‐cell contact (junctions) at the capillary level (Kriehuber et al 
2001, Mäkinen et al 2001, Robichaux et al 2010). 
Normal wound healing represents an ideal process to study regeneration whereby there is interplay 
of endothelial cells, fibroblasts, epithelial cells, myocytes, immunocompetent cells and stem cells, 
however wound biopsies or experimentation with a diseased human eye are difficult to acquire, if 
not impossible since one cannot remove tissue/retina required for the healing/sight itself (reviewed 
in Oberringer et al 2007). Although, interactions between different cell types as obtainable with 
biopsies are absent with single cell model, cell cultures such as HDMECs can be used to mimic wound 
trauma and cellular responses (Amadeu et al 2003). Furthermore, owing to their native in-vivo 
location in the endothelium, ECs such as HDMEC are adapted to respond to oxygen tension and 
pressure. Moreover, HDMEC being of microvascular lineage may display easily some of the 
glucotoxicity effect since high glucose is known to be injurious to endothelial cells of microvascular 
beds (Brownlee et al 2005). Consequently, HDMECs are good models to study EC response to glucose 
concentration, oxygen and pressure levels.  
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1.6.2 Porcine retinal explants 
Despite the several advantages of using single cell culture and in particular HDMECs as outlined 
above, single cell systems do not allow the analysis of intercellular interactions (Oberringer et al 
2007). Although, human studies are useful for generating data in regards to development of DR, they 
are not adaptable for the elucidation of mechanistic details due to several limitations, e.g. 
complexity and ethical issues (Jo et al 2013, Lai and Lo 2013). Moreover, in-vivo animal studies are 
limited by high costs and the need for ethical approval (Jo et al 2013, Lai and Lo 2013). More so, 
metabolic homeostasis induced upon the initiation of systemic diabetes in in-vivo diabetic models 
can confound interpretation of results (Matteucci et al 2015, Costa and Andrade 2015). Thus, ex 
vivo/in-vitro study models are needed for examining endothelial response in the retina in order to 
further appreciate molecular mechanisms in DR (Jo et al 2013, Lai and Lo 2013). 
Organotypic cultures of explanted retinal tissue preserves whole retina architecture and vessel 
networks (Matteucci et al 2015, Costa and Andrade 2015). Hence, a better picture of endothelial 
cells is gained when endothelial cells are studied in situ versus when explanted (Grant et al 1989). 
Therefore, explanted retinas give an added advantage for native endothelial cell examination in the 
context of relevant cell-cell interactions with resident cell types such as neurons and glial cells 
(Matteucci et al 2015, Costa and Andrade 2015). Also, because retinal vasculature is of microvascular 
bed, the endothelial response examined in this context gives relevant insight into endothelial 
characteristic or dysfunctions in retinal microvascular associated complications especially when 
examined in the relevant context of high glucose.  
Retinal explants can be maintained in-vitro without the need for tissue slicing. Whole intact retina 
preserves retinal architecture and most intraretinal connections, thereby facilitating the study of 
generalizable biological processes as well as those that are retinal-specific (Matteucci et al 2015). 
However, upon sacrifice, there is separation of the ocular bulb from the main retinal blood vessels 
and the optic nerve resulting in a lack of circulation and innervations (Ferrer-Martın et al 2014), 
which leads to early demise of the photoreceptors and physiological thinning of the ganglion cell 
layer (GCL) (Gancharova et al 2013, Thangaraj et al 2011). The porcine retina bears close 
resemblance in size, basic retinal structure and vasculature to that of the human eye, with some 
differences noted (Sanchez et al 2011, Lai and Lo 2013). Retinal explant culture began in the mid-
twentieth century with the early work by Tansley (1933), Ames and Hastings (1956), and several 
workers have since utilised organotypic retinal explant to examine retinal development, central 
nervous system regeneration, cell death and neuroprotection, electrophysiological activity, and 
genetic modification (reviewed in Bull et al 2011).  
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Mechanistic and cell-specific studies have also been carried out (Caffe et al 1989 and2001, Rzeczinski 
et al 2006, Gaddini et al 2009, Thangaraj et al 2011, reviewed in Matteucci et al 2015) including 
endothelial cell response in retinal angiogenesis (Knott et al 1999). The roles of high glucose on the 
retina have also been examined. Accruing results from different studies provide evidence of the 
susceptibility of retinal explants to extracellular high glucose in culture (He et al 2013, Matteucci 
2015). In one study, a time-dependent decrease in HO-1 expression in retinal explants was seen in 
response to high glucose which showed that hyperglycaemia causes reduction in antioxidant 
capacity in a time-dependent manner (He et al 2013). In addition, retinal photoreceptors reactivity to 
high glucose in diabetic animals has been documented (Du et al 2013). In ns2Akitamouse model of 
retinal complications, photoreceptor death was found to precede amacrine and ganglion cell death 
(Hombrebueno et al 2014). These studies demonstrated the effects of high glucose on the retina and 
retinal cells but a precise time-course of high glucose induced retinal cell death/deregulation has not 
yet been fully characterised (Matteucci et al 2015). 
Explants (vessels) are anchorage dependent (Barr-Nea and Barishak 1970, Caffe et al 1989, Discher et 
al 2005, Gaddini et al 2009, Kato et al 1983, Caffe et al 2001). Consequently, several methods of 
culture of explanted retinas have been developed in order to address this critical requirement for 
anchorage. Provision of substrates on which retinal tissues are placed for support have been used  as 
well as three dimensional (3D) culture of explanted retina (Barr-Nea and Barishak 1970, Caffe et al 
1989, Gaddini et al 2009, Kato et al 1983, Caffe et al 2001). Three dimensional (3D) cultures are more 
native to in-vivo milieu in comparison to two-dimensional (2D) cultures for many tissue and cell-
types (Tibbitt and Anseth 2009).  
Extra cellular matrix (ECM) proteins are molecules that present physical sites for cellular attachment 
and mediate key processes such as migration, proliferation, adhesion, differentiation and cell death 
(Tibbitt and Anseth 2009, Stendahl et al 2009). In addition, they modulate the binding and storage of 
growth factors, cytokines and soluble signalling molecules, thus regulating cell signalling.  Moreover, 
they provide biomechanical interactions that are critical to cell development and differentiation 
(Stendahl et al 2009). Fundamentally, ECMs provide anchorage to retinal cells during development 
(Galli-Resta et al 2008). Simple natural hydrogel (e.g. agarose) are inert and when incorporated with 
ECM protein such as collagen, mimics native ECM (Lake et al 2011). Complex matrices such as 
matrigel with several ECM protein mixtures can confound conclusions with experiments, although 
matrigel has a pivotal place in some studies such as in human embryonic stem cell studies (Hughes et 
al 2010). Here, explanted retinas from the porcine eye were cultured within biologically compatible 
and inert agarose (Lake et al 2011) incorporated with collagen type I protein, as a 3D matrix and used 
to study endothelial cells responses in depth in the context of cellular-interactions.  
  
51 
 
1.7 Hyperbaric oxygen 
 
The air we breathe contains 21% oxygen, 78% nitrogen, with the remaining 1% being contributed by 
the noble gases and carbon dioxide at normal seal level barometric pressure of 1 atmosphere of 
pressure absolute (ATA) which corresponds to 760 mm of mercury (760 mmHg). Under these 
conditions, the partial pressure of oxygen (Pao2) is 100 mmHg which supplies about 0.3 ml of oxygen 
per 100 ml of blood including haemoglobin bound oxygen (HBOT Trust 2018). Normally, the 
concentration of oxygen in the air we breathe in is sufficient for normal body metabolism and repair 
in tissue injury or illness (HBOT Trust 2018). Owing to their position within blood vessels, endothelial 
cells are exposed to arterial oxygen content of 75–100 mmHg (10–14%).  
Tissue oxygen (11%-1%) levels are lower in comparison to blood levels and descend to about 4% in 
the mitochondrion (Wangsa-Wirawan and Linsenmeier 2003, Yu et al 2001, and Carreau et al 2011). 
In retinal microvasculature, the oxygen level in inner segments of photoreceptors (mitochondria-
rich) after dark adaptation is between 0 and 5 mmHg (0.7%) increasing up to 20 mmHg after light 
adaptation and reaching up to 20 mmHg in the inner retina.  Hence, normal oxygen levels (normoxia) 
depend on the area of retina and dark/ light state (Wangsa-Wirawan and Linsenmeier 2003). 
Sustained local hypoxia (1.1%- 4.2% oxygen) in wound vicinity due to vascular compromise as well as 
hyperglycaemia-induced tissue pseudohypoxia is present in diabetes and these are associated with 
impaired wound healing. On the other hand, hypoxia drives vessel over-growth and uncontrolled 
angiogenesis which leads to vision loss in the retina (Williamson et al 1993, Catrina et al 2004). Low 
oxygen tension in the diabetic wound impairs collagen synthesis, epithelization, and leukocyte 
function which require an optimal oxygen range of 45 to 80 mm Hg (9.5% - 17%) to function 
(Knighton et al 1984, Naghibi et al 1987, Alien et al 1997 and Zykova et al 2000). In essence, tissue 
and cellular oxygen needs and oxygen availability is dependent upon tissue/cell type and how 
healthy the tissue/cell is. 
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Physiologically relevant increase in Pao2is attained at twice atmospheric pressure (2 ATA) breathing 
of 100% oxygen as this increases blood oxygen content to 3 ml oxygen in 100ml of blood (HBOT Trust 
2018). This means the gradient of transport of free oxygen in blood into tissue increases by 10-fold 
(HBOT Trust 2018). Essentially oxygen dissolution increases with pressures higher than the stipulated 
2 ATA. For instance, plasma oxygen concentrations of up to 1804 mmHg was achieved in with 
barometric pressures of 2.5 ATA with 95% oxygen (O2)(Hodges et al 2003). In clinical settings, 
hyperoxia is achieved by inhaling high levels of oxygen as in neonatal intensive care unit (Carreau et 
al 2011). Increased oxygen delivery to the tissue also forms the basis for hyperbaric oxygenation 
therapy (HBOT) for recalcitrant wound healing in diabetes and other indications (Godman et al 2010, 
Löndahl et al 2013, and Akgu¨et al 2014).  
 
1.7.1 Hyperbaric oxygen therapy 
Hyperbaric oxygen therapy (HBOT) is an adjunct treatment modality involving  the use of hyperbaric 
oxygen (HBO) which entails breathing in ≥ 95% oxygen at a pressure greater than the atmospheric 
pressure absolute (1 ATA) at sea level to provide sufficient tissue/plasma oxygenation (Godman et al 
2010, Löndahl et al 2013, Akgu¨et al 2014, HBOT Trust 2018). In the clinics, the treatment/session is 
administered in three phases; compression, treatment and decompression and the total duration is 
60-90 mins with sessions repeated. The amount of oxygen dissolved in the plasma is directly related 
to the applied pressure although there are limits for treatments in human patients (~ 2.0 -2.5 ATA) 
depending on local prescribing guidelines (HBOT Trust 2018). The Scottish clinical protocol for HBOT 
entails the use of three cycles of 30 mins exposure to pressures not exceeding 3 ATA with ≥95% 
medical gas (oxygen) with 5 mins air-breathing intervals for a total of up to 2 hours per session, with 
repeated sessions (Ritchie et al 2008).  
Compressed air has been used medically with variable success and little understanding of its 
mechanistic details. HBO was used clinically as early as mid-1800s. But, it was not until 1930s that it 
began to be safely used for the treatment of decompression illness in deep-sea divers. Clinical trials 
in the 1950s uncovered a number of beneficial outcomes from exposure to HBO, and HBO as a 
therapy in wound healing was first administered following the ‘chance’ discovery that coal miners 
poisoned with carbon monoxide healed faster when exposed to HBO. The Undersea and Hyperbaric 
Medical Society legislates and reviews clinical indications for HBOT through its committee on 
Hyperbaric Oxygen Therapy. HBO therapy is currently indicated for gas/air embolism, decompression 
illness and carbon monoxide poisoning. It is also used for necrotizing soft tissue infection, and non-
healing wounds, clostridial myonecrosis, sports injury and autism (HBOT Trust 2018).  
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HBO is indicated as an adjunct treatment for chronic recalcitrant ulcers for patients with diabetes. 
There are several randomised clinical trials (RCTs) reporting on HBO benefit in recalcitrant ulcer 
healing and reduction in incidences of amputations (Doctor et al 1992, Duzgun et al 2008). A meta-
analysis data associated HBO with improved healing and reduced risk of major amputations in 
patients with diabetic foot ulcers (DFUs) (Liu et al 2013). But the efficacy and safety profile of HBO in 
patients with diabetic foot ulcer has been obscured by controversy, mainly due to absence of clear 
mechanistic details (Zhao et al 2017). But based on the results of studies so far, this controversy has 
not proven true. Nine randomised clinical trials in 2017 involving 526 patients found significant 
increase in the incidence of healed ulcers (risk ratio [RR] = 2.22; P = 0.32), decrease in minor 
amputations (RR = 0.95; P = 0.91), decrease in major amputations (RR = 0.47; P = 0.14), and decrease 
in adverse events (RR = 1.00; P = 0.99) with HBO in comparison to standard therapy (ST) groups 
(Zhao et al 2017).  
In addition, HBO was associated with a greater reduction in the ulcer wound area versus ST 
(standard mean difference = 1.12; P = 0.04), demonstrating that HBO is a clinically meaningful 
adjuvant therapy for patients with diabetic foot ulcer (Zhao et al 2017). A Cochrane review found 
that HBO improved the rate of ulcer healing (Kranke et al 2015), which was consistent with the 
finding of Zhao et al 2017. There are a small number of studies that did not unravel HBO associated 
benefits; Kalani et al 2002, and Londahl et al 2010. As a caution, the population size for these studies 
were small and limiting, and larger population studies may be required to increase the statistical 
power and significance of these studies (Zhao et al 2017). In addition, it is also likely some patient 
factors such as poor glycemic control or immunological status may have contributed to the lack of 
response(s) in these studies. HBO is reported to decrease blood glucose levels post treatment 
(Karadurmus et al 2010) but it is pertinent to understand what effect(s) a patient’s glycemic control 
might have on the outcome of HBO therapy since poor glycemic control is associated with increased 
endothelial dysfunction; poor wound prognosis, heightened oxidative stress and inflammatory 
reactivity, with increased incidence of infection in wounds. In addition, it is important to understand 
the likely effects of poor glycemic status on outcomes in other indications for which HBO is utilised. 
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HBO effect is due to the compounding effects of physiological and biochemical changes resulting 
from hyperoxia and mechanisms due to gas laws (Akgu¨et al 2014). In converse to HBO, breathing in 
≥ 95 % of oxygen (O2) at 1 ATA (hyperoxia) or breathing atmospheric air at greater than 1 ATA 
(hyperbaric pressure) are not considered HBO and the current question is just how different/alike 
each of these components are to HBO. In-vivo, breathing in O2 at > 1 ATA is associated with 
increased production of ROS, a collective term for O2-derived free radicals as well as O2-derived non-
radical species such as hydrogen peroxide and hypochlorous acid (reviewed in Thom 2011). ROS and 
reactive nitrogen species (RNS) facilitate transduction cascades are possible molecular basis of HBO 
(reviewed in Thom 2011).HBO improves tissue oxygenation and many of its beneficial effects such as 
reduction of regional and local ischaemia can be linked to this, although there is variability in patient 
outcomes post HBO (Unfirer et al 2008, CADTH 2005, Fife et al 2007, and Roeckl-Wiedmann et al 
2005).  
In patients, HBO stimulates oxygen-dependent wound processes such as collagen synthesis, 
epithelization, and leukocyte mediated wound repair, release of bone marrow stem cells, and 
enhancement of host antimicrobial responses (Knighton et al 1984, Naghibi et al 1987, Alien et al 
1997 and Zykova et al 2000, Kalani et al 2002, and Sheehan et al 2003). Increased insulin sensitivity 
in HBO treated patients equivalent to that observed following moderate weight loss has also been 
reported (Wilkinson et al 2012). However, the possible use of HBO in retinal complication is still 
novel owing to a theoretical risk of a possible HBO-induced retinal neovascularisation, although 
accruing evidence appears to suggest otherwise. HBO-associated amelioration of retinal and macular 
occlusion has been reported (Oguz and Sobaci 2008). In addition, exposure of diabetic animal models 
to HBO was associated with amelioration of blood-retinal barrier breakdown (Chang et al 2006). 
Furthermore central retinal artery occlusion (CRAO) in diabetic patients was reportedly enhanced 
following HBO (Soares et al 2017).  
The role of HBO in diabetic foot ulcers is better defined in comparison to its role in DR. Chronic 
wounds are associated with low oxygen tensions and it is likely that HBO enhanced oxygen tension in 
wound tissue is a key mechanism for beneficial outcome (Doctor et al 1992, Duzgun et al 2008, 
Kranke et al 2015, Liu et al 2013, and Zhao et al 2017). Some of the mechanisms associated with HBO 
benefit in wound healing include; promotion of wound closure and increase in the number of 
endothelial progenitor cells (Gallagher et al 2006), increased cell proliferation (Boykin and Baylis 
2007), improved insulin sensitivity at wound site (Wilkinson et al 2012), activation of cellular 
proliferation pathways (Niu et al 2013), enhancement of neutrophil activity and antibiotic 
effectiveness, fibroblast activity, collagen synthesis and angiogenesis (Akgu¨et al 2014), and the 
stabilization of HIF-1α protein (Sunkari et al 2015).  
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Increased stabilization of HIF-1α leading to HIF-1 activation and signalling post HBO is linked with 
improved wound healing in diabetic mice via VEGF upregulation (Sunkari et al 2015). Furthermore, 
increased nrf2 activation and induction of nrf2-mediated genes including HO-1 following HBO has 
been reported (Godman et al 2010). In contrast, hyperoxia did not elicit a similar effect in the same 
samples, although hyperoxia is a known activator of the nrf2 pathway via ROS activation (Bellezza et 
al 2010), which may indicate that HBO and hyperoxia have different outcomes in regard to nrf2 
accumulation and stabilisation. Enhanced plasma antioxidant defence is evident post HBO and may 
contribute to wound healing resolution. In addition, angiogenesis and normal vascular tone may be 
restored via increased HBO-associated increase in NO, VEGF, IL-6 and decrease in ET-1 (Sureda et al 
2016). 
The role of the immune response of the individual undergoing HBO is important. 
Immunosuppression via downregulation of pro-inflammatory cytokines such IL-6, IL-1 and TNF-alpha 
post HBO have been reported (Benson et al 2003, Al-Waili 2006), while increased plasma IL-6 post 
HBO has also been reported (Sureda et al 2016). In contrast, hyperoxia was associated with 
enhancement of pro-inflammatory cytokine transcription and translation (Jensen et al 1992, Johnson 
et al 1997, Weisz et al 1997).  
Taken together, HBO continues to demonstrate positive benefit in several clinical and experimental 
settings. What is still needed is continued elucidation of its exact mechanism(s). An understanding of 
endothelial response to HBO is important in seeking to understand how HBO may mediate its effect. 
The lumina of all blood vessels are lined with endothelial cells (ECs), hence they play crucial roles in 
haemostasis, vascular tone, inflammation, and angiogenesis and they are central to the 
consideration of a response to HBO (Salgado et al 1994, Tjarnstrom et al 1999). EC morphology is 
closely associated with function and physiology and changes in EC morphology is linked with cellular 
events. The role of HBO on endothelial size and shape is not well studied yet, although the effects of 
hyperoxia on pulmonary endothelial cells and shear stress with elevated pressure have been the 
subject of several studies. 
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In–vivo ECs that populate the luminal surface of blood vessels in areas of high laminar shear stress 
are elongated and aligned while those in low shear stress areas are randomly orientated (Chung et al 
2000, Potter et al 2011). In vivo, ECs of all origin change their shape and size (contraction and 
retraction) leading to cell size decrease in response to shear stress (Barbee et al 1994, Malek and 
Izumo 1996, Chung et al 2000). Although ECs in static culture are polygonal, they become uniformly 
aligned when exposed to increased flow and shear stress (Malek and Izumo 1996). Increase in intra-
cellular calcium via tyrosine kinase activity and actin microtubule rearrangement are some of the 
mechanisms leading to ECs size and shape change in response to flow/mechanical stress (Malek and 
Izumo 1996). In-vivo, elevated pressure as relevant in HBO may not equate to increased shear stress 
from modified flow. However, hyperbaric conditions can increase perfusion and so this might have a 
knock on effect on shear stress.  
The effect of hyperoxia on pulmonary EC morphology has been documented. In pulmonary vascular 
beds for example, and in-vitro with cultured endothelial cells, hyperoxia is associated with enlarged 
EC sizes and alterations in morphology. It is notable that most of the works of hyperoxia-associated 
endothelial cell enlargement were carried out in endothelial cells of pulmonary origin. The 
mechanism includes hyperoxia mediated induction of ROS and oxidative stress in cultured 
endothelial which mediates increased endothelial [Ca2+] levels and actin cytoskeleton 
rearrangements. Consequently, hyperoxia induced ROS mediated actin rearrangement causes EC size 
enlargement (Bowden and Adamson 1974, Crapo et al 1980, Phillips et al 1988, Brueckl et al 2006, 
Roan et al 2012, and Attaye et al 2017). In the alveolar, hyperoxia is associated with increased ROS 
production leading to activated alveolar capillary endothelium which is characterised by increased 
adhesiveness causing accumulation of neutrophils. In addition, increased levels of ROS are linked 
with increased vascular permeability, coagulation, and collagen deposition and irreversible changes 
occurring within the alveolar space. Hyperoxia-associated vasoconstrictive effect on vascular 
endothelium is reported. In renal and mesenteric microvascular beds, hyperoxia is associated with 
decrease in EC size as a result of hyperoxia mediated decrease in endothelial nitric oxide (NO) and 
increased vasoconstrictors such as cyclooxygenase (Attaye et al 2017). Hyperoxia-induced 
vasoconstriction in human retina is reported to occur via hyperoxia-induced ET-1 upregulation 
(Dallinger et al 2000). Moreover, hyperoxia has been associated with cerebral vasoconstriction (Floyd 
et al 2003). 
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Increased EC paracellular permeability and breakdown of the blood-retinal barrier in DR are some of 
the in-vivo effects of high glucose toxicity on endothelial cells (Gillies et al 1997). Diabetic mouse 
models such as db/db mice showed altered endothelial cell morphology as a result of sustained 
exposure to high glucose (> 30 mM) (Peng et al 2016). This observation has also been documented in 
cultured endothelial cells, where high glucose was associated with whole EC phenotypic change in a 
glucose dependent mechanism involving PKCα activation (Hempel et al 1997).  
The endothelium releases ROS and vasoactive molecules such Ang II and ET-1 in response to 
mechanical stimuli (shear stress/stretch) (De Keulenaer et al 1998, Schramm et al 2012). 
Permeability factors such as the endothelium derived contracting factors such as ET-1 and Ang II and 
inflammatory cytokines induce endothelial size change (contraction and retraction, also termed 
‘rounding’), and this phenotype of rounding in cultured HUVEC cells was associated with increased 
endothelial junction permeability which enhanced trans-endothelial passage (Sandoval et al 2001, 
Leung et al 2002).  
The effects of HBO or its single components on EC metabolic activity appear to be divergent. A dose-
dependent hyperoxia mediated decrease in cell viability and proliferation was documented in human 
dermal microvascular endothelial cell (HMVEC) (Attaye et al 2017). Similarly, a hyperoxia associated 
decline in liver sinusoidal endothelial cells (LSECs) metabolic activity in comparison to normoxia is 
documented (Martinez et al 2008). HBO on the other hand was associated with a protective and 
stimulatory effect on metabolic activity using immortalized human microvascular endothelial cell 
Line-1 (HMEC-1) after challenge with HBO and an organic peroxide, t-butyl hydroperoxide (t-butyl 
OOH) (Godman et al 2010). The role(s) of hyperbaric pressure on endothelial cell metabolic activity is 
unclear and there have not been many reported studies on its role.  
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1.7.2 Limitations of HBOT 
At present there is no consistent clinical protocol for using HBO as a therapy (HBOT), with pressure 
and oxygen dose(s) and duration being largely variable (Ritchie et al 2008). Thus, many of the 
reported side effects of HBO, some of which are life threatening are often dose-related. Pulmonary 
complications such as pulmonary embolism and pneumothorax although rare (1:50,000-60,000) are 
the most severe potential side effect of HBO treatment (Löndahl et al 2013). In addition, oxygen 
toxicity such as seizures which are self-limiting with an end-treatment resolution has been reported 
albeit rare, with an incidence of 1 in every 10,000 treatment cases (Löndahl et al 2013). Reversible 
myopia and cataract are more common (Löndahl et al 2013) and HBOT poses a risk for 
hypoglycaemic episodes for patient managed on insulin (Löndahl et al 2013). Incidentally increased 
insulin sensitivity following HBO exposure is reported (Wilkinson et la 2012). Due to the highly 
pressurized environment, there is a risk of severe middle ear trauma which can lead to a non-
reversible loss in hearing in patient. Environmental hazards such as fire in the chamber are a 
potential risk with the presence of high oxygen levels in the pressurised environment and should be 
minimized by strict adherence to protocols. These complexities justify the need for more research to 
understand the pivotal mechanisms in HBO, in order to develop a more evidence-based practice 
especially for application in newer indications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
59 
 
1.8 Proposed study mechanism 
 
 
Figure 1.8 Proposed study mechanism(s)   
This schematic diagram illustrates key concepts in this study. The effects of changing glucose concentration, oxygen 
tension, pressure levels (i.e. treatments) on HDMECs targets; size change, and effects on transcription factors (decrease or 
increase) responsible for redox (Nrf2), inflammatory (NFĸB)and oxygen-sensing response (HIF1-α) are examined. In 
addition, targets of these pathways; IL-6 (at mRNA level) (NFĸB), HO-1 (Nrf2), and VEGF (HIF-1α) are studied and the 
expression of a specific endothelial cell marker, PECAM-1 is utilised for identifying endothelial specific response(s). 
Treatments administered; HBO = hyperbaric oxygen, HYP = hyperoxia, HYB = hyperbaric pressure or controls with or 
without (+/-) HG = high glucose.  
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1.9 Aim and objectives of the study 
This study aims to investigate the mechanisms of hyperbaric oxygen therapy in endothelial cells by 
examining endothelial cell responses to-inflammation, redox and HIF-1α signalling using a primary 
human dermal microvascular endothelial cells and a developed and validated porcine retinal explant 
cultured in three-dimensional matrices in the context of high glucose to simulate endothelial 
response to normal and disease context (diabetes) in HBO. The second overarching aim is to 
decipher what each component of HBO does in relation to pro-inflammation, redox response and 
HIF-1 signalling, in order to understand the mechanism(s) of HBOT more. 
 
 
1.10 Objectives of the study 
1. Develop and validate a retinal explant model of explanted retina from porcine cultured in an 
agarose-collagen bilayer three-dimensional matrix.  
2. Validate a developed HBO unit modelled after a clinical HBO therapy 
3. Determine the effect(s) of hyperbaric oxygen (HBO), hyperoxia (HYP), and hyperbaric 
pressure (HYB) or control condition (controls) in basal glucose or in combination with high 
glucose (HG) on three mechanistic pathways of pro-inflammation (Nuclear Factor kappa B; 
(NFᴋB)), redox (nuclear factor type-2 (Nrf2)), and oxygen signalling (hypoxia inducible factor 
type 1 (HIF-1)) using human dermal microvascular endothelial cells (HDMEC) and retinal 
endothelial cells. 
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Chapter 2.0: Materials and methods 
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2.0 Materials and methods 
 
 
2.1 Materials 
Primary human dermal microvascular endothelial cells (HDMEC), and reagents required for the 
maintenance and propagation of the cells were purchased from PromoCell (PromoCell, UK). Quality 
control tests were carried out by PromoCell prior to supply. Proprietary endothelial growth media 
MV (5.5 mM D-glucose) was used for HDMEC propagation and is outlined in detail in section 2.2.For 
high glucose treatment, HDMEC were exposed to 20 mM of D-glucose by supplementation of growth 
media (5.5 mM glucose) with 14.5 mM D-glucose to give a final concentration of 20 mM D-glucose. 
Retinal tissues used in explant culture were derived from porcine ocular globes kindly donated by a 
local abattoir from animals aged between 18-28 weeks weighing 70-80kg of both sex. Ocular globes 
(N ≥ 10) were transported on ice and were received in the lab for dissection within 1-2 hour of kill. All 
experiments were performed in accordance with UK legislation. Dulbecco’s modified eagle media 
(DMEM); 5.5 mM (low) or 25mM (high) D-glucose (ThermoFisher Scientific) was used for explant 
culture. Detailed methods used and the development of this model are outlined in section 2.3. 
Chemicals and reagents were purchased from a number of different companies and specific 
reference to each company is made the first time that chemical/reagent is used. 
 
 
2.2 Maintenance and propagation of HDMEC 
Cryopreserved proliferating primary HDMEC from an adult donor at Passage two (P2) containing ≥ 
500,000 viable cells in Cryo-SFM serum-free freezing medium transported on dry ice and 
subsequently stored in liquid nitrogen tanks were obtained from PromoCell. Cells were aseptically 
thawed at 37oC in a water bath, and transferred to a 25cm2 (T25) culture flask (Nunclon) with 10 ml 
of pre-warmed proprietary (PromoCell) HDMEC growth media composed of: 0.05 ml/ ml foetal calf 
serum, 0.004 ml/ ml endothelial cell growth supplement, 10 ng/ ml recombinant human epidermal 
growth factor, 90 µg/ ml heparin and 1 µg/ ml hydrocortisone. Cells were incubated overnight in a 
standard 5% CO2 incubator (Hera Cell 150, HeraCeus) for cell attachment.  
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Media was replaced after 16 hours and every two days thereafter. Cells were sub-cultured once they 
reached confluence (see Fig. 2.1) according to protocol (PromoCell). Cells were routinely expanded in 
T75 flasks (75cm2) for sub-culturing or in 24-well plate (1.9cm2) (Nunclon) for treatment at a cell 
density of 10,000-20,000 cells/cm2 as recommended (PromoCell) in pre-warmed growth media 
supplemented with 1% Penstrep (10, 000 U/Ml) (Life Technologies).All live cell-related work was 
aseptically performed in class II laminar flow cell culture cabinet (Aura 2000, HeraCeus). Routinely, 
cells were propagated in HDMEC growth media MV which contains low (5.5mM) of D-glucose which 
is physiological glucose level in-vivo.  
 
 
 
Figure 2. 1 Morphology of human dermal microvascular endothelial cells (HDMEC) 
Selected micrograph shows HDMEC monolayer at passage 5 at 80-90% confluence. HDMEC are characterised by the cobble 
stone appearance. Image was taken at magnification of 10X and scale bar represents 500 µm  
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HDMEC were sub-cultivated using proprietary Detach kit (PromoCell): Hepes BSS, 0.025% 
Trypsin/0.01% EDTA solution and Trypsin Neutralization solution (0.05% trypsin inhibitor/0.1% BSA) 
as recommended. Trypsinization kit was equilibrated to room temperature prior to use. Spent 
HDMEC growth media composed of: 0.05 ml/ ml fetal calf serum, 0.004 ml/ ml endothelial cell 
growth supplement, 10 ng/ ml recombinant human epidermal growth factor, 90 µg/ ml heparin and 
1 µg/ ml hydrocortisone was discarded and HDMEC monolayer rinsed gently with 100 µl Hepes BSS 
solution per cm2 of culture flask surface, and aspirated. HDMEC monolayer were incubated with 100 
µl Trypsin/EDTA solution per cm2 of culture flask for no longer than 10 minutes at room 
temperature, and examined under a light microscope (Leica DMIL) for cell detachment. Remaining 
adherent cells were dislodged by gently tapping the sides of the culture plate.  
Trypsinization was halted with 100µl per cm2 of vessel surface of Trypsin Neutralization solution. Cell 
suspensions were pelleted at 220 xg (Biofuge Primo R, HeraCeus) for 4 mins and supernatant 
discarded. Cell pellet was re-suspended in an appropriate volume of pre-warmed growth media. 
HDMEC were counted (see next paragraph) and seeded in 75cm2 (T75) flasks or in 24-well plates and 
incubated in a humidified 5% CO2 incubator at 37
oC.Cell counts were carried out to ensure accurate 
cell concentration seeding at sub cultivation and cryopreservation. HDMEC suspension in Eppendorf 
tubes were mixed and 20µl of cell suspension pipetted unto a Haemocytometer (Neubeur, Germany) 
filling the chamber completely by means of capillary action. Cells were counted under a light 
microscope with a 100x (10x ocular and 10x objective) magnification. Four sets of 16 squares in a 
Haemocytometer were counted with a handy tally counter applying the same system of count to all 
the 4 sets of count. The average of the total of the 4 sets of counts was taken and cell count was 
determined with the equation below (Equation2.1): 
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The factor 104 is a conversion factor reflecting the volume of the cell suspension present in one set 
of squares (1mm2 area) of the haemocytometer and is used to convert 10-4 ml to 1ml. Volume of one 
large square = 1mm x 0.1mm = 0.1cm x 0.1cm x 0.1cm =    10-4cm3 = 10-4ml. Trypan blue exclusion 
criteria was used to estimate cell viability. Cell suspension was mixed thorough by gentle pipetting 
with 0.4% v/v trypan blue dye at a 1:1 ratio and left to stand for no longer than 2mins to allow the 
dye to penetrate non-viable cells. Non-viable cells retain the blue dye which permeates damaged cell 
membrane, whilst intact membranes in only viable cells will prevent passive diffusion of dye. 
Haemocytometer (Neubeur, Germany) was filled with cell /trypan blue suspension by placing 
approximately 20ul of suspension near the edge of glass cover slip over the chamber and allowed to 
fill the chamber by means of capillary action. Cells were observed under the microscope with a 100x 
magnification (10x ocular and a 10x objective lens). Non-viable cells (which stained blue) were 
counted using the same systems as the live cell count and percentage (%) cell viability was calculated 
with the equation below (Equation2.2): 
 
 
 
 
 
 
 
 
 
 
 
 
 
𝑻𝒐𝒕𝒂𝒍 𝒄𝒆𝒍𝒍 𝒄𝒐𝒖𝒏𝒕
= 𝑨𝒗𝒆𝒓𝒂𝒈𝒆 𝒄𝒆𝒍𝒍 𝒄𝒐𝒖𝒏𝒕 𝒙 𝒅𝒊𝒍𝒖𝒕𝒊𝒐𝒏 𝒇𝒂𝒄𝒕𝒐𝒓 𝒙 𝟏𝟎𝟒 − −
− 𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟐. 𝟏 
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Routinely cells were > 95% viable. For cryopreservation, cells in suspension obtained after 
trypsinization were pelleted by centrifugation at 220 x g for 3 minutes, and the supernatant was 
discarded. Cell pellets were re-suspended in appropriate volume of proprietary cryopreservation 
medium, Cryo-SFM (PromoCell) at a concentration of 0.1 – 1 million cells/ml. Cell suspension was 
transferred to sterile Cryogenic-vials (Nunc, ThermoFisher) and frozen down gradually (-1oC/minute) 
in isopentane kept in a -80oC freezer overnight and subsequently stored long-term in liquid nitrogen 
tanks. 
HDMEC at passages P4-7 were seeded in six-well replicates (sixplicates) per sample in 24 well plates 
at cell concentrations of 35,000-38,000/well in normal HDMEC growth media MV for western blot 
and PCR assays, and for immunocytochemistry (ICC) in duplicates. Cells reached 70% confluence 
after 48 hours. Live cell photomicrographs of HDMEC prior to treatment were acquired at 200X for 
baseline size determination prior to treatment. For Resazurin assay, HDMEC were plated at a density 
of 6 x 103 cells/per well in clear 96-well plates in sixplicates reaching 70% confluence after 48 hours. 
Post treatments, HDMEC were imaged and live micrographs documented. For western blot and PCR 
assays, six identical wells from a 24-well plate were pooled per sample.  
For ICC, HDMEC in duplicates were stained with the relevant antibody per sample. HDMEC were 
exposed to high glucose by supplementing normal HDMEC growth media (containing 5.5 mM D-
glucose) with 14.5 mM D-glucose to give a final concentration of 20 mM glucose (Botusan et al 2008, 
Gadad et al 2013). One molar (1M) stock solutions of D-glucose (Sigma-Aldrich) were made up in 
HDMEC growth media and sterile filtered with 0.45microns syringe filter (Millipore) and stored at 4oC 
until use. Throughout the body of text, wherever reference is made to low (5.5 mM) glucose with 
HDMEC, physiological glucose level is implied. 
 
 
𝑪𝒆𝒍𝒍 𝒗𝒊𝒂𝒃𝒊𝒍𝒊𝒕𝒚 (%)
= 𝑻𝒐𝒕𝒂𝒍 𝒄𝒆𝒍𝒍 𝒄𝒐𝒖𝒏𝒕 ÷ 𝑻𝒐𝒕𝒂𝒍 𝒅𝒆𝒂𝒅 𝒄𝒆𝒍𝒍𝒔 (𝒔𝒕𝒂𝒊𝒏𝒆𝒅)𝒙 𝟏𝟎𝟎
− − − 𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟐. 𝟐. 
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2.3 Retinal explants 
Three dimension (3D) matrices were prepared using equal volumes of melted 1% agarose (BIOLINE) 
and collagen (0.5mg/ml) (Gibco, Life Technology) in low glucose (5.5 mM) Dulbecco’s modified 
essential medium (DMEM) (ThermoFisher Scientific) were mixed at room temperature (RT) to give 
0.5% agarose-collagen (0.25 mg /ml) (AC) co-gel scaffold (matrix) solution subsequently referred to 
as the matrix solution. A volume of 1.8ml of matrix solution was added per well of a 6-well plate, 
allowed to cool and solidify, forming the ‘bed-matrix’. Bed matrices were prepared on the day of 
experiments approximately 120 minutes before use and were kept in an incubator at 37oC (5% CO2, 
95% air) until use. Matrix solution for high glucose treated explants was made using high glucose (4.5 
g/L i.e. 25 mM) DMEM media. Ocular globes were aseptically cleaned of the muscle and fat tissue 
around the eye ball, sterilised in 70% ethanol and rinsed in ice-cold 0.1M phosphate buffered saline 
(PBS). Retinal tissues were extracted from ocular globes as described by Rzeczinski et al (2005) and 
Johnson and Martin (2008).  
Each globe was cut circumferentially at the Ora Serrata (corneo-scleral junction) with the tip of a 
sharp micro scissor, opening the retina into two halves. The anterior chamber made up of the 
cornea, lens and vitreous were removed and discarded. The posterior half with the retina attached 
to the optic nerve was briefly rinsed with sterile PBS to moisten and assist the removal of retinal 
tissues from the retinal epithelial layer (RPE). PBS was removed and the retina was gently scraped off 
the RPE, but left attached at the optic disc. A cut was made from the equator to the optic disc, 
without severing the retina. The optic nerve was pinched with forceps and held over the matrix bed. 
A sharp scissor was used to cut whole retina loose from the base of the optic disc (optic nerve head), 
and the retinal tissue was laid flat on the bed matrix. Retinal tissues were overlaid with cooled matrix 
solution at 37oC and allowed to solidify in a 5% CO2 37
oC incubator forming a sandwich (henceforth 
referred to as explants) (fig 2.2 below). In this orientation, the inner and outer retina is in immediate 
contact with the biomechanical support of the matrices. Explants in duplicates were overlaid with 
pre-warmed serum-free media low (1g/L) (5.5 mM) glucose or high (4.5g/L) (25 mM) glucose DMEM 
media. Explants were incubated briefly at 37oC in 5% CO2 for approximately 30 minutes and exposed 
to treatment as specified in the relevant experiments.  
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Post treatment, samples (HDMEC/explants) were maintained in their respective media and were 
harvested for post-culture assays at 2 h (retinal explants) or 4 h (HDMEC) and 24 h (retinal explants 
and HDMEC). Throughout the body of text, wherever reference is made to low (5.5 mM) glucose 
with explants, physiological glucose level is implied.  
 
 
 
Figure 2. 2 Three-dimension matrix formation 
A schematic diagram of retinal explant model (A), showing retinal tissue sandwiched in bilayer of a matrix composed of bed 
and top matrices, and overlaid with media. Full matrix depth as measured with a meter ruler  is ~ 7mm. Equal amounts of 
scaffold solution (0.5% agarose-collagen (0.25mg/ml) (AC) co-gel was used to make both bed and top matrices, hence each 
matrix is ~ 3.5 mm. B) Overhead micrograph of explant showing retinal tissue sandwiched between layers of agarose-
collagen bi-layer matrices.  
 
 
2.3.1 Methods used to validate retinal explant model 
The sections in 2.3.2 to 2.3.6 are the methods and initial experiments carried out on retinal explants 
for model validation. The results of these validations are reported in chapter 3.0 (validation of 
experimental model) in section 3.3.1. In order to determine the viability of the retinal vessels and the 
integrity of retinal tissues during culture (0 – 24 h), these confirmatory assessments listed below 
were performed.  This included: 
 
a) Determination of the level of oxygen (%) within the matrices at 4 mm depth as an estimation 
for oxygen concentration available to retinal tissues at approximately 4mm depth. 
b) Microscopic observation of explants (tissues and vessels) 
c) Measurement of response of explant vessel to a depolarising agent (potassium chloride, KCl) 
and a receptor agonist (angiotensin II, Ang II). Viability was also examined by the 
incorporation of collagen I from matrix within retinal layers. 
d) Determination of explant structural integrity using haematoxylin and eosin (H and E) 
staining. 
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2.3.2 Measurement of matrix oxygen level 
A Microx TX3 micro (140 µm) fibre optic oxygen (PSt1) meter (PreSens) was used to measure oxygen 
level (% O2 saturation) at 4 mm depth of the matrix at 0.5 h and 24 h.  At this depth, the oxygen 
electrode was beyond 3.5 mm depth, where the retinal tissue was laid but the electrode was not 
placed directly on the tissue. Measurements were taken by holding the electrode static with the 
electrode inserted into the media for 30s for baseline % O2level (controls). The electrode was 
lowered to 4 mm depth with a micromanipulator and measurements taken for 30 s. Because the 
electrode fibre optic fine-tip was easily damaged, only one-time readings were taken as attempts to 
re-insert the electrode to obtain replicates resulted in electrode damage. Measurements were 
carried out on six independent occasions (n = 6).  
 
 
2.3.3 Measurement of a contractile response 
Functional viability of explant vessel was ascertained with contractile response to 80mM of 
potassium chloride (KCl) and 0.5µM of angiotensin II (Ang II) (Ishizaki et al 2009, Kawamura et al 
2004) as recommended. Phosphate buffered saline (PBS) was used as control. Sequential application 
of treatment (PBS/KCl, or PBS/Ang II) on selected vessel was performed in order to reduce variability. 
A 7 mins lag was allowed after each treatment (PBS/KCl/Ang II) to allow adequate permeation of the 
treatments through the matrix to the explant vessels. KCl and Ang II treatment were carried out 
separately with PBS used as control. Once a treatment (e.g. PBS) was completed, equivalent volume 
of the treatment added in was removed and replaced with fresh media containing the next 
treatment (e.g. KCl or Ang II). This ensured minimal disturbance to the video capture. Hence 
contractile responses may also reflect residual effect from a previous treatment. Contractile 
responses were captured with video recording with a light microscope (Leica DM4000B) and an 
integrated camera (Leica DFC300-FX). 
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A total of 24vessels were tested with KCl (n = 8) and Ang II (n = 16) at 0.5 h and 24 h post culture on n 
= 8 independent occasions. Video recordings of contractile responses were stored and analysed with 
Image J software (https://imagej.nih.gov/ij/). A straight line tool was placed on a selected vessel as 
shown in fig 2.3 below to measure the vessel diameter which was used to generate plot 
profile/histogram/bar chart. In addition, from the straight line measurement of the vessel diameter, 
Image J calculates the mean grayscale and pixels across the selected area. Mean grayscale and pixel 
values were converted into microns (µm) to derive vessel dimension before and after control or 
treatments using a global scale of 0.44pixels/microns. Actual vessel dimension was obtained by 
dividing the values in microns (µm) with the objective magnification at which the contractile 
response recording was taken. Selected exemplary plot profiles and summary bar chart of contractile 
responses are presented in the result section. 
 
 
 
Figure 2. 3 Measurement of contractile response 
Image J straight-line tool was laid across a selected vessel with the line spanning adjacent ends as shown in the diagram. 
Mean grayscale and pixel values for the line measured is converted into microns µm) with a global scale (0.44 pixels = 1 
microns) and actual vessel diameter obtained by dividing value in microns with the objective lens magnification (100X). 
Scale bar 500µm  
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2.3.4. Explant harvest 
Explants in 6-well plates were gently washed within the wells with PBS three times (3X) for 5 minutes 
on gentle rotation. A total of 5ml of 10% neutral buffered formalin (NBF) was added per well and 
incubated overnight at 4oC. Holes were made through the matrix bilayer without disrupting the 
retinal tissue to facilitate penetration of the fixative. Explants were washed 3X in PBS and the 
matrices dismantled. Retinal tissues were embedded with optimal cutting temperature (OCT) 
medium (Tissue-Tek). Retinal tissues were cryosectioned into 20µm thick sections on Superfrost Plus 
and Colourfrost slides (Thermo Scientific) and stored in -20oC until use. Series of optimisations were 
carried out to achieve optimal harvest of retinal tissues from explants, cutting temperatures and 
section sizes.  
 
2.3.5 Haematoxylin and Eosin staining 
Sections were air-dried prior to use. Serial sections (20 µm) were stained with 0.1% Mayer 
haematoxylin (Sigma-Aldrich) for 10 mins, rinsed for 5mins in distilled water (ddH2O) and dipped 
briefly in 0.5% Eosin (Sigma-Aldrich). Samples were mounted with Histomount (National Diagnostics) 
and retinal morphology was visualised with an inverted light microscope with an attached camera 
(Leica DM4000B/DFC300-FX) at 200X magnification. Three different fields of view (micrographs) per 
section were obtained and experiments were repeated on more than nine independent 
experiments. 
 
 
2.3.6 Gomori Trichrome stain for Collagen 
Serial sections (20 µm) were briefly air-dried and incubated for 1 hour at 56oC in Bouin’s fixative 
(5%/9%/0.9% acetic acid/formaldehyde/picric acid) (Sigma Aldrich) in an oven. Modified Gomori 
trichrome stain was made in-house with the recipe; 0.6% Chromotrope 2R/ 0.3% Fast green FCF/ 
0.8% phosphotungstic acid with glacial acetic acid (National Diagnostics) in distilled water according 
to protocol (Gomori 1950). Specimens were washed thoroughly to remove the yellow Bouin’s stain 
and incubated with Modified Gomori (Green) trichrome solution for 20 mins as a contrasting stain to 
identify collagen; cytoplasm (red), fibrin (pink), collagen (green), and erythrocytes (red) (Garvey et al 
1996). Specimens were rinsed and the stain differentiated in 0.5% acetic acid for 2 mins. Slides were 
mounted with Histomount (National Diagnostics) and visualized with a light microscope with an 
attached camera (Leica DM4000B/DFC300-FX) at 200X magnification. Three fields (micrographs) per 
section was captured and experiments were repeated on more than nine independent occasions. 
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2.4. Immunohistochemistry and 
immunocytochemistry 
A standard protocol for immunohistochemistry (IHC) (Abcam) was utilized to examine the expression 
of targets; hypoxia inducible factor (HIF) 1 alpha (α) and platelet endothelial cell adhesion molecule, 
PECAM-1) also referred to as cluster of differentiation (CD31). Serial sections (20 µm) were air-dried 
and specimens blocked with 10% normal serum (Goat) with 1% bovine serum albumin (BSA) (Santa 
Cruz) in Tris buffered saline (TBS) for 2 h at room temperature (RT). Specimens were incubated 
overnight at 4oC with mouse monoclonal primary antibodies supplied after validation by the 
manufacturers (see Table 2.1 for full list of antibodies and manufacturers/suppliers).Manufacturer’s 
product codes are included in table 2.1 which can be used to obtain specific information on the 
antibodies. Specimens were washed gently three times (3X) for 5mins in TBST.  
Non-specific endogenous peroxidase was blocked with 0.3% H2O2 in TBS for 15 mins at RT. Primary 
antibodies were detected with fluorescently labelled DyLight 488 Goat directed against the heavy (H) 
and light (L) chains of mouse immunoglobulin (anti-mouse IgG (H+L)) Highly crossed Adsorbed 
secondary antibody (1:200) (ThermoFisher Scientific) incubated for 1 h in RT. Specimens were 
washed 3X with TBS and counterstained with 1 µg/ml of 4′,6-diamidino-2-phenylindole (DAPI) for 15 
mins at RT. Slides were mounted with water soluble Histomount(Vector Labs) and visualized with an 
inverted fluorescent microscope (Leica DMIL) at 200X magnification and documented. Three fields 
(micrographs) per target were captured and experiments were repeated on more than 15 
independent occasions. Target antigen on cell/tissue was labelled with an unconjugated specific 
mouse monoclonal primary antibody and Green fluorophore conjugated DyLight 488-Conjugated 
goat anti-mouse secondary antibody directed against the primary antibody was used for detection.  
Immunocytochemistry (ICC) (immunofluorescence, IF) staining of human dermal microvascular 
endothelial cells (HDMEC) was carried out as recommended (ThermoFisher Scientific) to study the 
expression of targets; HIF-1α, vascular endothelial growth factor (VEGF), nuclear factor erythroid 2–
related factor 2 (nrf2), and PECAM-1. HDMEC were fixed with 100% methanol for 5 mins at RT and 
washed briefly with PBS. Cells were permeabilized and non-specific interaction blocked with an in-
house one-step permeabilization/blocking solution according to recipe; 1% BSA (Santa Cruz) /10% 
normal goat serum (Invitrogen) /0.3M glycine (Sigma-Aldrich) in 0.1% PBS (Sigma Aldrich) 
/0.1%Tween-20 (Bio-Rad). Blocking solution was removed and wells blotted dry.  
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Cells were incubated with primary antibodies overnight at 4oC as outlined in table 2.1. Cells were 
washed 2X with PBS and incubated with Goat anti-mouse IgG, DyLight 488 conjugated highly cross-
adsorbed secondary antibody (1:500) in the dark for 60 mins at RT, washed and counterstained with 
4', 6-diamidino-2-phenylindole (DAPI) (1:1000; Invitrogen, ThermoFisher Scientific, UK) for 15 mins 
(Fig. 2.3). Samples were washed twice in PBS. The last wash was left in the wells and cells were 
imaged using Leica DMIL microscope with an integrated camera (Leica DC200) at 400X magnification. 
Series of optimization were carried out to ascertain primary and secondary antibody dilutions and 
incubation prior to experimental studies.PECAM-1/CD31 expression was studied in both IHC and ICC. 
To avoid confusion, the name PECAM-1 is used in all instances. All IHC and ICC assays with samples 
set up in duplicates were repeated at least 3 times (n ≥ 3). For imaging, at least three fields of views 
were taken per well per target.  
 
 
2.5. Immunoblotting (Western blot) 
Six identical wells of human dermal microvascular endothelial cells (HDMEC) in 24-well plates were 
pooled per sample. Total cell and sub-cellular lysates were prepared. HDMEC were lysed in Radio 
immunoprecipitation buffer (RIPA) (Cell signalling Technology) as recommended. RIPA buffer was 
supplemented with 1mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich) prior to use. 
Adherent HDMEC were rinsed with ice-cold PBS scraped off the culture plate dish using a cold plastic 
cell scraper with a lysis buffer, radio-immunoprecipitation assay (RIPA) buffer into pre-cooled micro-
centrifuge tubes. Lysates were sheared on ice for 3s at a power setting of 2-continous and 
maintained on constant agitation for 30 min at 4oC. Cells were pelleted for 20 min at 16,000 x g at 
4oC, the supernatant was carefully removed and placed in a fresh tube on ice and stored long-term at 
-20oC. Sub-cellular lysates were prepared with fractionation buffers using differential centrifugation 
according to protocol (Abcam).  
Fractionation buffer was prepared in-house: 20mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid) (Hepes, pH 7.4) (Sigma-Aldrich), 10mM Potassium chloride (KCl) (Sigma-Aldrich), 2mM 
Magnesium chloride (MgCl2) (Sigma-Aldrich), 1mM  Ethylenediaminetetraacetic acid (EDTA) (Sigma-
Aldrich) and 1mM Ethylene glycol-bis (β-aminoethyl ether (EGTA) (Sigma-Aldrich), nuclear fraction; 
Tris buffered saline (TBS) in 0.1% sodium dodecyl sulphate (SDS) (Sigma-Aldrich). Prior to use, buffer 
was supplemented with 1mM Dithiothreitol (DTT) (Sigma-Aldrich) and 1X Protease inhibitor (PI iii) 
(Sigma-Aldrich).  
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HDMEC were scraped from plates with appropriate volumes of buffer into Eppendorf tubes.  The cell 
suspensions were passed through a 1 ML 27 gauge needle until cells were lysed (≥ 10 times). Lysates 
were incubated on ice for 20 minutes and were centrifuged at 720 xg (MultiFuge1, HeraCeus) for 5 
mins. Supernatant and pellets were separated and stored on ice. The supernatant containing all 
cellular components (cytosolic) minus the nuclei (pellet) was briefly agitated (3 seconds on ice at a 
power setting of 2-continous) and stored at -20oC until use. The pellets containing the nuclei were 
washed in appropriate volume of fractionation buffer, dispersed with a pipette and passed through a 
25 gauge needle 10 times. The suspension was centrifuged at 720 xg for 10 minutes, the supernatant 
discarded and the pellet containing the nuclei was re-suspended in TBS with 0.1% SDS and sonicated 
briefly to shear genomic DNA and homogenize the lysates (3 s on ice at a power setting of 2-
continuous). All lysates were incubated on ice prior to storage and were stored long-term at -20oC 
until use.  
Bicinchoninic acid assay (BCA) kit was used to determine sample protein concentration according to 
protocol (Sigma-Aldrich). Stock (2 mg/ml) BSA protein standards were serially diluted with de-ionised 
MiliQ water; 0 (blank), 200, 400, 600, 800 and 1000 µg / ml in duplicates in clear 96-well plate on ice. 
BCA working reagent (WR) was prepared by mixing 50 parts of BCA Reagent A with 1 part BCA 
Reagent B (50:1, Reagent A: B). Protein standards were mixed with BCA working reagent at a ratio of 
1:8, i.e. 25 µl of protein standard was mixed with 200 µl of working reagent in clear 96-well plate, 
covered and mixed, and incubated for 30 minutes at 37oC. Optical density was read at 562nm with 
Synergy HT (Biotek) microplate reader spectrophotometer (Gen 5 vs 2.04).  
Standard curve of net absorbance versus protein concentration was plotted and a line of best-fit 
drawn through the points (Fig. 2.4) and equation of relationship between absorbance (nm) and 
protein concentration (µg/ml) derived (Equation 2.3). To quantify the protein concentration of the 
unknowns, samples were diluted with appropriate volumes of MiliQ water on ice. Samples in 
duplicates were incubated with BCA working reagent (50:1, Reagent A: B) at a ratio of 1:8 (according 
to manufacturer’s instruction) in clear 96-well plate and mixed. The plate was incubated for 30 
minutes at 37oC. Optical density was read and sample protein concentrations were determined using 
the BCA standard curve equation 2.3. 
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(R2 = 0.9964, Where Y = average optical density and X equals to protein concentration in µg/ml) 
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Figure 2. 4 Standard curve of BCA protein assay 
Stock BSA (2 mg / ml) was diluted in pure MiliQ water to serial dilutions; 0, 200, 400, 600, 800 and 1000 µg / ml. Optical 
density (OD) (absorbance) was measured at 560 nm wavelength. OD was corrected by subtracting blank OD (zero standard) 
from blank and standards, and samples. Corrected OD (net absorbance, nm) was plotted against BSA standard protein 
concentrations. A line of best fit was drawn through the points. Concentrations of unknown samples were determined by 
reference to the equation 2.3 from the standard plot.  
 
 
 
𝒀 = 𝟎. 𝟎𝟎𝟏𝒙 + 𝟎. 𝟎𝟏𝟓𝟐 − − − − − − − − − −𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟐. 𝟑 
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Samples were denatured in 2X Laemmli buffer (Bio-Rad); 65.8 mM Tris-HCl pH 6.8, 26.3% (w/v) 
glycerol, 2.1% SDS, and 0.01% bromophenol blue with 2-β-mercaptoethanol (Bio-Rad) for 6 mins at 
95oC. Lysed protein samples were separated on an in-house hand-casted 8% separation gel 
(separation range, 25-200kDa) (MiliQ H2O, 30% acrylamide (Bio-Rad), 1.5M Tris pH8.8, 10% SDS (Bio-
Rad), 10% Ammonium persulphate (APS)(Sigma-Aldrich), and tetramethylethylenediamine (TEMED) 
(Bio-Rad) and 6% stacking gel (stacker) (MiliQ H2O, 30% acrylamide (Bio-Rad), 0.5M Tris pH6.8, 10% 
SDS (Bio-Rad), 10% Ammonium persulphate (APS)(Sigma-Aldrich), and TEMED (Bio-Rad). A total of 30 
µg of total cell and cytosolic lysates, and 25µg of nuclear lysates were used. Pre-stained dual colour 
molecular weight marker (10-250 kDa) (Bio-Rad) was included to estimate protein band sizes. 
Samples were electrophoresed in a Bio-Rad MINI-PROTEAN system in 1X running Tris-Glycine SDS 
(TGS) buffer (Bio-Rad) initially at low voltage; 90 Volts until samples reached the end of the stacker, 
to make sure proteins entered the separation gel with minimal disruption.  
Voltage was increased to 150 volts until samples reached end of the run. Electrophoresed protein in 
SDS-PAGE gels were blotted onto an Amersham HybondTM P 0.45μm 150mm x 4mm Polyvinylidene 
difluoride (PVDF) membrane (GE Healthcare, LifeSciences) in a 1X transfer Tris-Glycine (TG) buffer 
(Bio-Rad) at ambient temperature for 150 mins at 100 Volts. These were found to be optimal 
conditions of transfer following prior use of a range of transfer times and voltages to ensure the 
majority of the protein had transferred to the membrane. Protein-bound PVDF membranes were 
blocked in 3% bovine serum albumin (BSA) (Santa Cruz) in 1X Tris buffered saline (TBS) on gentle 
rotation for 60 mins at room temperature (RT) to reduce non-specific binding.  
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Membranes were incubated overnight in mouse monoclonal primary antibodies diluted in 1.5% 
BSA/TBS at 4oC (see list in table 2.1). Antibodies after the first use were supplemented with 0.02% 
sodium azide (Sigma-Aldrich) to inhibit microbial growth. The optimal antibody concentration was 
determined prior to use and is reported along with a full list of antibodies, and ancillary products in 
Table 2.1. Membranes were washed 3X in Tris buffered saline-0.1% Tween 20 (TBST) (20mM Tris, 
150mM NaCl, pH 2.2) for 5 mins and incubated in 1:1000 Goat anti-mouse IgG_ Horseradish 
peroxidase (HRP) conjugated secondary antibody diluted in 1.5% BSA/TBS for 120 mins at RT. 
Membranes were washed 10X with TBST for 5 mins each wash and detected protein was visualised 
by exposure to enhanced chemiluminescence (ECL) lumninol-peroxide substrate (ThermoFisher 
Scientific) for 5 mins.  Excess ECL substrate was blotted off and membranes were carefully placed in 
a chemiluminescent image acquisition charge-coupled device (CCD), PeqLab Fusion FX7 camera 
(Vilber, Germany). Results were documented and stored as micrographs of blots. Each band on the 
micrograph represents a sample of pooled population of HDMEC from 6-identical wells (sixplicates) 
of a 24-well plate format. All experiments with western blots were repeated a minimum of 3 times (n 
≥ 3).  
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Table 2. 1 Antibodies and ancillary materials 
Description of 
antibodies 
Type Dilutions used 
(1xTBS) 
Manufacturer 
Anti-HIF1α mouse 
monoclonal IgG1 
 
Primary IHC (1:20) ThermoFisher Scientific (UK)  
(MA1-516) 
IF (1:50); WB 
(1:100) 
Santa Cruz Biotechnology 
(USA) (28b:sc-13515) 
Anti-Nrf2 mouse 
monoclonal 
(IgG2a) 
Primary IF (1:50) Abcam (ab89443) 
Anti-Nrf2 mouse 
monoclonal (IgG1) 
Primary WB (1:100) Santa Cruz Biotechnology 
(USA)  
(A-10: sc-365949) 
Anti-VEGF mouse 
monoclonal (IgG1) 
Primary IF (1:50); WB 
(1:100) 
Santa Cruz Biotechnology 
(USA) 
 (C-1: sc-7269) 
Anti-CD31 
monoclonal 
mouse IgG 
Primary IF (1:50); IHC 
(:20) 
Sigma- Aldrich (P8590) 
Anti-NFκB p65 
(IgG1) 
Primary WB (1:100) Santa Cruz Biotechnology 
(USA)  
(F-6: sc-8008) 
Anti-HO-1 (IgG1) Primary WB (1:100) Santa Cruz Biotechnology 
(USA)  
(A-3: sc-136960) 
Anti-β-actin 
monoclonal 
mouse IgG1 
Primary WB (1:500) St John’s Laboratory 
(STJ96941) 
Goat anti-mouse 
IgG DyLight 488 
conjugated 
Secondary IHC (1:200), IF 
(1:1000) 
Thermo Scientific (35503) 
Goat anti-mouse 
IgG-HRP 
monoclonal 
Secondary WB (1:1000) Santa Cruz (D1614) 
Normal goat 
serum 
-  10% Invitrogen (ThermoFisher 
Scientific) (PCN5000) 
DAPI 
NuBlue fixed cell 
stain ready probe 
reagent 
-  1µg/ml Molecular probes, Life 
Technology (R37606) 
BSA -  2 mg / ml (stock) Santa Cruz  
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2.6 Gene expression 
All RNA and PCR-related work were carried out in a laminar flow cabinet fitted with HEPA-filtered air 
(MDH, Zurich). Total RNA was extracted using the guanidium thiocyanate-phenol-chloroform 
extraction method Chomcynski and Sacchi (1987) with a total volume of 800µl of Trizol reagent (Life 
Technology) per sample. Six identical wells were pooled per sample and homogenised by gently 
pipetting several times in Trizol, at room temperature (RT) for 5 mins in order for the complete 
dissociation of the nucleoprotein complex to take place. Chloroform (160µl) (ThermoFisher) was 
added and mixed thoroughly for 60s and incubated at RT for 3 mins. Samples were centrifuged at 
12,000 x g (MultiFuge1, HeraCeus) for 15 mins at 4oC. Homogenates separated into a clear upper 
aqueous phase, which contains RNA, a middle layer (interphase-white), and a red lower organic 
phase, containing DNA and proteins.  
Approximately 50% of the total volume of the aqueous phase was removed into a fresh Eppendorf. 
RNA was precipitated with 400µl of 100% isopropanol (Thermo Fischer), incubated at RT for 10 mins 
and centrifuged at 12,000 xg for a further 10 mins at 4oC. The supernatant was carefully removed, 
leaving the RNA pellet (gel-like) on the side and bottom of the tube. Pellets were washed with 800 µl 
of 75% ethanol, vortexed briefly and centrifuged at 7,500 xg for 5 mins. The wash was discarded and 
pellets briefly air-dried for 10 minutes. Total RNA was quantified spectrophotometrically with a ultra-
violet (UV) spectrophotometer (NanoDrop LifeSciences) at 260 nm. RNA purity using the 260/280 nm 
ratio documented with NanoDrop were routinely found to be 2.0 indicating a high quality of RNA.  
The RNA was also resolved within a 1% agarose gel in 1X Tris-borate-EDTA (TBE) (ThermoFisher 
Scientific (Fig. 2.5).  
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Figure 2. 5 Resolution of RNA extracted from HDMEC 
Resolution of RNA extracted from HDMEC within a non-denaturing 1% agarose gel and electrophoresed with 1X 
Tris/Borate/EDTA (TBE) buffer (Sigma-Aldrich) at 80 volts for 50 minutes and visualised with PeqLab Fusion using 1X Gel 
Red nucleic acid gel stain (Biotium) as filter. Blot image shows 28S:18S band ratios that were roughly 2:1 with a high 
intensity signal at 28S vs 18S and 5S rRNA. The ratios of RNA samples were routinely 2.0. 
 
 
A total of 0.5µg of RNA per sample was reverse transcribed to complementary DNA (cDNA)using a 
high capacity cDNA reverse transcription kit catalysed by 1X rMoMuLV MultiScribe Reverse 
Transcriptase (50 U/µL) as recommended (ThermoFisher Scientific) (CatLog # 4368814) using 
conditions outlined in table 2.2. 
 
 
 
 
 
 
 
 
 
 
 
 
28S
18S
5S
tRNA
HDMECs RNA
example 1 example 2
B
  
81 
 
Table 2. 2 CDNA thermal cycler program 
 Step 1 Step 2 Step 3 Step 4 
Temperature (oC) 25 37 85 4 
Time (min) 10 120 5 ͚ 
 
 
 
The cDNA was used for end-point Reverse Transcriptase PCR (RT-PCR) and Real-Time Quantitative 
PCR (qPCR). A reaction master mix (2X) containing; 2X RT buffer, 8mM dNTP mix, 2X RT random 
primers (ThermoFisher Scientific) were mixed in nuclease-free water (BIOLINE) in single Eppendorf 
tubes. The tubes were centrifuged briefly at 4oC to spin down the content and to eliminate air-
bubbles and reverse transcription carried out in iCycler thermal cycler using validated thermal cycle 
program (Table2.2). Samples (cDNA) were diluted to appropriate volumes in Rnase/DNase-free 
water and stored at -20oC. End-point reverse transcriptase polymerase chain reaction (PCR) (RT-PCR) 
was used to detect mRNA in cDNA transcripts from RNA samples (Schmittgen et al 2000). 
Appropriate volumes of 10 ng of template (cDNA) in PCR-grade RNase-free water were used.  
RT-PCR reaction was catalysed by Taq DNA polymerase in a 2X concentrate REDTaq ReadyMix PCR kit 
with 0.2mM magnesium chloride (MgCl2) and 80µM 99% pure deoxynucleotides in a red inert dye 
(Sigma-Aldrich), with 0.25 µM of forward and reverse primers for; B2m, HIF-1α, IL-6, and TNFα. 
Primers were designed using primer design software accessed via the National Centre for 
Biotechnology Information (NCBI) website (https://www.ncbi.nlm.nih.gov).  Specificity was 
confirmed by follow up with Basic Local Alignment Search Tool (BLAST) also available from NCBI to 
ensure there was no cross identity with other sequences within the genome. BLAST results showing 
gene accession numbers, sequence similarity index to ensure specificity which confirmed identity 
(%), BLAST score of the match (%), gaps score (%) query score (%) and E value (which describes 
random background noise) are listed in table 2.3 below. Primer name, sequence, accession number, 
melting temperature Tm and size (bp) are listed in table 2.4 below. 
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   Table 2. 3 Primer BLAST reports 
a) Homo sapiens beta-2-microglobulin (B2M), mRNA, Accession number 
NM_004048.2. Blast Results showing regions of similarity between FASTA 
sequence of gene of interest and other sequences; 100% identity (987 out of 987), 
a score of 1823 out of 1823 query, 0% gaps (0/987), E value = 0.0 
b) Homo sapiens hypoxia inducible factor 1 alpha subunit (HIF1A), transcript variant 
1, mRNA Accession number NM_001530.3; 100% identity (4082 out of 4082), a 
score of 1823 out of 1823 query, 0% gaps (0/4082), E value = 0.0 
c) Homo sapiens interleukin 6 (IL6), transcript variant 1, mRNA, Accession number 
NM_000600.4; 100% identity (1197 out of 1197), a score of 2211 out of 2211 
query, 0% gaps (0/1197), E value = 0.0 
d) Homo sapiens tumour necrosis factor (TNF), mRNA, Accession number 
NM_000594.3; 100% identity (1686 out of 1686), a score of 1823 out of 3114 
query, 0% gaps (0/1686), E value = 0.0. 
 
 
 
All targets as retrieved with their accession numbers had gaps scores of 0 %, E-values of 0.0 and 
scored 100% for identity and match scores. Full list of primer names, amplicon size (bp) and 
sequences, melting temperature (annealing temperature, TM), accession numbers are listed in the 
table 2.4. 
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      Table 2. 4 Primers and sequence details 
 
        F, forward primer; R, reverse primer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oligo name Primer sequence (5’-3’) Tm Accessi
on 
# 
Size 
(bp) 
 
B2M  
Beta-2-microglobulin 
 
     F: 5’-GGGCATTCCTGAAGCTGACA-3’ 
 
     R: 5’-TGGAGTACGCTGGATAGCCT-3’ 
 
 
67.6 
 
63.7 
 
 
 
NM_00
4048  
 
 
109 
 
HIF1A  
Hypoxia inducible 
factor 1 alpha subunit 
 
F: 5’-GAGGGAGCCAGCGCTTAG-3’ 
 
    R: 5’-ACTTATCTTTTTCTTGTCGTTCGC-3’ 
 
65.2 
63.4 
 
NM_00
1530 
 
116 
 
IL6 
Interleukin 6 
 
    F: 5’-TCAATATTAGAGTCTCAACCCCCA-3’ 
 
     R: 5’-TTCTCTTTCGTTCCCGGTGG-3’ 
 
64.4 
 
68.2 
 
NM_00
0600.4 
 
 
90 
 
TNFA  
Tumour necrosis 
factor 
 
 
F: 5’-TCCCCAGGGACCTCTCTCTA-3’ 
 
R: 5’-GGGTTTGCTACAACATGGGC-3’ 
 
65.0 
66.3 
 
NM_00
0594.3 
 
108 
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PCR reaction mix was gently vortexed, centrifuged and amplified using a 2-step PCR cycling 
parameters as set out in table 2.5. Samples of amplified DNA were loaded directly onto a 1% agarose 
gel and electrophoresed with 1X Tris/Borate/EDTA (TBE) buffer (Sigma-Aldrich) at 80 volts for 50 
minutes and visualised with PeqLab Fusion using 1X Gel Red nucleic acid gel stain (Biotium) as filter. 
Results are documented as micrographs of PCR products (bands). A sample (band) on micrograph 
represents pooled population of HDMEC from 6-identical wells (sixplicates). All experiments with 
end-point PCR were repeated a minimum of 3 times (n ≥ 3). Real-time PCR was performed on 
duplicate samples using Applied Biosystems 7900HT Real-Time PCR System with 0.25 µM of human 
IL-6 and B2m primers (table 2.4), and 2X SYBR Green with ROX reference dye (Applied Biosystems, 
catalogue # 4309155)with a total of 10ng of cDNA template in a final volume of 20µl in 96-well 
optical plate format (Applied Biosystems).  Thermal cycle and amplification parameters are set out in 
table 2.6 and 2.7. 
 
 
Table 2. 5 Thermal cycler program for End-point RT-PCR  
 Step Temperature Duration Cycles 
1. Initial denaturation 95oC 1 min 1x 
2. Amplification 
-Denaturation 
-Anneal 
95oC 
65oC 
1 min 
1 min 
40x 
 
 
1x 
- 
3. Final extension 
Hold 
68oC 
4oC 
7 min 
͚ 
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Table 2. 6 Standard cycling mode for Real-time qPCR 
Step  Temperature Duration Cycles  
UDG activation 50oC 2 mins Hold 
Dual-Lock DNA 
Polymerase 
95oC 2 mins Hold 
Denature 95oC 15s 40 
 Anneal/Extend 60oC 1 min 
 
 
 
Table 2. 7 Dissociation curve conditions for Real-time qPCR 
Step Ramp rate  Temperature Time  
1 1.6oC/s 95oC 15s 
2 1.6oC/s 60oC 1min 
3 0.15oC/s 95oC 15s 
 
 
 
Melt curve was analysed with RQ manager 1.2 software (Applied Biosystems) to discriminate 
between specific products having a melting temperature (Tm) of ≥ 78
oC and non-specific primer-
primer products with a Tm of ≤ 78
oC. Assessment of Real-time qPCR products were based on melting 
curve results only. Data were normalized to human B2m mRNA levels as an endogenous control and 
expressed relative to untreated control (calibrator) using the formula 2-ΔΔCT (fold change) where CT is 
the threshold cycle number since, B2Mand IL-6 primers were at equivalent efficiencies (≥ 90%) 
(Winer et al 1999, Schmittgen et al 2000). Untreated samples in 5% CO2 normal incubator conditions 
in 5.5 mM glucose media were assigned calibrator (Livak and Schmittgen 2001). Change in 
expression was determined with equation 2.4, and fold change calculated using equation 2.5. Six 
identical wells of HDMEC in a 24-well plate format were pooled per RNA sample. Real time assays 
were set up in duplicates, and repeated n = 3 independent occasions.  
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𝑪𝒉𝒂𝒏𝒈𝒆 𝒊𝒏 𝒆𝒙𝒑𝒓𝒆𝒔𝒔𝒊𝒐𝒏 (∆∆𝑪𝒕)
= 𝑨𝒗𝒆𝒓𝒂𝒈𝒆 𝑪𝒕(𝑻𝒂𝒓𝒈𝒆𝒕 𝒕𝒓𝒆𝒂𝒕𝒆𝒅)
−  𝑨𝒗𝒆𝒓𝒂𝒈𝒆 𝑪𝒕(𝑻𝒂𝒓𝒈𝒆𝒕 𝒖𝒏𝒕𝒓𝒆𝒂𝒕𝒆𝒅) 
 
                                                ------------------------Equation 2.4 
 
𝑭𝒐𝒍𝒅 𝒄𝒉𝒂𝒏𝒈𝒆 = 𝟐−∆∆𝑪𝒕-------------------Equation 2.5 
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2.7 Resazurin assay 
Resazurin (CST) was used to examine cell metabolic activity post treatments (Ahmed et al 1994, 
Nakayama et al 1997 and Nociari et al 1998). Resazurin (7-hydroxy-3H-phenoxazin-3-one 10-oxide) 
assay is based on the ability of metabolically viable cells to reduce blue Resazurin dye to a highly 
fluorescent and measurable pink resorufin in a reaction catalysed by dehydrogenase (Ahmed et al, 
1994, Nakayama et al 1997, Zalata et al 1998, Perrot et al 2003). In Resazurin assay, fluorescence is 
proportional to cell metabolic activity and because Resazurin is only reduced to fluorescent resorufin 
in metabolically viable cells, the assay can be used to estimate the impact of treatments on cell 
metabolic activity (Ahmed et al, 1994).  
Resazurin assay was performed only with HDMEC samples and explants were not analysed for 
metabolic activities. Control experiments were carried out by seeding cells according to the general 
guidelines (10,000-20,000cells/cm2) given by PromoCell, although this was not specific for Resazurin 
assay. HDMEC were seeded in clear 96-well plates (surface area of 0.32cm2) plates at a density of 
1,000, 2,000, 5,000, 6,000 and 10,000cells per well in 100 µl of normal growth media. Blank (no cell) 
control contained 100-µl media but with no cells incubated. Fluorescence from no-cell control 
sample was subtracted from cell-incubated wells to obtain the relative fluorescence units (RFU), an 
indicator of metabolic activity expressed in x 104. Samples in triplicates were incubated at 37oC in a 
5% CO2 incubator and reached approximately70% confluence after 48 hours, and were treated with 
10µl Resazurin (10X) solution (CST) per well in the dark. Fluorescence was measured at 0, 6, and 24 h 
using a Synergy HT microplate reader (Biotek) at 530-570nm excitation wavelength and 585-590nm 
emission wavelength. Prior to treatment, growth media were refreshed with 100µl of media 
containing 5.5 / 20 mM D-glucose.  
For experiments, HDMEC were exposed to treatments with equivalent controls (untreated) 
incubated in a normal 5% incubator. A no-cell blank control was included as blank to derive RFU 
values. HDMEC media were mixed with 10% Resazurin, and incubated in the dark in a 5% CO2 
incubator for 24 h. Fluorescence was read at 530-570nm excitation wavelength and 585-590nm 
emission wavelength using a Synergy HT microplate reader (Biotek). RFU was obtained by 
subtracting average RFU values of no-cell control from samples. All experiments were repeated at 
least 3 times (n ≥ 3) and data as reported in the relevant result section represents mean OD ± SEM.  
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2.8 Hyperbaric oxygen chamber 
Treatment of samples (HDMEC or explants) was carried out within a bespoke validated hyperbaric 
oxygen (HBO) unit developed in-house in collaboration with Mr Allan McPherson from the School of 
Engineering department at Robert Gordon University and underwent full safety testing prior to use. 
The figure, 2.6 is a schematic diagram detailing the procedures undertaken in setting up the HBO 
unit. All procedures were performed in an air-tight hyperbaric unit (chamber) made from Perspex. 
Perspex (Poly (methyl methacrylate)) also known as acrylic glass is a transparent thermoplastic 
lightweight or shatter-resistant alternative to glass. Samples undergoing treatments were placed 
inside the chamber. The anterior and posterior ends of the chamber are fitted with air-tight inserts 
for gas inlet with a pressure-voltage converter patch lead and an outlet for monitoring oxygen levels. 
Two gas supply cylinders; a 95/5% O2/CO2 (hyperoxia) medical gas (BOC) (orange) and a 21% 
O2/Air/Nitrogen (normoxia) (ARC) (green) were used (1). Gas cylinders were connected to the 
chamber via a Y-shaped tube (green and orange). A Y-shaped gas inlet was necessary for the 
administration of HBO since gas cycling between hyperoxia and normoxia was required for HBO. To 
alternate between gases, a clamp was used to shunt gas supply from the cylinder that was not in use. 
For instance, if the gas in use at the time was medical gas, the gas inlet for Air/Nitrogen was shunted 
and vice versa.  
A Honeywell gauge gas pressure sensor mounted on the anterior end of the unit transduces 
pressures (up to 150psi) to measurable units of voltage (1.5-12V) using a voltammeter. A data logger 
(Pico Technologies) was used to record and document output of gas pressures. Once samples were 
placed within the chamber, the chamber posterior end was tightly secured at the end with six steel 
Ki8.8 bolts and six steel washers and chamber placed within a 37oC incubator. The gas cylinder in use 
was switched on and the posterior gas outlet tube was attached to a Frith’s stone fully inserted into 
a beaker of water kept at 37oC. Gas saturation in the beaker of water was monitored with a 
Strathkelvin oxygen meter until saturation was reached (validations determined time taken for 
oxygen meter to reach saturation was 2.2 ± 0 mins, n = 6). This was rounded up to 3 mins. After 3 
mins, the outlet tube was securely closed by folding it over and clamping.  
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Figure 2. 6 Schematic representation of treatment in chamber 
Samples were incubated in the chamber on a stable platform. Chamber was tightly secured and outlet tube was placed into 
a glass beaker of water at 37
o
C containing a calibrated oxygen electrode (Strathkelvin 782 v1). Two separate gas cylinders 
containing medical gas (95% O2/ 5% CO2) (orange) and 21% O2/ Air/N2 (green) were connected via a Y-tube to a central 
tube into the chamber. The gas in use was released to flush and saturate chamber for 3 mins prior to use, while the gas not 
in use was turned off by clamping gas tube. Pressure was either maintained at 0 bar (1 ATA) or elevated to + 1.2 bar (2.2 
ATA) using gas gauge switch for the appropriate cylinders. The gas gauge for hyperoxia alone treatment was maintained at 
0 bar, while medial gas was used to flush and saturate chamber and for the entire incubation duration. The gas gauge was 
elevated to + 1.2 bar (2.2 ATA) in combination with medical gas during the hyperoxia cycle (HBO). During, the air breathing 
cycle, the medical gas was clamped and 21% O2/Air/N2 gas (normoxia) was used to flush the chamber for 3 mins. The 
chamber was secured thereafter and pressure elevated to 2.2 ATA with 21% O2/Air/N2 gas for additional 5mins to complete 
a cycle of hyperbaric oxygen. Three cycles of hyperoxia with elevated pressure, and 2 cycles of normoxia with elevated 
pressure was carried out per HBO procedure. The physical element (i.e. pressure) within the chamber was relayed via a 
pressure sensing lead patch to a voltmeter. Pressure – voltage (Volts) was logged with PicoLog and saved on hard disk of a 
laptop computer. Oxygen readings with Strathkelvin are manually documented. Once oxygen saturation was reached, the 
outlet tube was tightly secured until treatments were completed.  
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Samples were exposed to hyperoxia at normobaric (0 bar relative to atmospheric pressure) or 
hyperbaric pressure (+ 1.2 bar relative to atmospheric pressure = 2.2 atmospheric pressure absolute, 
(ATA)) in normoxia for 90 mins or combinations of both hyperoxia and hyperbaric pressure (2.2 ATA) 
(HBO) for 3 cycles of 30 mins duration with 2 cycles of 8 mins intermittent ‘air’ (normoxia) at 2.2ATA, 
giving a total treatment duration of 106 minutes. This procedure was consistent with current clinical 
protocol in the United Kingdom (Bennett et al 2016). However, the normal 5-mins air breathing 
(Bennett et al 2016) was adjusted to 8 mins in this study. The additional 3 mins allowed for proper 
chamber saturation with incoming gas when alternating between gases (e.g. when changing from 
hyperoxia to normoxia, and vice versa). Equivalent samples were incubated in a normal 5% CO2 
incubator (Control samples). Hyperoxia and hyperbaric pressure treatment alone were controls for 
HBO to examine the effects of the single components. Post incubation, gas gauges were turned off 
and cylinder (s) switched off. The unit was de-assembled, and returned to a normal 5% CO2 
incubator. The figure (2.7) below is a schematic representation of the HBO procedure which involved 
gas cycling and alternation between hyperoxia and normoxia at hyperbaric pressures.  
 
 
 
 
 
 
Figure 2. 7 Schematic representation of HBO cycling 
The HBO procedure as shown in the schematic diagram above was closely aligned to the UK HBOT clinical protocol (Bennett 
et al 2016). A single inlet/outlet system was used, and protocol was adjusted to include an additional 3 mins before and 
after 5-mins of Air/Nitrogen gas (21% oxygen) to allow for complete saturation of the chamber with the relevant gas.  
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HDMEC require 5% CO2 for optimal incubation and a bench control (exposed to 21% O2/Air/N2) was 
set up to assess the effect of using less than 5% CO2 for up to 90 mins incubation. Bench controls 
were kept within a bench top incubator at 37oC concurrently with hyperbaric pressure samples, but 
not within the pressurised chamber. Thus ‘Bench’ controls differed from hyperbaric pressure 
samples only in respect to elevated pressure, 2.2 ATA. A Honeywell gauge gas pressure sensor, of up 
to 150psi (1.5-12V) was used to convert gas pressure to voltage (Volts, recorded as millivolts, mV).  
Data (mV) were logged via a data logger (Pico Technologies) connected to a Lenovo laptop. To 
demonstrate the data logger was sensitive to the pressure-voltage variation, a series of test runs 
were performed. Based on these initial validation (see Fig. 3.9, A), the data logger was sensitive to 
pressure –voltage variations at 1 ATA (0 bar) or 2.2 ATA (+ 1.2 bar). Subsequently, validations 
(control experiments, N = 6) (Fig. 3.9, B) were carried out to ascertain the relationship between gas 
pressure and voltage. External variations that might increase pressure (in addition to the applied gas 
pressures) include relative humidity and any substantial changes in the atmospheric pressures on the 
days of experiments. To determine voltage at zero bar (1 ATA), the gas pressures of 21% O2 
(Air/Nitrogen) or 95% O2/5% CO2 at 1 ATA were monitored and recorded with a data logger. Pressure 
was elevated by +1.2 bar (i.e. 2.2 ATA), and voltage readings recorded. Average voltage value at 0 
and +1.2 bar were 6mV (SD 0.001) and 15mV (SD 0.000) respectively. A straight line graph was 
plotted to determine the equation of relationship (Equation 2.6) between voltage and pressure using 
GraphPad Prism: 
 
 
 
 
 
 
‘ 
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Where Y equals the independent variable, voltage and X equals the dependent variable, Pressure.  
 
The equation above shows the relationship between pressure (bar) (a physical property) and a 
measurable quantity, voltage (Volts). Thus, the gas pressures relayed were correlated to the voltage 
measured. External factors such as relative humidity and atmospheric pressure affect total gas 
pressure in the chamber. Hence, in order to help reduce external variations, the chamber was made 
airtight by securing tightly. Results of the various validations undertaken in setting up the hyperbaric 
oxygen unit are reported in chapter 3.0 sections 3.3.2.  
 
 
2.9 HDMEC size measurement 
Live cell (HDMEC) images were captured before (baseline) and 4 h post treatment using a light 
microscope (Leica DM4000B) and an attached camera (Leica DFC300-FX) at 200X magnification. 
Experiments were repeated on five independent occasions. Photomicrographs were independently 
coded. Inclusion and exclusion criteria were set prior to measurements and used for all images. 
Coded images of HDMECs were analysed with an Image J program with a global scale was set to 
0.22pixels/µm. The perimeter (size), i.e. the total distance around cells (HDMEC) with clearly defined 
borders were traced and measured with the Image J free-hand drawing tool. Sample identities were 
revealed post image analysis. Statistical analysis was carried out with Graph Pad Prism vs 5.0. 
 
2.10 Fluorescence intensity determination 
The fluorescence intensities of stained photomicrographs of HDMEC captured at 4 h and 24 h post 
treatment of nrf2 were measured with Image J program. Photomicrographs with debris and non-
specific (non-cell associated) fluorescence were excluded. Photomicrographs were captured at 400X 
magnification, and a global scale of 0.44 pixels / micron (µm) was used. Photomicrographs measured 
were from 2-3 fields (micrographs) captured from more than three independent experiments as 
reported in the ICC method section (2.4).   
 
 
𝑌 = 𝟎. 𝟎𝟎𝟕𝟓𝑿 + 𝟎. 𝟎𝟎𝟔 − − − − − − − − − −𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 2. 𝟔. 
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2.11 Statistical analysis 
Data were statistically analysed using GraphPad Prism 5.0 software (GraphPad Software Inc. USA). 
The normality of data from HDMEC size and metabolic activity assay where replicates were n ≥ 18 
was ascertained with a Shapiro-Wilk’s test for Gaussian distribution. Column statistics option was 
used to determine mean, standard error of mean (SEM) at 95% confidence intervals (CI) for 
fluorescence intensity and real-time PCR data where replicates were n ≤ 18. Data reporting matrix 
oxygen measurement, contractile responses, and hyperbaric model validations are presented as 
mean ± SD. Cell work data reporting HDMEC sizes, metabolic activity and mRNA expression are 
presented as mean ± SEM. The SEM was chosen for cell (biological) data, not standard deviation (SD) 
which provides an idea of the variability of a single observation, in order to represent the spread of 
the mean so as to give indication of the reliability of the mean of the data as the experiments were 
repeated n ≥ 3 independent occasions. Where SD is used to report data, it is clearly noted in the 
relevant section, otherwise SEM is implied. One way (1way) analysis of variance (ANOVA) was used 
to test the means between all samples (*), and Tukey’s post hoc test to compare all columns 
(samples) was performed if 1way ANOVA was successful with overall p value; *p < 0.05, **p < 0.01, 
***p < 0.0001. Student t-test was used to make comparison between samples in the same treatment 
group for glucose effect where relevant. Bonferroni’s post hoc analysis was used to compare 
selected columns of samples for metabolic activity analysis; low glucose samples: HBO versus 
hyperoxia versus hyperbaric pressure, and high glucose samples: HBO versus hyperoxia versus 
hyperbaric pressure 
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Chapter 3.0: Validation of experimental 
models 
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3.1 Introduction 
In this chapter the validation of the retinal explant model and the experimental HBO chamber is 
presented. Endothelial cells are best studied in-situ because their constitutive phenotype is altered 
when explanted (Grant et al 1989). It is well accepted that single cell systems do not present the 
whole picture in mechanistic studies (Oberringer et al 2007). Hence, there is a need to examine 
single cell-based assay results in more complex systems. Realistic insights are best provided using 
animal models and human subjects. However, such studies have limitations that are met by using ex-
vivo models (Oberringer et al 2007, reviewed in Jo et al 2013, Lai and Lo 2013, Matteucci et al 2015, 
and Costa and Andrade 2015). The primary determinants of retinal cell survival in cultured isolated 
retina are neither nutritive supply from the choroid, oxygen supply, or the provision of RPE, but the 
provision of a biomechanical milieu (Taylor et al 2014). In vivo, the retina resides in a highly 
biomechanical environment where adhesive tensile and hydrostatic forces come into play (Marmor 
et al 1994). Retinal biomechanical scaffolding and biochemical homeostasis is controlled by Mueller 
cells through their regulation of intermediate filaments such as glial fibrillary acidic protein (GFAP) 
and vimentin (reviewed in Taylor et al 2014). Absence of biomechanical support in retinal tissue 
culture results in pyknosis, an irreversible condensation of chromatin in the nucleus of a retinal cell 
undergoing necrosis or apoptosis (Taylor et al 2014). In addition, isolated adult retinal sheets 
cultured under standard condition display degeneration very early because of gliosis (Kaempf et al 
2008, Kobuch et al 2008, Fernandez-Bueno et al 2008, Taylor et al 2014). During gliosis, Mueller cells 
(the principal glial cell of the retina) become activated, losing their metabolic function and structural 
integrity in times of retinal injury and diseases. Also, the deaths of other neuronal cell types are 
accelerated in gliosis. Hence, retinal gliosis is the major limiting factor for retinal culture using 
standard conditions without a biomechanical support (Caffe et al 1989, and 2001, Taylor et al 2014). 
Furthermore, the rapid disintegration of explanted retinas cultured in media in serum-containing 
media has been reported. Therefore the exclusion of serum in media decreases the rate of retinal 
degeneration (Caffe et al 1989). 
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The culture of explanted retinas has been in existence since 1930s, with different approaches used 
by different workers to expedite retinal viability. Different biomechanical supports or platforms have 
been utilised. A retinal model of human retinal angiogenesis comprised of retinal tissue embedded 
within a fibrin-agar matrix was employed by Knott et al 1999. In addition, a porous polycarbonate 
culture membrane (0.4 µm) was used by Taylor et al 2014. In this study a biomechanical scaffold 
(matrix) was utilised in the culture of isolated porcine retina as described in the method section 
(2.3).  
Agarose is porous (0.4-1 µm), inert, and biocompatible and forms a fine web-like matrix in 
combination with collagen fibres (Lake et al 2011). Here, porcine retinal tissues cultured as three-
dimension (3D) explants were used to examine endothelial cell responses. Isolated whole retinal 
tissues were sandwiched within agarose-collagen bilayer matrices with the outer and inner retina in 
immediate contact with matrices. This method of retinal culture utilised is expected to delay retinal 
degeneration and provide extracellular cues with the provision of a biomechanical scaffold (agarose 
matrix) and an extracellular matrix protein, collagen (Caffe et al 1989, Lake et al 2011, Taylor et al 
2015).  
Hyperbaric oxygen therapy (HBOT) is a treatment modality involving the use of hyperbaric oxygen 
(HBO) which entails breathing in ≥95% oxygen (O2) breathing at a pressure greater than 1 absolute 
atmosphere (ATA) that is, greater than the atmospheric pressure at sea level (Löndahl 2013, HBOT 
Trust 2018). HBO protocol is modified in practice to suit local facilities and circumstances. Variations 
exist in the total number of sessions (30 - 60), pressure used (2.0 - 2.5 ATA), length of each session 
(60 - 120 minutes), frequency (once or twice a day), adoption of a 5-minute reprieve in every 30-
minute interval for preventing oxygen toxicity and continued administration of pure oxygen during 
the decompression period (Bennett et al 2016, HBOT Trust 2018). HBO protocol as modelled in this 
study was closely aligned to clinical HBO therapy regimen in the United Kingdom (UK). Validations of 
the retinal explant and HBO chamber were carried out to ensure protocol and method robustness as 
these methods were developed during the course of this study.  
The aim in this chapter is to demonstrate the suitability and robustness of the two models (retinal 
explants and experimental HBO model) utilized in this study. Here, the retinal explant model 
development, protocols and assays validated in relation to oxygen availability, retinal tissue integrity 
and vessel functionality are presented. In addition, validations of HBO protocol, method and model 
development in relation to pressure, temperature, oxygen and pH monitoring are also presented. 
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3.2. Methods 
 
3.2.1 Retinal explants 
Porcine ocular globes (n ≥ 10) donated from a local abattoir were cleaned and sterilised. Retinal 
tissues were extracted as described (Rzeczinski et al 2005 and Johnson and Martin 2008), and 
cultured within three dimension (3D) matrices (explants) made from 0.5% agarose (BIOLINE) and 
collagen (0.25mg/ml) (Gibco, Life Technology) in low (5.5 mM) or high (25 mM) D-glucose DMEM 
media (ThermoFisher Scientific). The total matrix depth was 7mm. Explants were incubated in media 
of low or high glucose 30 mins before treatment and harvested at 2 h and 24 h post treatment. Full 
details of methods utilised for validating the retinal explant model are reported in the general 
materials and methods chapter 2.0; explant culture (section 2.3.1), matrix oxygen measurement 
(section 2.3.2), measurement of contractile response (section 2.3.3), explant harvest (section 2.3.4), 
haematoxylin and eosin staining (section 2.3.5), and Gomori Trichrome stain for collagen (section 
2.3.6). See section 3.3.1 for results of retinal explant validations. 
 
 
3.2.2 Hyperbaric oxygen model 
A Honeywell gauge gas pressure sensor was used to monitor and convert gas pressure to voltage 
(millivolts, mV) and logged with PicoLog data logger. To demonstrate the sensitivity of pressure 
(ATA) conversion to mV, initial control experiments, n = 6 were performed to define the relationship 
between gas pressure and voltage (see section 3.3.2). The determination of pressure- voltage (mV) 
conversion was derived based on the equation below (equation 3.1) using a PicoLog software. 
External factors other than the applied gas pressure such as relative humidity and any substantial 
changes in the atmospheric pressures were accounted for with the equation of the relationship 
between gas pressure and voltage transmitted (mV). Thirty (30) mins prior to experiments, all units 
were switched on to acclimatize. The equation below (3.1) shows the relationship between pressure 
(ATA) and voltage (millivolts, mV). 
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Where Y equals the independent variable, voltage and X equals the dependent variable, Pressure.  
 
The gas pressures within the chamber at normal atmospheric pressure (1 ATA) at 21% or at 95% 
oxygen were measured, converted to voltage and recorded as mV, and measurements were 
repeated with the pressure cylinder increased to +1.2 bar (2.2 ATA) and the corresponding mV values 
recorded. The average (n = 22) voltages (mV) which was an indicator of the average applied gas 
pressure within the chamber at 1 ATA and 2.2 ATA were plotted. Results of pressure-voltage (mV) 
validation are reported in section 3.3.2. Oxygen saturation in the chamber was measured with a 
Strathkelvin oxygen meter (v782). Electrodes were calibrated at high point (100% saturation) and 
zero-point (0% O2). For high point calibration, electrodes were placed in air-bubbled distilled water at 
37oC. Zero-point was calibrated in 2% sodium sulphite solution at 37oC. Results of calibration are 
presented as plots of average O2 saturation (%) from n = 3 independent calibration measurements 
(section 3.3.2). The HBO chamber was tightly secured and the chamber was flushed continuously 
with the relevant gas. The outlet tube at the posterior end of chamber was opened, and a Frith’s 
stone fitted and placed into a beaker of water at 37oC containing an oxygen sensor meter. Oxygen 
saturation in the chamber was monitored in this way to establish oxygen saturation at normoxia 
(21% Air/Nitrogen) and hyperoxia (95% O2/5% CO2). In addition, time taken (in mins) to reach 
saturation was determined, to inform on the duration needed to reach saturation point with the 
relevant gas. Results are reported in section 3.3.2. The effect(s) of treatment on media buffering 
capacity was also verified.  Moreover, since the gas mixture for normoxia (21% O2/Air/Nitrogen) 
contained less than 5% CO2, the effect of using normoxia gas with less than 5% CO2 on media 
buffering capacity was ascertained. Hence, validation (n = 4) of media buffering capacity was 
undertaken.  
The pH of HDMEC incubated media were measured with a pH meter (Denver Instruments) after 120 
mins of incubation in the chamber in the presence of hyperoxia (at 1 ATA/ 2.2 ATA) or normoxia 
(2ATA) or controls. Equivalent controls were incubated within the bench top and a normal 5% 
CO2incubator. HDMEC are best maintained at 37°C. To ascertain any variations in temperature which 
might impact pH or oxygen dissolution since the hyperbaric chamber was placed within a bench top 
incubator during operation, validations (n = 5) were undertaken with control experiments to exclude 
variability in temperatures within the chamber.  
𝒀 = 𝟎. 𝟎𝟎𝟕𝟓𝑿 + 𝟎. 𝟎𝟎𝟔 − − − − − − − − − − − − − −
− 𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟑. 𝟏. 
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To do this, a mercury thermometer was inserted within chamber (internal reading) and was 
compared with readings from an external thermometer on the bench top incubator (external). 
 
3.3. Results 
 
 
3.3.1. Retinal explant 
Mean (n = 6) oxygen concentration (%) in media (control) at 0.5 h and 24 h were 14.8% ± 1.7 and 
23% ± 0.0 respectively relative to atmospheric air at 1 ATA. Oxygen saturation at 4mm depth of the 
matrix at 0.5 h and 24 h were 14.3% ± 1.1 and 18.3% ± 1.5 respectively relative to atmospheric air at 
1 ATA. The observed mean matrix oxygen saturation of 14.3% and 18.3% corresponded to a partial 
pressure of oxygen (PaO2) of 57 mmHg and 76 mmHg respectively at sea level (1 ATA) (Hodges et al 
k2003). Based on a 1 way analysis of variance (ANOVA), there were significant differences between 
the means of all samples (p < 0.0003, n = 4). Based on Tukey’s post hoc analysis, levels of oxygen 
within matrices (4mm depth) at 0.5 h and 24 h were not statistically different in comparison to their 
respective controls (p > 0.05). Moreover mean oxygen saturation in matrices at 24 h was not 
significantly different relative to 0.5 h (p > 0.05) suggesting explants at both these two time points 
were at comparable oxygen levels despite the prevailing atmospheric oxygen levels. Oxygen 
saturation in control (media) at 24 h was significantly higher in comparison to the control at 0.5 h (p 
< 0.0001) and matrix at 0.5 h (p < 0.0001).The differences in oxygen levels (controls) might be 
reflective of differences in the atmospheric oxygen levels at these times of measurement.  
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Figure 3. 1 Oxygen saturation at 0.5 h and 24 h 
Mean oxygen saturation at 0.5 h and 24 h in media (control), were 14.8% ± 1.7 and 23% ±0.0 respectively, and in the 
matrices, 14.3 % ± 1.1 and 18.3 % ± 1.5 respectively. Oxygen saturation in matrices at 0.5 h and 24 h were not significantly 
different versus their respective media control at 0.5 h and 24 h (p > 0.05). There was no significant difference in oxygen 
levels in matrices at both times although oxygen saturation was higher at 24 h versus 0.5 h. Data is representative of the 
mean ± SD of six independent measurements. 
 
Visual inspection of retinal explants for signs of tissue degradation was undertaken with a light 
microscope on more than 15 independent occasions. Exemplar micrographs are presented in fig 3.2 
below. In comparison to equivalent retinal tissues cultured as free-floating culture in 2D, explant 
tissues and vessels structure were better maintained for more than 48 h without signs of 
disintegration. But retinal tissues and vessels degradation was evident in 2D cultured retinas after 24 
h and was further exaggerated after48h.   
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Figure 3. 2 Representative images of explants and 2D control. 
Explant tissues and vessels showed vessel intactness and absence of degradation for up to 48 h without signs of tearing or 
degradation (A-D), with slight signs of disintegration seen at 72 h. Retinal tissue and vessel disruption and disintegration 
was evident within 24 h of culture in 2D plates, which was exaggerated after 24 h (E-H). 
 
 
Morphological results (micrographs) were consolidated with histological examination. Results of 
retinal explants (fig 3.3) were consistent with typical retinal layers, nuclear bodies, and structures 
such as vascular networks (stained red), with erythrocytes (red) at 0.5 h (A) and 24 h (B) and were 
comparable to uncultured extracted retina (C), and uncultured non extracted retina fixed within the 
eye globe (D). Explants’ photoreceptors at 24 h (B) showed dark/black spots which may be dead cell-
bodies. Taken together, retinal layers demarcated by H and E stain were consistent with typical 
retinal structure and the major layers of the retina were clearly distinguishable confirming retinal 
tissue integrity.  
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Figure 3. 3 Representative Hand E results at 0.5 h and 24 h 
Selected micrographs of retinal explant at 0.5 h (40X) and 24 h (20X) post culture. Retinal layers in explants were identified; 
photoreceptors, outer nuclear layer (ONL), outer plexiform layer (OPL), Inner nuclear layer (INL), Inner plexiform layer (IPL) 
and ganglion cell layer (GCL). Explant retinal tissues at 0.5 h (A) and 24 h (B) were comparable to uncultured controls (40X), 
(extracted retina, C), and retina fixed within globe (D) in regards to presence of retinal layers. Explants’ photoreceptors 
(circled, white) at 24 h showed dark/black spots which may be due to an early photoreceptor injury or cell-death. Scale bar 
500µm  
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The composition of Gomori assay employed in this study was modified green Gomori: Chromotrope 
2R, Fast/light green and phosphotungstic acid with glacial acetic acid to give contrasting 
identification of collagen; cytoplasm (red), fibrin (pink), collagen (light or FCF green), and 
erythrocytes (red) (Garvey et al 1996). The dark stained (possibly green) contrasted from the 
pink/red (cytoplasmic/red blood cells) components of Gomori stain may indicate positivity of retinal 
explant section for collagen fibre (FCF/light green) at 0.5 h (B), 4 h (C) and 24 h (fig 3.4). Unstained 
tissue (A) counterstained with eosin alone (A) showed pink (eosin)cytoplasmic stain of the retinal 
outer nuclear layer (ONL), inner nuclear layer (INL) and the ganglion cell layer (GCL) without any 
Gomori stain. Retinal layers appear to have retained the green Gomori at 4 h in comparison to other 
time-points. In addition, based on the distribution of the dark Gomori stained (FCF green) which 
might be indicative of collagen fibre, the distribution of collagen (green/blue) appears to be localized 
to areas that corresponded with the outer nuclear layer (ONL), inner nuclear layer (INL), and ganglion 
cell layer (GCL). In addition to collagen, erythrocytes (red) were positively identified at all the time 
points (0.5 h, 4 h and 24 h), which may further add weight to the presence of viable red blood cells, 
thereby corroborating the presence of retinal vessel integrity (Garvey et al 1996).Sections were not 
counterstained with H & E in order not to mask any positivity for collagen but proper identification of 
Gomori positivity (green) may have been masked by poor image resolution.   
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Figure 3. 4 Representative modified Gomori results 
Selected micrograph of retinal explant sections at 0.5 h (B), 4 h (C) and 24 h (D) and unstained section (A) (control) 
counterstained with eosin to reveal cytoplasmic details. Dark stained Gomori may indicate structural collagen (FCF 
greenish) since sections were not counterstained with H & E in order not to mask any positivity for collagen, red blood cells 
(erythrocytes) (red), cytoplasm (red). Therefore the dark stained components of the Gomori sections might be indicative of 
collagen-fibre positivity but proper delineation of the FCF green stain may have been limited by the poor resolution of the 
images. Magnifications 400X. Scale bar 500µm  
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The functional viability of the explant vessels was demonstrated with contractile responses to KCl 
and Ang II. To illustratethe concept of contractile response, a selected retinal explant vessel at 24 h 
with a baseline diameter of 17µm before treatment with KCl, contracted to less than16 µm after KCl 
stimulation with 80 mM KCl(fig 3.5).  
 
 
 
Figure 3.5 Illustration of contractile response (KCl) 
Retinal explant vessel at 24 h responded to KCl evidenced by contractile response, which caused a reduction in the site 
measured from 17µm to less than 16µm. Final KCl concentration in the culture plate was 80 mM. Images were taken with a 
10X objective lens. 
 
 
Representative plot profiles of contractile responses to KCl (fig 3.6) and Ang II (fig 3.7) are presented 
to further illustrate contractile response. The y-axis is the Gray value which is the sum of all the 
pixels within the area measured and reflects the intensity, whilst the x-axis (distance in pixel) is a 
measure of the vessel diameter (in pixels which can be related to the actual diameter) by converting 
with a global scale at the magnification taken. For the purpose of illustration, the distance (in pixels) 
is used here, although the later results are analysed with diameter in microns. The profiles begin 
from the left (start) and end at the right (“End”). There was an inward shift in the distance (pixel) 
after stimulation with both KCl and Ang II versus their respective controls (“Before treatment”) at 24 
h. Bar plots of the plot profiles presented also demonstrates the vessel diameter decrease after KCl 
(fig 3.6C) or Ang II (fig 3.7 C) versus their respective controls (vessel dimension before treatment).  
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The plot profiles were automatically generated from Image J and the differences in the Y-axis scale 
might be reflective of the change in the vessel diameter post KCl addition as illustrated in the bar 
plot. In the Ang II result (fig 3.7), the scales remained the same because the effect of contractile 
effect (change in vessel diameter, less than 10 pixel units) was not as pronounced as the KCl effect 
(approximately 50 pixel units change). These representative plot profiles and their corresponding bar 
charts were further examples to illustrate contractile profiles, hence statistical analyses are not 
applied at this stage except that the mean and SD (error bar) were reported as shown.  
 
 
 
Figure 3. 6 Representative plot profiles (KCl) at 24 h 
The distance in pixel (x-axis) showed an inward shift with the addition of KCL (B) in comparison to control (Before 
treatment) (A). Plot profile showing decrease in vessel diameter after KCl versus before and after treatment is shown with a 
sample bar chart, C. The plot profiles were automatically generated from Image J and the differences in the Y-axis scale 
might be reflective of the change in the vessel diameter (decrease) post KCl addition as shown with the bar plot. 
Representative bar chart is mean ± SD. 
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Figure 3. 7 Representative plot profiles (Ang II) at 24 h 
The distance in pixel (x-axis) showed an inward shift with the addition of Ang II (B) in comparison to control (Before 
treatment) (A). Decrease in vessel diameter after Ang II versus before treatment is shown with the bar chart, C. In the 
example above, the Ang II effect (change in vessel diameter) did not appear as pronounced as the KCl effect. 
Representative bar chart is mean ± SD. 
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A total of 24 retinal vessels were tested with KCL (n = 8) and Ang II (n = 16) in n = 8 independent 
experiments. Responses were characterised as decrease (contraction) or increase (dilation) in vessel 
sizes relative to baseline (i.e. control). Summary of retinal vessel functionality by contractile response 
is presented with fig 3.8. The data in fig 3.8 represents change in vessel diameter (µm) (extent of 
contractile response or effect) measured from video recordings of selected vessels relative to the 
baseline (control) determined using equation 3.2. Original size at baseline (A) was subtracted from 
vessel size after treatment (KCl or Ang II) (B). The difference was divided by the original size (A) and 
expressed as a percentage (%).  
 
 
 
 
The large SD associated with the data might be reflective of differences in pixel intensities across the 
selected vessel as well as variations associated with movements/agitations in the culture plates 
picked up during recordings. The average sizes for vessels used for KCl effect determination were 
35±19 µm (0.5 h) and 27 ± 15 µm (24 h), and for Ang II; 72 ±18 µm (0.5 h) and 69± 7 µm (24 h). Thus, 
the high variability in responses may have been due to the use of vessels of various diameters. 
Moreover, distinction was not made of the type(s) of vessels or site (s) of treatment administration 
which could impact on the level or even the absence of response.  
However, nearly 70% (16 out of 24) of vessels tested showed contraction in response to KCl and Ang 
II which suggests functional viability. A total of 8 vessels (33%) showed increase in size in diameter 
after treatment relative to the control. KCl appeared to elicit more pronounced effect versus Ang II, 
although the effect was not statistically significant (p > 0.05) due to large standard deviations (SD). 
Since contractile response on Image J is measured by the differences in pixel intensities across a 
selected vessel, the large SD may be reflective of the differences in pixel intensities (grayscale) 
between adjacent ends of a vessel. Thus areas in the outer walls of a vessel may be lower in pixel 
intensity due to the lighter depth of red blood colour versus areas in the middle of the vessel. Data 
are reported as averages sizes ± SD.  
 
Size after treatment (B) – Original size (A)/Original size (A) X 100 
--------------------------------Equation 3.2 
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Figure 3. 8 Functional viability (KCl/Ang II) at 0.5 h and 24 h 
Data representing video recording of change in vessel diameter following addition of Ang II or KCl. Large SD associated with 
responses might be due to differences in pixel intensities across the selected vessel as well as variations associated with 
movement/agitation picked up during recordings. Also the variability in responses may be due intrinsic due to the 
differences in the vessel sizes/types which may have impacted on the level/absence of responses. Nearly 70% of explant 
vessels showed contractile responses to KCl or Ang II at 0.5 h and 24 h relative to controls. From the plots, the effect with 
KCl appears to be more versus to Ang II. Profiles are representative of n = 8 for KCl and = 16 for Ang II, n = 24 independent 
occasion and is representative of mean ± SD.  
 
 
 
Taken together, explant vessel viability and functionality during the period of culture was 
satisfactorily demonstrated with contractile responses to KCl and Ang II.  
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3.3.2. Hyperbaric oxygen model 
Gas pressure conversion to voltage (mV) was successful and sample traces of voltage in millivolts 
(mV) at 1 ATA and at 2.2 ATA are shown (fig 3.9, A) from which the pressure-voltage (mV) 
relationship (B) was derived. Average (n = 6) voltage value at 1 ATA and 2.2 ATA were 5.5 mV ± 0.0 
and 15 mV ± 0.0 respectively (B). To demonstrate consistency, measurements of n = 22 were taken 
(fig 3.9, C). Average voltage (mV) at 1 ATA and 2.2 ATA were 6 mV ± 0.0 and 15 mV ±0.0 which was 
consistent with the earlier validation with no significant variation seen between the two validations 
(p > 0.05). HBO procedure required gas pressure cycling between normoxia and hyperoxia, and the 
sensitivity of the pressure sensor to gas pressure cycling was demonstrated (D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
111 
 
 
Figure 3. 9 Pressure-Voltage conversion 
Gas pressure at 1 ATA and 2.2 ATA were converted to voltage (in millivolts) with a Honeywell gauge gas pressure sensor. 
Voltage (mV) measurements were assessed prior and during experiments to ensure consistency using the PicoLog voltage 
traces. Pressure to voltage conversion was not significantly different between initial validation and tests (p > 0.05). Cycling 
of pressure was possible as shown in the figure (D). Initial pressure validation was undertaken on six independent 
occasions. Further pressure-voltage validations were repeated n = 22. 
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Electrodes for the oxygen meter were calibrated at high point (100%) and zero point (0%) (fig 3.10 
A). Oxygen saturation (%) relative to atmospheric air as measured with a Strathkelvin oxygen meter 
(v782)  in air bubbled distilled water were 68%± 1.3 (control), and increased to 165% with the 
addition of 95% O2/5% CO2 gas (hyperoxia) at 1 ATA, and increasing further to 1200% ± 151 (p < 
0.0001, n =3) when pressure was elevated to 2.2 ATA. These % saturation equates to 320mmHg 
(control), 780 mmHg (95% O2 at 1 ATA) and 5700 mmHg (HBO) partial pressures of oxygen (Pao2) at 
sea level (Hodges et al 2003). Oxygen saturation was significantly higher in 95% O2 bubbled distilled 
water at elevated pressure of 2.2 ATA versus 1 ATA (p < 0.001), and air bubbled water at 1 ATA 
(control) (p < 0.0001). In converse, oxygen saturation was not significantly higher (p > 0.05) in 95% O2 
bubbled distilled water versus air (21% O2) bubbled water (p > 0.05). This demonstrated that 
elevated pressure (2.2 ATA) increases oxygen dissolution versus 1 ATA at constant temperature of 
37oC.  
The average time (n = 3) required to flush the chamber with relevant gas at 1 ATA or 2.2 ATA was 2.2 
mins ± 0.3, which was rounded up to 3 mins. This informed the time taken for the chamber to be 
saturated with the relevant gas for all experiments. 
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Figure 3. 10 Oxygen meter calibration and saturation 
Oxygen meter (v782) was calibrated at zero (0%) and high point (100%) as recommended by manufacturer (Strathkelvin). 
Oxygen saturation in chamber was measured in three independent experiments. Oxygen saturation was significantly higher 
in 95%bubbled distilled water at 2.2 ATA in comparison to controls; 95% O2 bubbled water at 1 ATA (p < 0.0001) and air-
bubbled water at 1 ATA (p < 0.001). Data is representative of n = 3 independent validations. Data is representative of mean 
oxygen saturation (%) ± SD. 
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Average  pH (n = 3) of HDMEC incubated media harvested after 120 mins of incubation of HDMEC in 
hyperbaric conditions; HBO and hyperbaric pressure were 7.3 ± 0.1 and 7.4 ± 0.1 respectively versus 
controls; bench top incubator (7.4 ± 0.1) and a normal 5% CO2 incubator (7.1 ± 0.1). The pH at all 
conditions; HBO, hyperbaric pressure and bench top incubator were higher in comparison to normal 
5% CO2 incubator, but these differences were not statistically significant (p > 0.05, n = 5 ) at 95% 
confidence level.  
 
 
 
Figure 3. 11 Media buffering capacity 
Media pH harvested from HDMEC incubated media after 120 mins of incubation in HBO, hyperbaric pressure, controls; 
bench top incubator and a normal 5% incubator were not significantly different (p > 0.05) and although media pH of 5% 
incubator  was lower versus the rest of the samples, it was not statistically different (p > 0.05). Data is representative of n = 
3 independent validations and it is representative of mean ± SD. 
 
 
 
Average temperature for internal (inside chamber) and external (within the incubator housing the 
chamber, n = 5 were 37oC ±0.0, and 37oC±0.1 respectively and no significant difference was seen (p > 
0.05).  
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3.4. Discussion 
Anchorage is vital for retinal tissue and vessel viability (Discher et al 2005). Here, provision for a 
biomechanical scaffold (anchorage) to preserve retinal tissue and vessel integrity was made with 
agarose-collagen three-dimension (3D) bilayer matrices within which whole retinal tissues were 
embedded and cultured as explants. This method of culture was employed to reduce retinal 
degradation due to rapid gliosis which occurs in free floating retinal cultures (Taylor et al 2014, 
Kaempf et al 2008, Kobuch et al 2008, and Fernandez-Bueno 2008).  
Circulation and innervations ceases upon the separation of the ocular globe from the main retinal 
blood vessels and the optic nerve, which will impact on tissue/cellular oxygen availability (Ferrer-
Martın et al 2014). Thus, oxygen availability to explants is a critical need in the absence of circulation. 
Oxygen availability within matrices was successfully validated. Based on the results obtained, matrix 
oxygen saturation (%) at 0.5 h and 24 h were comparable to their respective controls (media) (p > 
0.05). This showed the matrices did not pose a significant barrier/retardant to oxygen availability 
relative to the prevailing atmospheric oxygen levels. Matrix oxygen saturation (%) expressed as Pao2, 
at 0.5 h and 24 h were 57 mm Hg and 76 mmHg respectively. These values are higher than tissue and 
retinal compartments oxygen levels; inner segment of photoreceptors (0-5 mmHg), which goes to up 
20 mmHg in light and inner retinal oxygen is 20 mmHg (Yu and Cringle 2001, Wangsa-Wirawan and 
Linsenmeier 2003). Although the absence of circulation in the explant might impact global retinal 
circulation in explants and consequently circulating oxygen supply for vessels and tissues, the 
matrices are not likely to perturb in-vitro atmospheric oxygen availability to the retinal tissues based 
on the determined oxygen saturation (%) within matrices. Whilst matrix oxygen content was 
measured as part of the validation, matrix oxygen saturation was not measured during exposure to 
HBO treatments. However, since HBO is known to increase oxygen dissolution, it is likely that HBO 
will increase matrix oxygen content but this would have to be ascertained with further studies.  
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Morphological evidence showed retinal tissue preservation for more than 48 h in comparison to 
controls (2D) cultures. In 2D cultures, retinal tissues showed early (within 24 h) tissue and vessel 
disintegration which was exaggerated with time. This suggested the provision of a 3D environment 
enhanced retinal tissue preservation when compared to 2D culture which appears to be consistent 
(Knott et al 1999, Discher et al 2005, Taylor et al 2014). In future, it might be useful to delineate the 
mechanisms leading to dampened gliosis in retinal explants as a result of the agarose-collagen 3D 
matrix approach. Retinal explant cultures have been maintained for more than 2 weeks (Knott et al 
1999, Caffe et al 2001). In these studies, the provision of a 3D environment was essential to the 
experimental design, which further illustrates the argument here of the beneficial role of the agarose 
collagen matrix, although the maintenance (48 h) of the matrix here pales in comparison to the 
aforementioned works. ECM proteins such as collagen are important for key endothelial cell 
functions such as proliferation, differentiation, adherence, and cell-cell communication (Stendahl et 
al 2009 and Ulrich et al 2010, and Taylor et al 2015). It is likely the inclusion of collagen in matrices 
contributed positively to the longer preservation of explants on 3D matrices versus 2D.  
Gomori (dark/green) stained sections of retinal explants at 0.5 h, 4 h, and 24 h but more so at 4 h 
may indicate collagen incorporation from matrix into retinal tissues relative to control (unstained 
retinal section). In addition, Gomori stained collagen appeared to be associated with areas 
corresponding to the ONL, INL and GCL of the retina.  Furthermore, erythrocyte (red) appeared to 
co-localise with the areas of the retina which stained positive for collagen, highlighting the likelihood 
of collagen uptake via vessel networks.  It will be useful in any future studies to verify collagen 
uptake from matrices into retinal layers and to show any functional relevance of collagen uptake e.g. 
inclusion as ECM component by  staining explant sek2ctions with primary antibodies such as vinculin 
to check for focal adhesions between matrix collagen and retinal cytoskeleton. 
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Routine Haematoxylin and eosin (H and E) histological stain is used for retinal layer identification 
(Knott et al 1999 and Caffe et al 2001). When stained with H and E, the retina is a layered structure; 
the outer nuclear layer (ONL) containing the cell bodies of photoreceptors (rods and cones), the 
inner nuclear layer (INL), and the ganglion cell layer (GCL). These three nuclear layers are separated 
by two synaptic (plexiform) layers; the outer plexiform layer (OPL) lies between the ONL and the INL 
and the inner plexiform layer (IPL) which separates the INL and GCL (Gregg et al 2013). Therefore, 
the results of Hand E stained retinal sections which revealed clearly defined retinal layers are 
consistent with the typical retinal layered structure previously described (Taylor et al 2013, Knott et 
al 1999, Kaempf et al 2008, Kobuch et al 2008, and Fernandez-Bueno et al 2008). This result further 
consolidated the earlier observation with a light microscope and strengthens the hypothesis that 
culturing retinal tissues as explants on agarose-collagen matrices preserves retinal tissue integrity. 
Early demise of the photoreceptors and physiological thinning of the ganglion cell layer (GCL) occur 
as a result of blood flow cessation and nerve connection severance post sacrifice (Gancharova et al 
2013, Thangaraj et al 2011). Phenomenon such as thinning of the GCL was not seen within the time 
points under experiment in this study. However, observation was made of necrotic (dark-stained) 
cell-bodies associated with the area of the photoreceptor layer at 24 h in the vicinity of the 
photoreceptor – RPE (retinal epithelium) boundary. It is likely that trauma associated with excision of 
the retinal tissue from the RPE contributed to photoreceptor damage in the segment with necrotic 
like dark-stain cell bodies.  
Explant vessel functionality was satisfactorily demonstrated with a depolarising agent, KCl and a 
receptor specific agonist, Ang II. Nearly 70% (16 out of the 24 vessels) tested contracted in response 
to KCl or Ang II, whilst a total of 8 vessels (33%) showed increase in vessel sizes after treatment 
relative to control. In addition, more than 33% of the contractile responders were of effect sizes ≥ 
10% ± SD which is regarded as substantial effect. In general, Ang II appeared to elicit a lesser effect in 
comparison to KCl. In addition, its effect was very variable and it is likely Ang II response is much 
more complex in comparison to KCl. In pigs, Ang II is found in the Muller cells, retinal vessel 
endothelial cells, ganglion cells, photoreceptor cells, sub retinal fluid, vitreous fluid and choroid 
(reviewed in Choudhary et al 2017). Hence, Ang II response could have been elicited in any of these 
cells within the porcine retina, although only vessel associated effects were examined in this 
instance.  
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Ang II elicits most of its well-known vascular effects including vasoconstriction through its well-
known receptor, angiotensin receptor 1 (AT1R). On the other hand, AT receptor 2 (AT2R) is not well 
defined but it is proposed to oppose the actions of the AT1R contributing to vasodilatory effects 
rather than vasoconstriction (reviewed in Choudhary et al 2017). Therefore, theoretically 
vasoconstriction response by AT1R in explant vessels may have been blocked by AT2R. Although the 
distribution of AT1R and AT2R in pig retinal blood vessel is not well defined, in human retina, AT1R is 
more abundant and appears to be more associated with blood vessel responses than AT2R 
(Senanayake et al 2007, Choudhary et al 2017). Furthermore, Ang II effect is associated with the 
release of endothelial derived relaxing factors (EDRFs) such as NO which exhibits vasodilatation 
effect. Thus the possibility of Ang II associated EDRF release leading to vessel size increase as seen 
with some of the explant vessel is very likely. Moreover, the response of retinal vessels to Ang II is 
dependent on the site or type of vessel being stimulated (Kawamura et al 2004), with 3rd order (17-
19µm), and the smallest arterioles, 7-12µm being described as responders, while larger (A2 and A1) 
arterioles with luminal diameter of 79 ± 8µm and 126± 6µm are non-responder (Kulkarni et al 1999). 
Therefore, variability in response may have also accrued from this possibility. More so, the relatively 
low effect of Ang II in comparison to KCl may be due to the sizes of the explant vessels utilised in this 
study since the average vessel diameters for Ang II assays; at 0.5 and 24 h; 71.7 ±18 µm and 69.2 ± 7 
µm respectively were larger than the sizes described for responders (Kulkarni et al 1999. Moreover, 
because distinction was not easily made on the type of vessel being stimulated, it is possible some of 
the vessels tested were lymphatic, which would not respond to Ang II. These underline the 
complexity of Ang II response and might explain the large variability.  
Taken together, retinal vessel functionality by contractile response of explant vessel was sufficiently 
demonstrated with the outstanding (nearly 70%) effect with KCl and KCl which may indicate vessel 
viability and function at the times measured.  
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HBO therapy is a treatment carried out in diabetic patients with co-existing recalcitrant ulcers. HBO 
is also indicated for treatment of non-diabetic conditions such as poisoning, autism etc. There are set 
regimens for its administration and these can vary depending on the local guideline (HBOT Trust 
2018, Ritchie et al 2008). Therefore, to replicate clinical HBO procedure in order to understand its 
mechanisms, validations were necessary to ensure appropriate pressure and oxygen levels were 
applied in addition to controlling external factors such as temperature and pH which affects oxygen 
dissolution. It was also important to demonstrate robust gas cycling (i.e. changing from hyperoxia to 
normoxia) in HBO procedure was achieved without losing hyperbaric pressure (i.e. pressure was 
maintained at 2.2 ATA).  
Based on the results detailed previously in section 3.3.2, the conversion of gas pressure to a 
measurable and observable property, voltage (mV) was consistent without wide variations (SD 0.0, n 
= 22). This demonstrated the high sensitivity of the pressure-voltage converter that was used 
(Honeywell) as well as the relative constancy of the environment under which HBO experiments 
were undertaken. In vivo, pH and temperature can impact oxygen dissolution (Anaesthesia UK 2018). 
Therefore, constancy in pH and temperature in the HBO model setting was validated. The results 
showed no significant variation with respect to temperature and pH in samples (HDMEC) after 120 
mins of exposure to treatments; HBO or its single component controls; hyperoxia and hyperbaric 
pressure versus controls in normal 5% CO2 incubator (p > 0.05). In addition, the pH measured post 
HBO (7.3 ± 0.1) /hyperbaric pressure (7.4 ± 0.1) were within acceptable ranges for cell culture similar 
to the controls (7.1 ± 0.1 (Arora 2013). It likely, the treatments were associated with stress, which 
may have raised media pH immediately post treatments. However, treatments were not likely to 
affect media buffering capacity because such raises in pH post treatments relative to control were 
not significant (p > 0.05). There are studies that have reported on the impact of 
extracellular/intracellular pH on endothelial cell physiology (Capellini et al 2013). Based on the pH 
results, HDMEC physiology are not expected to be affected, since the validations established the pH 
post treatments were not statistically different from the controls.  
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With respect to validation of the HBO unit, a key observation was that HBO gave rise to significantly 
higher oxygen dissolution in water in comparison to hyperoxia alone (p < 0.0001). While it is 
appreciated that distilled water posed no barrier to diffusion in comparison to the complex systems 
of diffusion transport in the human body, this observation highlights a key principle of HBO therapy 
which is its ability to increase oxygen dissolution (HBOT Trust 2018, Ritchie et al 2008, and Godman 
et al 2010). Plasma PaO2 of up to 1804 mmHg was achieved at 2.5 ATA, which was 10-fold higher 
than the normal PaO2 at sea level (1 ATA) (Hodges et al 2003). Likewise, in this study, PaO2 with HBO 
at 2.2 ATA (5700 mmHg) was significantly 18X higher than the control (air bubbled water) (320 
mmHg) at 1 ATA and 7X higher than hyperoxia bubbled water in the absence of elevated pressure at 
1 ATA (780 mmHg).  
In summary, the retinal explant model was validated, and the integrity of the tissues and vessels 
were demonstrated. HBO was validated with respect to pressure, oxygen saturation, pH and 
temperature. Importantly, increased oxygenation with HBO was demonstrated which is consistent 
(Ritchie et al 2008, Thom 2011, HBOT Trust 2018).  
Increased oxygenation is associated with increased production and signalling of reactive species such 
as ROS and RNS (Thom 2011). Both of these reactive species are implicated in the beneficial 
mechanisms of HBO (Godman et al 2008, Ritchie et al 2018, Thom 2011), but also are associated with 
endothelial deregulations as seen in diabetic perturbations (Cai and Harrison 2000, Tiganis 2011). In 
the next chapter, the effects of increased oxygen and pressure levels in high glucose concentration 
on the morphology (size) and metabolic activities of human dermal microvascular endothelial cells 
(HDMEC) were studied.  
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3.5. Limitations 
There were wide variations in contractile response assays which may in part be indicative of the 
differences that are intrinsic, for example due to vessel specific variations; vessel size, vessel type, 
site of application etc. since the electrotonic responses of retinal vasculature differs based on these 
factors (Nakaizumi et al 2012). In addition, the method of video capture and limitations with the 
magnifications of the microscope used limited the possibility of differentiating what vessel types are 
selected for stimulation in order to elicit response since not all vascular beds are responsive to KCl 
and Ang II (e.g. lymph vessels), and Ang II associated responses are dependent on the vessel size 
(type) (Nakaizumi et al 2012). Confounding factors to Ang II induced contraction such as EDRFs or 
AT2R induced antagonism were not controlled or excluded prior to Ang II stimulation. In any future 
experimental design contractile assay could be performed only on designated vessel type, to reduce 
inherent variability in response. EDRF or AT2R blockade prior to Ang II stimulation might have helped 
to reduce the variability and complexity in order to appreciate true Ang II effects. The validation of 
matrix oxygen was not extended to measure oxygen content post HBO, or hyperoxia and hyperbaric 
pressure as conducted for HDMEC. It is likely this aspect would have provided an insight into the 
possible role of HBO (and its single constituents) on oxygen dissolution within matrices.  
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Chapter 4.0: Endothelial cell size and 
metabolic activity 
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4.1 Hypothesis 
The changing concentration of glucose, oxygen tension and pressure has an effect on human dermal 
microvascular endothelial cell morphology leading to changes in size and metabolic activity.  
 
4.2 Introduction 
In chapter 3.0, the protocol and method used for the HBO model development were confirmed to be 
robust and repeatable. Here, HDMEC were exposed to treatments in the validated HBO chamber in 
the context of high glucose. Post treatments, the impact of HBO, or its single components on HDMEC 
morphology or metabolic activity in the context of high glucose was assessed with analysis of HDMEC 
live images and metabolic activities (relative fluorescent units) (RFU) with Resazurin relative to 
controls.  
The endothelium releases ROS and vasoactive molecules such as Ang II and endothelin -1 (ET-1) in 
response to mechanical stimuli (shear stress/stretch) (De Keulenaer et al 1998, Schramm et al 2012). 
Hyperoxia in the context of HBO administration enhances blood oxygenation and increased ROS 
production is a key mechanism in HBO associated beneficial effects (Thom 2011, HBOT Trust 2018). 
Therefore, it is imperative to understand the effect(s) of increased oxygenation on endothelial cells 
which are in immediate contact with increased levels of oxygen and the attendant mechano- 
associated stimuli (shear stress/elevated pressure).  
The physiological functions of endothelial cells are dependent and reflective of their morphology. In 
static in-vitro culture, ECs exhibit a non-aligned polygonal cobblestone appearance (Phillips et al 
1988; Malek and Izumo 1996 Chung et al 2000; Leung et al 2002 and Potter et al 2011). Depending 
on the stimulus, cultured endothelial cells exhibit cell-specific change in shape and size. In pulmonary 
vascular beds, size enlargement of endothelial cells occur in response to hyperoxia due to ROS 
elevation which is associated with an increase in endothelial [Ca2+] levels and actin cytoskeleton 
rearrangements (Bowden and Adamson 1974, Crapo et al 1980, Phillips et al 1988, Brueckl et al 
2006, Roan et al 2012 and Attaye et al 2017).  
 
 
 
 
 
 
  
124 
 
On the other hand, in renal and mesenteric microvascular beds, hyperoxia results in a decrease in EC 
size due to hyperoxia mediated decrease in endothelial nitric oxide (NO) and increase in 
vasoconstrictors such as cyclooxygenase (Attaye et al 2017). Moreover, hyperoxia-induced retinal 
vasoconstriction in the human retina occurs via hyperoxia-induced ET-1 upregulation (Dallinger et al 
2000). Furthermore, hyperoxia is associated with cerebral vasoconstriction (Floyd et al 2003). The 
impact of hyperoxia on endothelial cells of dermal origin is not well reported. Therefore, an insight 
can be gained from this study on the effect of hyperoxia on HDMEC which is of a dermal origin. 
The morphological shape of endothelial cells in-vivo is closely related to their location within the 
vessel lumen. Luminal endothelial cells in areas of high laminar shear stress are elongated and 
aligned while those in low shear stress areas are randomly orientated (Chung et al 2000, Potter et al 
2011). Likewise, endothelial cells in static culture change their polygonal shape and adopt uniform 
alignment (retracted and smaller in size) in response to increased flow and shear stress, or elevated 
pressure which has a knock on effect on shear stress (Malek and Izumo 1996). Cell alignment in 
response to flow or shear stress is common to ECs of all vascular beds (Barbee et al 1994, Malek and 
Izumo 1996, Chung et al 2000). Increased intra-cellular calcium via tyrosine kinase activity and actin 
microtubule rearrangement independent of PKC activation is proposed as a mechanism (Malek and 
Izumo 1996).  
Permeability factors including high glucose and inflammatory cytokines also exert influence on 
endothelial cell morphology (Himmel et al 1993, Malek and Izumo 1996, and Leung et al 2017). In 
cultured endothelial cells, high glucose induced whole phenotypic change in a glucose dependent 
mechanism involving PKCα activation (Hempel et al 1997). In vivo (db/db mice), high glucose induced 
endothelial cell shape to a mesenchymal (spindle) (Peng et al 2016). In addition, ultrastructural 
alterations in endothelial cells was induced by high glucose (25 mM) in human aortic EC (HAEC) 
cultured for 1–2 weeks and in (the vasculature of mice and golden Syrian hamsters at 6 weeks and 
6 months, respectively after streptozotocin injection have been documented (Simionescu et al 1996, 
Popov and Simionescu 2006). High glucose associated changes in human vascular endothelial cell 
contraction and hyperpermeability is proposed to be due to cytoskeleton configuration as a result of 
hyperglycaemia induced AGE and RAGE/Rho signalling pathway (Hirose et al 2009).  
Inflammatory cytokines and endothelium derived factors (EDRFs) such as Ang II and ET-1 are another 
class of permeability factors which are associated with ‘rounding’ i.e. retraction and contraction of 
endothelial cells leading to reduction in EC size (Himmel et al 1993, Malek and Izumo 1996 and Leung 
et al 2002).  
 
 
  
125 
 
Endothelial cells are quiescent with little change on their metabolic need, but they increase 
metabolic need when switching from quiescent to vascular sprouting (De Bock et al 2013, 
Doddaballapur et al 2015). There are not many studies that have investigated the direct effect of 
hyperbaric oxygen (HBO) on endothelial cell metabolic activity. A HBO associated protective effect 
on the metabolic activity of immortalized human microvascular endothelial cell (HMEC-1) was shown 
(Godman et al 2010), which suggested that HBO may be associated with the reversal/modulation of 
hyperoxia-associated metabolic activity decline in endothelial cells. The likelihood of HBO alleviation 
of metabolic decline in HDMEC will be tested in this study. In this chapter, the aim is to examine 
effect (s) of HBO and its single components on the morphology (size) and metabolic activity of 
human dermal microvascular endothelial cell (HDMEC) in the context of high glucose in comparison 
to control conditions. 
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4.3 Materials and Methods 
HDMEC in low or high glucose HDMEC growth media (MV) were exposed to treatment as previously 
described in chapter 2 section 2.8. Post treatment, HDMECs were incubated in a normal 5% CO2 
incubator for 4 h  and images of live HDMEC were captured and used for size analysis. Full detail of 
image capture and size measurements are covered in the materials and methods section in chapter 
2.0 section 2.9. HDMEC in low or high glucose HDMEC growth media (MV) were also incubated with 
Resazurin post treatment for 24 h. Prior to carrying out Resazurin assay in experimental samples, 
control experiments were carried out to determine optimal seeding density and incubation duration. 
All Resazurin optimisation experiments were carried with HDMEC in control condition in low glucose. 
HDMEC were seeded in clear 96-well plates (surface area of 0.32cm2) at a density of 1 x103, 2x 103, 5 
x 103, 8 x 103, and 10 x 103 per well in 100 µl of HDMEC growth media (MV) according to kit 
manufacturer’s (Cell Signalling Technology, CST) seeding density and HDMEC supplier (PromoCell) 
recommendations. Blank (no cell) control with 100-µl of media was set up as control. Fluorescence 
from the no-cell control wells was subtracted from cell-incubated wells to obtain the relative 
fluorescence units (RFU), an indicator of metabolic activity expressed in x 104. For initial validation to 
determine optimal cell density per well and incubation time, samples in triplicates were incubated at 
37oC in a 5% CO2 incubator and reached approximately 70% confluence after 48 h. HDMEC were 
treated with 10µl Resazurin (10X) solution (CST) per well in the dark. Fluorescence was measured at 
0, 6, and 24 h using a Synergy HT microplate reader (Biotek) at 530-570nm excitation wavelength 
and 585-590nm emission wavelength. Results of Resazurin optimisation are presented first in the 
result section for Resazurin assay (4.4.2) before experimental assay results in the same section. More 
details of the Resazurin assay are described in chapter 2.0 sections 2.7. In all experiments non-
confluent HDMEC were incubated with Resazurin for 24 h. Non confluent HDMEC at cell plating 
density of 5 x 103 were used for Resazurin assay since confluent cultures are associated with 
senescence.  
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To determine the effects of treatment on HDMEC sizes (P4-7), photomicrographs of live HDMEC 
were captured as described in chapter 2 section 2.9. A total of n = 40 photomicrographs from four 
independent experiment (10 micrographs/experiment) were coded independently (blinded). Before 
actual measurements, trial measurements with Image J free-hand tool were undertaken and 
repeated several times on the same cell and/or with several samples until measurements with 
minimal standard deviations (<10%) were reached. Measurement of coded samples was undertaken 
by measuring the perimeter (size) around HDMEC with clearly defined borders as shown in fig 4.1 (A) 
by tracing around the cell with an Image J free-hand drawing tool, as shown in fig 4.1, B (circled for 
illustration). The identities were revealed post image analysis. Analysis was performed with 1way 
Anova and Tukey’s post hoc test in Graph Pad Prism vs 5.0.  
 
 
 
Figure 4. 1 Illustration of HDMEC size measurement 
K8HDMEC sizes were measured with Image J free hand drawing tool. Marked cells, (A) with visible borders were traced 
around the perimeter with a free drawing tool (highlighted in yellow) (B). Therefore the values in the result section in 
microns (µm) represents mean values (n = 40) measured for cells (HDMEC) for controls and treatment conditions. The 
values represents the distance around cells rather the diameter or length.  
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4.4 Results 
 
 
4.4.1 Effect of varying glucose concentrations, oxygen 
tension and pressure on HDMEC morphology and size. 
Control HDMEC in low glucose showed typical cobblestone polygonal HDMEC morphology at 4 h (fig 
4.2, A). HDMEC in high glucose showed no distinct difference in phenotype relative to low glucose 
samples. Likewise, HDMEC in HBO displayed typical cobblestone/polygonal morphology relative to 
controls (fig 4.2, C and D). When hyperbaric pressure alone was applied, HDMEC appeared stretched 
and retracted around the cell edges (Fig. 4.3, A and B) in comparison to control. However, although 
these cells in hyperbaric pressure condition exhibited retracted and stretched morphology, their 
mean sizes were not significantly different from the control samples (p > 0.05). In converse, HDMECs 
in hyperoxia appeared engorged and spread out (fig 4.3, C and D). These morphological alteration 
post hyperoxia in low glucose was associated with a significant increase in HDMEC size relative to 
control (p < 0.05) (fig 4.4). In the representative images (fig 4.2-4.3), close-up images of single cells 
have been inserted for all the conditions to better delineate any effect of treatment on HDMEC sizes. 
For instance, a representative cell in the control condition (insert) has a distance of approximately 
1400 µm around it i.e. perimeter/circumference rather diameter or length. This value relates to the 
size for the cell and reported as mean size (n= 40) ± SEM from four independent experiment.  
 
 
 
 
 
 
  
129 
 
 
Figure 4. 2 HDMEC morphology in control and HBO at 4 h 
Live cell image of HDMECs at 4 h post treatment in control condition in low (A) and high (B) glucose showed no distortions 
from typical HDMEC morphology (see fig 2.1). Similarly, HDMEC exposed to HBO treatment did not show any distortions 
and remained similar in characteristics (shape and size) to HDMECs in control condition. Representative cell (insert) with 
cross-sectional area (perimeter) of approximately 1400 µm (this value is the distance around the selected cell which may be 
reflective of its perimeter/circumference). Images were reduced to 50% of their original size to fit the page. Result 
represents mean size (µm) (n= 40) ± SEM from four independent experiments. Scale bar = 1000 µm. 
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Figure 4.3 HDMECs morphology in hyperbaric pressure and hyperoxia at 4 h 
Live cell photomicrographs of HDMEC taken 4 h after exposure to hyperbaric pressure in low (A) and high (B) glucose 
appeared stretched and more rounded in comparison to controls (see fig 4.1, A). On the other hand, HDMECs exposed to 
hyperoxia in low (C) and high (D) glucose appeared engorged and spread out in comparison to control. Images were 
reduced to 50% of their original size to fit the page. Result represents mean size (µm) (n= 40) ± SEM from four independent 
experiments. Scale bar = 1000 µm.  
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One-way analysis of variance indicated that mean (n = 40) HDMEC sizes were significantly changed 
between samples (p < 0.0001, n = 8) (fig 4.4). This value (i.e. size) is the distance around a selected 
cell which is reflective of its perimeter/circumference, rather than the cell diameter or length 
expressed as mean sizes (n = 40) (see fig 4.1 for illustration). Tukey’s post hoc analysis showed the 
mean sizes of HDMEC in low glucose post hyperoxia were significantly higher in size in comparison to 
control (p < 0.05). In addition, the mean sizes of HDMEC in hyperoxia were significantly higher in 
comparison to HBO (p < 0.05) and hyperbaric pressure (p < 0.01). Glucose effect on HDMEC sizes for 
control or treated samples was not significant (p > 0.01), although a pattern of high glucose 
associated increase in sizes appeared imminent for HDMEC in control and HBO conditions (p > 0.05). 
HDMEC in hyperbaric pressure showed a pattern of decreased sizes which may be reflective of the 
observed retracted morphology however their sizes were not significantly changed in comparison to 
control samples (p > 0.05).   
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Figure 4.4 Effect of treatments on HDMECs sizes 
A 1way ANOVA determined significant differences (***p =0.0001, n = 8) between the means of all sample. 
HDMEC sizes did not change with respect to glucose concentration for HDMEC in control condition. Similarly following 
exposure to HBO, no glucose associated changes were seen. HDMEC in HBO and hyperbaric pressure were comparable in 
size to control condition samples (p > 0.05). HDMEC in hyperoxia in low glucose had significantly higher sizes in comparison 
to control (p < 0.05), HBO (p < 0.05), and hyperbaric pressure (p < 0.01). The values plotted are the mean ± SEM distances 
around the selected cells (n = 40 per sample) which may be reflective of its perimeter/circumference). Result represents 
mean size (µm) (n= 40) ± SEM from four independent experiments. 
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4.4.2 Resazurin metabolic activity assay 
Results for Resazurin assay optimisation for the determination of optimal seeding density and 
optimal incubation time are shown in the figure fig 4.5. As shown from the figure, Resazurin 
detection was highest at 24 h (B) in comparison to 6 h. Maximum colour change was seen after 24 h, 
with seeding densities of 5 x103, 8 x 103 and 10 x 103 (A), which indicated showed the optimal 
incubation period was 24 h. These changes were quantified by determining the relative fluorescent 
units (RFU).  Line plots shows a linear change in RFU with increasing plating density which is 
indicative of a linear conversion of Resazurin in relation to metabolic activity (Ahmed et al 1994), but 
higher plating densities of 8 x 103 and 10 x 103 per well were associated with a plateauing in RFU 
values (C and D), which suggests the conversion of blue Resazurin to pink resorufin at these cell 
densities was no longer directly proportional. Bar charts are coloured to reflect picture in A. Based 
on these optimisation, a cell concentration of 5 x103 cells (HDMECs) per well and incubation time of 
24 h was used for Resazurin assay. In all validation and experiments including Resazurin experiments, 
non-confluent HDMEC were incubated with Resazurin for 24 h.   
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Figure 4.5 Resazurin assay optimisation 
Maximum Resazurin colour change was seen at 24 h (A and B), with a slight colour change at 6 h. Resazurin conversion was 
quantified as RFU, an indicator of metabolic activity. Plot (B), shows RFU values for different cell densities of HDMEC in 
control conditions at 6 h and 24 h. Bar charts are coloured to reflect picture in A. Resazurin conversion at 24 h showed 
linear Resazurin conversion in relation to cell density (C). Higher cell densities of ≥ 8 x10
3
 were associated with Resazurin 
conversion plateau (D) where there was no longer linear conversion of Resazurin to resorufin. Plating cell density of 5 x 10
3
 
showed linear conversion and was considered optimal plating density for Resazurin assay. 
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When data from Resazurin experiment were analysed there were significant inter-batch variations in 
RFU (p < 0.05) between replicates warranting data normalisation. Samples in hyperoxia showed a 
pattern of decreased metabolic activity as a group in comparison to controls and the rest of the 
samples. Thus, HDMEC in hyperoxia with significantly larger sizes appeared to have the lowest 
metabolic activity. Post normalisation, 1way Anova identified differences in mean metabolic 
activities between samples (p < 0.05). Using Tukey’s post-hoc analysis, there were no significant 
differences in mean metabolic activities between all samples in comparison to the control (p> 0.05). 
A Bonferroni’s analysis indicated significant reduction in metabolic activities for HDMEC in hyperoxia 
(low glucose ) in comparison to hyperbaric pressure (p < 0.05) but it was not significant relative to 
control  (p > 0.05) (fig 4.6). Statistically significant glucose effect on metabolic activities was not 
evident (p > 0.05) (p > 0.05) 
 
 
Figure 4.6 Metabolic activity of HDMEC after normalisation 
HDMEC metabolic activity was changed between samples (p < 0.05) based on 1way Anova. Tukey’s post-hoc did not reveal 
significant differences in metabolic activity between samples (p > 0.05) but a statistically less stringent Bonferroni’s 
comparison showed significant decrease in metabolic activity for samples in hyperoxia (low glucose) in comparison to 
samples in hyperbaric pressure (p < 0.05), but not to controls (p > 0.05). Data is representative of mean (RFU) (5.5 mM: 
control, HBO, hyperbaric pressure, n = 30, hyperoxia, n = 18) of sixplicates repeated on five (controls/HBO, hyperbaric 
pressure), or three (hyperoxia) independent occasions.  
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4.5 Discussion 
HDMEC is made up of 87% human dermal lymphatic endothelial cells (HDLEC) and 13% blood 
endothelial cells (BEC). Therefore, the vast majority of HDMEC are of HDLEC origin. HDMEC are 
approximately 60-100 µm in length and 27-54 µm in diameter (width) (PromoCell). In this study, the 
total length around selected cells, i.e. perimeter or circumference (n = 40) rather than length or 
diameter (width) were determined to ascertain the impact of treatment on HDMEC sizes 
(morphology). Hyperoxia (in low glucose) was associated with HDMEC that were significantly bigger 
in size in comparison to control and HBO (p < 0.05), and hyperbaric pressure (p < 0.01). In addition, 
HDMEC in hyperoxia showed a pattern of diminished metabolic activity relative to control (p > 0.05). 
The metabolic activity of HDMEC in hyperoxia was significantly lower in comparison to hyperbaric 
pressure (p < 0.05) but this analysis was based on Bonferroni’s analysis, and the data requires more 
experimental repeats in order to establish a stronger link.  
The results here showed sufficiently some previously reported alterations in endothelial cell 
morphology in response to hyperoxia and elevated pressure (Bowden and Adamson 1974, Crapo et 
al 1980, and Brueckl et al 2006, Phillips et al 1988; Malek and Izumo 1996 Chung et al 2000; Leung et 
al 2002 and Potter et al 2011). Hyperoxia associated change in HDMEC sizes appeared to corroborate 
their enlarged/engorged phenotype of HDMEC post hyperoxic treatment. Although, HDMEC in 
hyperbaric pressure appeared retracted and rounded morphologically, their altered phenotype was 
not associated with statistically significant change in their mean sizes relative to control. To further 
establish the implications of these results, it is important to have more robust experiments, with 
larger data sets and perhaps longer incubation periods with excellent cell analysis software e.g. 
CellProfilerTM in combination with Bioinformatics.  
Theoretically HBO should result in higher ROS or oxygen associated signalling/effect in comparison to 
hyperoxia since HBO is associated with higher oxygenation (Thom 2011). Yet as seen from this study, 
hyperoxia and not HBO was associated with significant alterations in HDMEC morphology, with a 
pattern of dampened metabolic activity. This suggests the effects of hyperoxia alone and the 
compounded use hyperoxia and hyperbaric pressure (HBO) on HDMEC are distinct and poses 
pertinent question(s) as to the likely mechanism(s) elicited in hyperoxia in comparison to HBO and 
vice versa.  
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It is noteworthy that hyperoxia-associated endothelial cell size enlargement has predominantly been 
reported in studies of hyperoxia in pulmonary context owing to ROS mediation. Thus in this study, 
hyperoxia associated size increase in HDMEC is suggestive of ROS associated/mediated effect. But 
ROS blockade studies are necessary to accurately pin-point ROS involvement. In addition, it is 
needful to establish downstream mediators that were central to HDMEC size enlargement post 
hyperoxia. Fundamentally, since HDMEC are dermal in origin, this result represents a new insight on 
the possible role of hyperoxia on dermal endothelial cell and warrants further investigation to 
establish its exact effects and mechanisms.  
The enzyme 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 3 (PFKPB3) offers a direct link 
between endothelial cell morphology and metabolic activities (Doddaballapur et al 2015). Decreased 
expression of PFKFB3 enzyme is associated with a stress-mediated modulation of endothelial cell 
phenotype (Doddaballapur et al 2015). Hence, inference could be made to the possibility of 
hyperoxic stress-mediated inhibition of PFKFB3 (decreased expression) and modulation of HDMEC 
phenotype (size). And because the modulation of HDMEC size post hyperoxia was significantly 
evident in low glucose, this strengthens the indication of a hyperoxia alone effect. Since PFKPB3 links 
stress and endothelial phenotype with metabolic activity, it would be worthwhile to examine further 
the expression levels of this enzyme post HBO or hyperoxia as it may also reveal further evidence.  
Mechanical stimuli (shear stress/stretch) in the endothelium are associated with increased secretion 
of permeability mediators such as inflammatory cytokines and vasoconstrictors Ang II and increased 
ROS production (De Keulenaer et al 1998, Schramm et al 2012). HDMEC exposed to hyperbaric 
pressure showed phenotypic retraction and contraction, although their mean sizes were not 
significantly different relative to the control (p > 0.05). Such phenotypic retraction in response to 
hyperbaric pressure is likely an adaptive response in response to elevated pressure acting on their 
cell surfaces. Phenotypic retraction and contraction is associated with the release of mediators such 
as cytokines (De Keulenaer et al 1998, Schramm et al 2012). Importantly, endothelial cells activate 
the expression of an endothelial specific mediator, the platelet endothelial cell adhesion molecule -1 
(PECAM-1) in response to mechanical stresses/stimuli such as retraction and contraction (Conway 
and Schwartz 2014). Thus it is likely, these treatments will be associated with changes in the 
expression of mediators in comparison to control. However, this inference needs to be established 
with further experiments. 
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Glucose effect on HDMEC morphology was not statistically significant although a pattern of high 
glucose associated increase in HDMEC mean sizes appeared imminent in the control and HBO 
conditions (p >0.05). Human umbilical vein endothelial cells (HUVEC) exposed to 60 – 120 mM of 
glucose for up to 168 h exhibited endothelial – mesenchymal phenotype (polygonal – spindle) 
transition with manifest changes in sizes (Yu et al 2017). In addition, increased endothelial cell 
contraction and VE-cadherin junctional permeability was observed with glucose concentrations of 20 
mM (Hempel et al 1997, Sandoval et al 2001). More so, ultrastructural alterations in human aortic EC 
(HAEC) cultured for 1–2 weeks in high glucose (25 mM), and mice/golden Syrian 
after streptozotocin injection are reported (Simionescu et al 1996, Popov and Simionescu 2006). In 
human vascular endothelial cell, high glucose associated contraction and hyperpermeability were 
caused by hyperglycaemia induced AGE and RAGE/Rho signalling pathway and AGE formation 
(Hirose et al 2009). Incidentally, AGE induction by hyperglycaemia requires long duration (≥ 2 weeks). 
Hence, it is likely the glucose concentration used (20 mM) and duration of incubation (4 h) in this 
study was not sufficient to instigate substantially pronounced and observable phenotypic changes in 
HDMEC. As a caution, the absence of measurable phenotypic change does not completely negate the 
likelihood of glucose-mediated effect, which may have been obscured to light image microscopy. In 
retrospect, a confocal might have been advantageous in revealing these deeper structural 
details/deregulations.   
Resazurin conversion to resorufin by dehydrogenase enzymes in viable cells is visually assessed by 
the colour change from blue to bright pink (Ahmed et al 1994). From the optimisation experiments, 
it was apparent the metabolic activities of HDMEC were not acutely (6 h) changed in control 
condition even at high plating densities ≥ 8 x103 per well. Also, although there was an observable 
colour change at 6 h which was indicative of metabolic activity, maximal colour change was seen 
only after 24 h which is suggestive of a slow metabolic phenotype in comparison to the aggressively 
fast metabolic phenotype of transformed cells or sprouting endothelial cells (Ahmed et al, 1994, 
Nakayama et al 1997, Zalata et al 1998, Perrot et al 2003, De Bock et al 2013 and Doddaballapur et al 
2015).  
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In summary, a key observation in this chapter is the modulation of characteristics in HBO that were 
widely out of norm in hyperoxia (mean HDMEC size). The use of HBO or hyperbaric pressure alone 
was not associated with significant changes in HDMEC sizes or metabolic activity relative to the 
control samples. Morphologically, based on live cell images, HDMEC in hyperbaric pressure appeared 
retracted in comparison to cells in control condition although this morphological change was not 
linked with a significant change in their mean sizes relative to control. Furthermore, varying 
concentrations of glucose was not associated with a significant effect on HDMEC size or metabolic 
activity.  
Cells mount inflammatory and redox response as a protective mechanism. Arguably HBO is 
associated with both stress and ROS activation (Thom, 2011). The pertinent question is why/how the 
changes associated with hyperoxia were not seen with HBO. There is likely a HBO stress/trauma 
response that is far more protective, and possibly more sustained and more extensive to give such 
balanced effect in the presence of perturbations that otherwise drove phenotypic and biochemical 
changes in hyperoxia. Therefore, in the next chapter, redox and pro-inflammatory responses are 
investigated.  
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4.6 Limitations 
Live HDMEC imaging and size measurements were carried out using Image J analysis of 
photomicrographs captured with a light microscope. Cellular details were sometimes obscured, thus 
limiting the total number of HDMEC analysed per condition, because only cells with clearly defined 
edges were measured (n = 40). Had larger number of cells been analysed, the power of the 
experiment and statistical outcome may have been more significant. Therefore, it is needful in any 
further studies to use better imaging and cell size analysis software such as CellProfilerTM.  In 
retrospect, a cell plasma membrane stain such as CellMask Plasma Membrane Stains (Invitrogen, 
ThermoFisher) could have been used to stain and delineate HDMEC cell edges more precisely. Due to 
limitations with magnification of the imaging microscope, it was not possible to assess HDMEC cell-
cell adhesion/junction in order to ascertain any glucose-mediated disruption of junctional networks.  
ROS elevation was not investigated in the study. Instead, inference to treatment mediated ROS 
elevation was made based on what is reported in relation to hyperoxia/hyperbaric pressure/HBO 
(Thom 2009 and 2011, De Keulenaer et al 1998, Schramm et al 2012). To rightly establish the role of 
ROS, ROS blockade ideally could have been incorporated in the experimental design. To circumvent 
this limitation, the expression of nrf2 is examined in the next chapter but a study could have been 
included to investigate the effects of ROS blockade on some of the experimental outcomes including 
HDMEC morphology and nrf2 expressions. 
Although the premise of this study was the examination of the effects of conditions on HDMEC 
morphology, size and metabolic activity in the context of high glucose, significant high glucose 
related changes were not identified and although high-glucose associated trends were imminent (p > 
0.05). The time of incubation of HDMEC in high glucose prior to imaging may have been too short (4 
h), and a longer incubation period would have been more revelatory. In experimental designs where 
a glucose concentration of 25 mM was utilised in HAEC, a longer duration of culture (1-2 weeks) was 
employed (Simionescu et al 1996, Popov and Simionescu 2006). Moreover it is possible the glucose 
concentration used was not optimal for inducing such rapid morphological changes since previous 
work in HUVEC using 60-120 mM glucose was associated with significant size changes in HUVECs (Yu 
et al 2017). Finally, microscopy with a confocal might have been advantageous in revealing deep 
structural details/deregulations due to high glucose. 
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Chapter 5.0: Inflammatory and Redox 
Responses
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5.1 Hypothesis 
The changing concentration of glucose, oxygen tension and pressure has an effect on human dermal 
microvascular endothelial cell redox and immunological responses. 
 
5.2 Introduction 
 In chapter 4.0, the morphology (size and shape) of HDMECs was significantly changed in hyperoxia 
(low glucose) in comparison to control. Under the duration of study (4 h), no significant glucose 
associated effects on HDMEC size was seen. Endothelial cells are sensitive to varying glucose 
concentration, oxygen levels and mechanical (shear/stretch) stimuli (Ruderman et al 1992, Brownlee 
et al 1989 and 2005, Akgu¨et al 2014). Elevated glucose, hyperoxia and mechanical shear/stretch 
stress increase ROS production both in-vitro and in-vivo (Brownlee, 2005, Li et al 2011, Hsieh et al 
2009, reviewed in Nguyen et al 2009), and in-vitro application of elevated pressures of ≥ 2.2 ATA has 
a knock on effect on mechanical stimuli (shear/stretch stress) on cultured endothelial cells (Godman 
et al 2010). Acute short-term ROS is beneficial in the right milieu. For instance HBO exerts some of its 
beneficial effects via ROS and reactive nitrogen species (RNS) (Thom 2011, Godman et al 2010, and 
HBOT Trust 2018). In addition, acute ROS generation is a defensive mechanism to forestall sustained 
oxidative damage. However, sustained elevated ROS level causes endothelial dysfunction (reviewed 
in Knott and Forrester 2003, Du et al 2003, reviewed in Falanga 2005, Brownlee 2005, and Adamis 
2008).  
The nuclear factor erythroid 2-related factor 2 (nrf2) is a key transcription factor that regulates the 
expression of genes involved in cytoprotection, cellular metabolism and ageing (reviewed in Nguyen 
et al 2009, Heiss et al 2013). It is likely present in the plasma membrane as part of the plasma 
membrane redox system (PMRS), a system associated with cell survival and membrane homeostasis 
under stress conditions such as high intracellular glucose (Hyun et al 2006, Leiser and Miller 2010, 
Saraswat and Rizvi 2017). Nrf2 is distributed in the cytosol and translocate to the nucleus when 
stabilised (reviewed in Nguyen et al 2009). Constitutive expression of nrf2 in the cytosol in 
unstressed conditions is not a regulated process (Nguyen et al 2009). However, the accumulation 
and activation of nrf2 is controlled in the basal steady state by Keap 1. Two aspects in nrf2 regulation 
are key; nrf2 degradation or accumulation. Mechanism(s) that reduces Keap 1 access to nrf2 or 
decreases GSK-3β-mediated phosphorylation of nrf2 increases nrf2 stabilization leading to its 
activation (Nguyen et al 2009, Siewart et al 2003).  
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Nrf2 is closely associated with insulin and glucose metabolism. The activation of nrf2 by insulin in 
cells results in increased cellular uptake of glucose (Heiss et al 2013). Nrf2 does not alter glycolysis or 
oxidative metabolism, however in high glucose; nrf2 mediates increased glucose uptake and 
shunting of glucose to the pentose phosphate pathway (PPP) for the production of NADPH and 
ribose-5-phosphate (Heiss et al 2013). Incidentally, several enzymes of the PPP including glucose-6 
phosphate dehydrogenase (G6PD) are under the control of nrf2.   
Nrf2 is involved in the modulation of several targets. The anti-oxidant response element (ARE) on 
target such as heme-oxygenase (HO-1) is modulated by nrf2 (Keum and Choi 2014). ROS is a signal 
for the nuclear factor kappa-light-chain-enhancer of activated B cells (NFĸB) activation. In cells, the 
intersection of ROS-mediated activation of pro-death c-Jun N-terminal kinases (JNK) signalling and 
NFᴋB activation is modulated by nrf2 (Bellezza et al 2010). In endothelial cells, interleukin 6 (IL6) 
mRNA is constitutively expressed and important immunological responses are executed via IL-6 
signalling. For instance, endothelial cells (EC) respond to ROS/stretch/ shear stress via IL-6 signalling 
in an NFĸB dependent manner (Tanaka et al 2014). Hence, ROS/stimuli mediated activation of JNK/ 
NFĸB culminates in nrf2 activation because the promoter sequence on NFE2/2 (Nrf2) gene contains a 
binding site for NFĸB (Rushworth et al 2012 and Xiang et al 2014). Fundamentally, in cells, this 
intersection (cross-talk) between ROS/JNK and NFᴋB/nrf2 is pro-survival and demonstrates a critical 
link between pro-inflammatory and redox response (Bellezza et al 2010).  
The aim of the study is to understand the role of varying glucose concentration, oxygen and pressure 
on redox and pro-inflammatory responses in HDMEC by examining the protein expressions of nrf2 
and NFĸB. In addition, the protein and mRNA expressions of HO -1, a target of nrf2, and IL-6, an 
activator of NFᴋB respectively are examined. This study will inform on HDMEC redox and pro-
inflammatory responses post HBO in the context of high glucose. The contributions of the single 
components of HBO will also be deciphered.   
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5.3 Materials and method 
Full details of materials and method are reported in the general material and methods section in 
chapter 2.0 sections; immunocytochemistry (ICC) (2.4), Western blot (WB) (2.5), mRNA (2.6). Details 
that are specific to the method used in this chapter are presented below.   
 
 
5.3.1 Cell culture and assays 
HDMECs cells were grown at a density of 35,000-38,000 cells/well according to the recommended 
seeding density (PromoCell) in 24-well plates in HDMEC growth media containing low (5.5 mM) or 
high glucose. For high glucose treatments, cells were incubated in HDMEC growth media 
supplemented with 14.5 mM D-glucose to give a final concentration of 20 mM. HDMEC were 
exposed to HBO (or hyperoxia or hyperbaric pressure with equivalent samples incubated in a normal 
5% incubator in control conditions (control) (refer to chapter 2.0 section 2.8).  At 4 h and 24 h post 
incubation, HDMEC were harvested for assays. Immunocytochemical (ICC) stained HDMECs were 
incubated overnight at 4oC with primary antibodies (1:50); anti-nrf2 (Santa Cruz), followed with 
incubation in goat anti-mouse IgG, DyLight 488 conjugated highly cross-adsorbed secondary antibody 
(1:500) (ThermoFisher Scientific). HDMEC were counterstained with DAPI and at 400X magnification. 
Results are presented as representative micrographs from 3 or more independent experiments. 
Western blot (WB) PVDF membranes were incubated with primary targets (1:100); anti-nrf2, anti-
HO-1, and anti-NFĸB (Santa Cruz) overnight, followed with anti-β-actin (St Johns Labs, UK) as loading 
control, and detected with goat anti-mouse IgG Horseradish peroxidase (HRP) conjugated secondary 
antibody diluted in 1.5% BSA/TBS, and visualised by chemiluminescence. Results are presented as 
micrographs of blots from n = 3 separate experiments relative to β-actin level.  
WB results are preliminary because the protein expression and actin loading controls showed wide 
variations and therefore warrants further experimental investigations to obtain robust and 
repeatable results. 
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Polymerase chain reaction was performed with 0.25µM of validated forward and reverse primers 
for; human beta-2-microglobulin (B2M) primers; F: 5’-GGGCATTCCTGAAGCTGACA-3’; R: 5’-
TGGAGTACGCTGGATAGCCT-3’ and interleukin (IL)-6 primer; F: 5’-TCAATATTAGAGTCTCAACCCCCA-3’; 
R: 5’-TTCTCTTTCGTTCCCGGTGG-3’ with 2X PowerUP SYBR Green Master Mix with ROX reference 
(catalogue # 4309155) (ThermoFisher Scientific) and a total of 10ng of cDNA from HDMECs in 
duplicate performed on three independent occasions. Post analysis check with melt curve was 
performed to discriminate between specific PCR products and non-specific primer-primer products. 
The fold change method was used for determination of IL-6 mRNA expression relative to β2m and 
study calibrator (untreated 5.5 mM sample in control condition) (Winer et al 1999 and Schmittgen et 
al 2000). Primer set efficiency determination and inspection of PCR product with melt curve were 
performed as initial validation. To ascertain primer efficiencies, serial dilutions of cDNA HDMEC with 
0.25 µM of forward and reverse primers of β2m and Il-6 in duplicates were prepared. Amplification 
was performed as described in materials and method (chapter 2.0 section 2.6) and average cycle 
threshold (CT) calculated per sample. Average CTs were plotted against log10 of the serial cDNAs to 
generate a standard curve for β2m and IL-6. The efficiency of primers was calculated with equation 
5.1 below. A melt curve was used as quality check for PCR product formed. Experimental PCR assay 
were set up in duplicates and were repeated in 3 separate experiments. Statistical analysis was 
performed as reported in chapter 2.0, section 2.11.  
 
 
 
 
 
 
 
 
 
% Efficiency = (10 - (1/gradient)-1) x 100 
--------------------- Equation 5.1 
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5.4 Results 
 
5.4.1 Effect of glucose concentration, oxygen tension and 
pressure on redox response. 
 
Redox responses were studied by examining the expressions of nrf2 protein expressions (levels). 
Nrf2 is rapidly cleared (t1/2 = 20 mins) after synthesis but, its half-life increases to 200 mins post 
stabilisation (Canning et al 2015). Based on n =2 independent experimental replicates of nuclear 
HDMECs lysates pooled from six identical wells per sample at 4 h post treatment, nuclear nrf2 
expression at 4 h appeared elevated in response to treatment with HBO, hyperoxia and hyperbaric 
pressure in comparison to controls. Based on the available WB result, glucose effect on nrf2 
expression was not evident (fig 5.1). The actin loading controls were variable and the blot contained 
some non-specific stains and poor image resolution which made it difficult to clearly delineate 
bands. Therefore, the presented WB blots are preliminary and further WB studies are needed for 
more robust and repeatable results. Immunocytochemical (ICC) staining of HDMEC samples at 4 h 
and 24 h was used to ascertain nrf2 expression and to have a preliminary indication of cellular 
distribution of nrf2 in response to glucose concentration, oxygen and/or pressure. Although, HDMEC 
WB results were highly variable, ICC stained data as shown in figs 5.2-5.5 showed  satisfactory 
expression and cellular distribution of nrf2 (figs 5.2 – 5.5).   
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Figure 5. 1 Western blots of nrf2 at 4 h 
Nuclear Evcimen nrf2 protein appeared elevated post HBO, hyperoxia and hyperbaric pressure in comparison to control at 
4 h. The blot contains some non-specific stains and poor image resolution which made it difficult to delineate bands. In 
addition, actin loading controls were variable. Data is based on n =2 independent experimental replicates of nuclear 
HDMECs lysates pooled from six identical wells per sample at 4 h post treatment. 
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In the following paragraphs, exemplary ICC photomicrographs of anti-nrf2 stained HDMEC are 
presented. Distinction is made of non-specific staining (possibly debris) which are not cell/structure 
associated (false-positives) (exemplified by red circle). Where relevant, arrow heads were used to 
highlight details. In general, the intensity of nrf2 signal which is an indication of nrf2 levels 
(immunoreactivity/expression) appeared lower in control in comparison to treated samples (fig 5.2 
vs 5.3 – 5.5). In addition, nrf2 intensity appeared lower in high glucose in comparison to low glucose 
for HDMECs in control conditions (fig 5.2, A vs B). Moreover, the distribution of nrf2 signal in HDMEC 
in control condition appeared predominantly cytoplasmic associated irrespective of glucose 
concentration or time.  
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Figure 5. 2 ICC of nrf2in control condition at 4 h and 24 h 
The signal intensity of nrf2 in control sample was low which may suggest low basal levels. In addition, nrf2 signal intensity 
appeared lower in high glucose at 4 h (B) in comparison to low glucose (A). Moreover, the distribution of nrf2 appeared 
predominantly cytoplasmic associated. Selected images are representative of n = 3 independent experimental replicates. 
Magnifications 400X. Scale bar 500µm  
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HBO treated HDMEC (fig 5.3) appeared consistent with stronger nrf2 signal intensity in comparison 
to control. In addition, nrf2 distribution in HBO treated HDMEC showed nuclear and plasma 
membrane association at 4 h and 24 h relative to control. Moreover, nrf2 level and distribution post 
HBO appeared unchanged irrespective of glucose concentration or time relative to control.   
  
 
 
 
Figure 5. 3 ICC of nrf2 in HBO at 4 h and 24 h 
Nrf2 signal in HDMEC which is indicative of its expression (immunoreactivity) appeared higher post HBO in comparison to 
control. In addition, nrf2 level or distribution did not appear to change with respect to glucose concentration or time post 
HBO in comparison to controls. Moreover, nrf2 distribution post HBO seemed consistent with nuclear (white arrowheads), 
and plasma membrane association (white arrowheads). Selected images are representative of n = 3 independent 
experimental replicates. Magnifications 400X. Scale bar 500µm     
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HDMEC treated with hyperoxia (fig 5.4) showed nrf2 accumulation at 4 h relative to control. Nrf2 
distribution appeared consistent with perinuclear association post hyperoxia in comparison to 
control. Curiously, nrf2 signal post hyperoxia and more so in high glucose were decreased at 24 h 
relative to 4 h. Hyperoxia associated enlargement in HDMEC size and actin cytoskeleton striation 
were more apparent at 4 h relative to 24 h and more so in the low glucose samples in comparison to 
control.  
 
 
 
Figure 5. 4 ICC of nrf2 protein in hyperoxia at 4 h and 24 h 
HDMEC exposed to hyperoxia showed nrf2 accumulation in perinuclear associated areas at 4 h. Hyperoxia associated nrf2 
expression was diminished at 24 h and more so in high glucose in comparison to 4 h. Selected images are representative of 
n = 3 independent experimental replicates. Magnifications 400X. Scale bar 500µm  
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Hyperbaric pressure treated HDMEC were associated with higher nrf2 signal in comparison to control 
which may be indicative of nrf2 accumulation in hyperbaric pressure in comparison to control (fig 
5.5). In converse to control, nrf2 signal post hyperbaric pressure did not seem affected by glucose 
concentration or time. Moreover, nrf2 distribution appeared consistent with nuclear and plasma 
membrane association, with some perinuclear association in comparison to control.  
 
 
 
 
Figure 5. 5 ICC of nrf2 protein in hyperbaric pressure at 4 h and 24 h 
Nrf2 accumulation appeared evident post hyperbaric pressure in comparison to control. Nrf2 accumulation post hyperbaric 
pressure appeared consistent with nuclear and plasma membrane association with some perinuclear association. Selected 
images are representative of n = 3 independent experimental replicates. Magnifications 400X. Scale bar 500µm
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Nrf2 fluorescent signal intensities in HDMEC post treatments were quantified (fig 5.6). There was a 
net decrease in nrf2 intensity in response to high glucose in comparison to low glucose in the control 
condition (p < 0.05). The earlier observations of nrf2 accumulation with ICC micrographs (figs 5.2 -
5.5) were further demonstrated. In low glucose, there were net increases in nrf2 intensities post 
HBO (p < 0.0001), hyperoxia (p < 0.0001) and hyperbaric pressure (p < 0.05), and in high glucose, net 
increases post HBO (p < 0.0001), hyperoxia (p < 0.0001) and hyperbaric pressure (p < 0.05) in 
comparison to controls at 4 h. In addition, nrf2 signal intensities in low glucose were significantly 
higher post HBO (p < 0.0001), hyperoxia (p < 0.0001) and hyperbaric pressure (p < 0.01), and in high 
glucose, HBO (p < 0.0001) and hyperbaric pressure (p < 0.01) in comparison to controls at 24 h. Nrf2 
signal intensity was dampened post hyperoxia (high glucose) but remained sustained post HBO 
irrespective of glucose concentration in comparison to controls (p < 0.001) after 24 h. 
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Figure 5. 6 Fluorescence intensity of nrf2 signal at 4 h and 24 h 
Mean nrf2 signal intensities were significantly different between samples (***p < 0.0001, n = 8) and (*p < 0.0001, n = 8). At 
4 h, nrf2 signal intensity was decreased in HDMEC in high glucose in comparison to low glucose in the control cndition (p < 
0.05). HDMEC in low or high glucose post HBO, hyperoxia or hyperbaric pressure were associated with significant increases 
in nrf2 intensities (accumulation) in comparison to controls; HBO (p < 0.0001), hyperoxia (p < 0.0001), hyperbaric pressure 
(p < 0.05). After 24 h, nrf2 level for HDMEC in low or high glucose in HBO, hyperoxia or hyperbaric pressure continued to be 
significantly higher in comparison to controls excluding HDMEC in hyperoxia in high glucose where signal intensity was no 
longer significantly higher in comparison to control (p > 0.05). Also at 24 h, nrf2 signal intensity for HDMEC in high glucose 
post hyperoxia was signifficantly lower in comparison to HBO (p < 0.05). Data is based on n = 9 replicates for all samples 
otherwise stated for 4 h; hyperoxia low/high glucose, n = 6 and 7 respectively), for 24 h, control condition low/high glucose 
(n = 9), HBO low/high glucose, n = 4 and 6 respectively, HBO low/high glucose (n = 4 and 6 respectively), hyperoxia low 
glucose (n = 7), hyperbaric pressure low/high glucose (n = 7).  
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Nrf2 protein stabilization and nuclear activation is associated with induction of the cytoprotective 
heme oxygenase (HO-1). To test the possibility of HO-1 induction, WB analysis of HDMEC extracts at 
24 h were performed. But, WB results of HDMECs lysates blotted with anti-HO-1 and their actin 
loading controls were variable making it difficult to draw definite conclusions although some 
preliminary trends were apparent (fig 5.7). HO-1 levels appeared elevated in response to high 
glucose in comparison to low glucose samples for HDMEC in control condition. Similarly, HO-1 levels 
for HBO treated HDMEC appeared elevated in high glucose in comparison to their low glucose 
counterparts. On the other hand, it appears hyperoxia alone was sufficient to induce HO-1, and a 
concomitant hyperoxia and glucose effect on HO-1 induction was not easily discernible. Overall, HO-
1 levels appeared elevated in response to treatments; HBO, hyperoxia and hyperbaric pressure in 
comparison to control. These results are considered to be preliminary and experiments would need 
to be repeated to confirm these data. 
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Figure 5. 7 Western blots of HO-1 protein at 24 h 
HO-1 appeared elevated in control condition and HBO in response to glucose concentration, but a concomitant hyperoxia 
and high glucose effect on HO-1 elevation was not so apparent. In addition, HO-1 levels appeared elevated in response to 
treatments; HBO, hyperoxia and hyperbaric pressure in comparison to control (low glucose). Data is based on n =2 
independent experimental replicates of cytosolic HDMECs lysates pooled from six identical wells per sample at 24 h post 
treatment. Results are preliminary due to inconsistencies in HO-1 expression and actin loading controls.  
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5.4.2 Effect of glucose concentration, oxygen tension and 
pressure on inflammatory response 
Inflammatory responses were studied by examining the expression of IL-6 mRNA and NFᴋB protein in 
total lysates of HDMEC at 4 h. Beta-microglobulin (β2m) and IL-6 primer sets efficiencies were 105% 
and 90% (A and B), which were within efficient primer set range (90-110%) (Livak and Schmittgen 
2001, Primer Design 2018). Amplification cycles were earlier than 35 cycles confirming the absence 
of genomic DNA (C and D) (Livak and Schmittgen). A melt curve analysis (E and F) showed good 
quality PCR product for β2m and IL-6 primers with true product peaks at melting temperatures 
within 80oC -90OC (Livak and Schmittgen, 2001). IL-6 melt curve had a primer dimer with Tm (65-
75oC) (Livak and Schmittgen) (Fig. 5.8). 
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Figure 5. 8 Primer set efficiency 
Efficiencies of B2m and IL-6 primer sets were 105 % and 90 %r (A and B). Amplifications were earlier than 33 cycles. No 
primer dimer signal was seen in B2m and IL-6 amplification plots (C and D). Melt curve for B2m showed a distinct PCR 
product peak at Tm ≥80
o
C (E and F). IL-6 peak had an additional signal at Tm (65-75
o
C) which may be primer-dimer. 
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Endothelial cell (EC) responses to stimuli such as ROS and stretch and shear stress are transduced to 
a cellular pro-inflammatory response by IL-6 via sequential activation of IKKs and NFᴋB in a ROS 
dependent manner (Kobayashi et al 2003). To test the possibility of immunological response in 
HDMEC post treatments, the expression of Il-6 mRNA was examined with real-time qPCR. The 
average threshold values (CT) of samples post normalisation and fold determination with β2m were 
expressed relative to control (calibrator). Therefore, the bar plot (fig 5.9) represents the extent of 
change (downregulation/suppression) (fold change) of IL-mRNA relative to β2m/calibrator.  
Analysis of the qPCR data with 1way ANOVA with Tukey’s pot hoc tests showed IL-6 mRNA 
expression changed significantly between the means of all samples (p < 0.0001, n = 8) (fig 5.9). 
HDMEC in control condition showed no significant glucose-dependent change in IL-6 mRNA level (p > 
0.05). Post exposure to treatments, there were significant suppression of IL-6 mRNA for HDMEC in 
low glucose; HBO (5.2-fold, p < 0.0001), hyperoxia (2-fold (p < 0.0001), hyperbaric pressure (2-fold; p 
< 0.0001) and in high glucose; HBO (4.9-fold, p < 0.0001), hyperoxia (3-fold, p < 0.0001) and 
hyperbaric pressure (2-fold, p < 0.0001) relative to β2m/calibrator. In HBO, a significant high glucose 
associated decrease in IL-6 mRNA suppression relative to the low glucose counterpart was seen (p < 
0.01). In hyperoxia, high glucose resulted in increased IL-6 mRNA suppression relative to the low 
glucose counterpart (p < 0.0001). No significant glucose associated change was evident for samples 
in hyperbaric pressure (p > 0.05).  
Taken together, IL-6 mRNA was significantly suppressed (downregulated) following treatments; HBO, 
hyperoxia and hyperbaric pressure but more so post HBO relative to controls. In addition, IL-6 mRNA 
was less suppressed in high glucose post HBO, whilst more suppressed post hyperoxia in comparison 
to low the glucose counterpart. 
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Figure 5. 9 IL-6 mRNA at 4 h 
Mean IL-6 mRNA in HDMEC changed significantly between samples at 4 h (p < 0.0001, n = 8). Bar chart represents fold 
change in IL-6 mRNA (downregulation) relative to β2m/calibrator. For HDMEC in low glucose, IL-6 mRNA was significantly 
downregulated post HBO (5.2-fold (p < 0.0001), hyperoxia (2-fold) (p < 0.0001), hyperbaric pressure (2-fold) (p < 0.0001), 
and in high glucose a significant decrease post HBO (4.9-fold) (p < 0.0001), hyperoxia (3-fold) (p < 0.0001), and hyperbaric 
pressure (2-fold)  (p <0.001) relative to β2m/calibrator. In HBO, a significant high glucose associated decrease in IL-6 mRNA 
suppression relative to the low glucose counterpart was present (p < 0.01). In hyperoxia, high glucose resulted in an 
increase in IL-6 mRNA suppression relative to the low glucose sample (p < 0.0001). No significant glucose associated change 
was evident for samples in hyperbaric pressure (p > 0.05). Experiments were repeated in n = 3 independent occasions and 
the reported data is representative of fold change in IL-6 mRNA post normalisation and relative to β2m (reference) 
/calibrator (untreated control). Control LG (n = 6), control HG (n =5), HBO, LG 5.5 mM (n = 4), HBO, HG 20 mM (n = 4), 
hyperoxia LG (n = 4), hyperoxia HG (n =6), hyperbaric pressure LG (n= 6), and hyperbaric pressure HG (n = 3). LG = low 
glucose, HG = high glucose. 
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NFᴋB is activated by IL-6 and cross-talks with ROS/JNK dependent nrf2 redox pathway activation in a 
pro-survival cellular response (Tanaka et al 2014, Bellezza et al 2010, Rushworth et al 2012 and Xiang 
et al 2014, reviewed in Evcimen and King 2007). Activated NFᴋB (p65) expression was examined with 
WB but replicates of NFᴋB WB data and their actin loading controls were variable. Preliminary WB 
results show NFᴋB (p65) detection in HDMEC (fig 5.10). NFᴋB appeared unchanged in response to 
high glucose in the control condition and HBO relative to control which may be indicative of basal 
NFᴋB levels. NFĸB appeared elevated post hyperoxia and hyperbaric pressure but more so post 
hyperoxia relative to control. Variability in actin loading may have made it impossible to clearly 
delineate glucose effect in the different conditions. 
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Figure 5. 10 Western blots of NFᴋB protein in HDMEC at 4 h 
NFĸB levels in control condition appeared unchanged in response to high glucose in comparison to low glucose. In addition 
NFᴋB levels appeared basal post HBO relative to control. NFᴋB appeared elevated post hyperoxia and hyperbaric pressure 
but more so post hyperoxia relative to control. There were variabilities in NFᴋB expression between replicates and actin 
loading controls necessitating further studies for robust WB results. Also, glucose associated effects did not appear evident 
but variability in actin loading may have contributed to the lack of distinction of glucose effects. Data is based on n =2 
independent experimental replicates of total HDMECs lysates pooled from six identical wells per sample at 4 h post 
treatment. 
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5.5 Discussion 
In this study, varying glucose concentrations, oxygen and pressure resulted in redox and pro-
inflammatory responses in HDMEC. Nrf2 is rapidly cleared after synthesis with a t1/2 of 20 mins which 
increases to 200 mins post stabilisation (Canning et al 2015). For that reason, nrf2 detection and 
accumulation at 4 h (HBO, hyperoxia and hyperbaric pressure) and at 24 h (more so in HBO and 
hyperbaric pressure) are indicative of nrf2 stabilisation post treatments relative to control. HBO 
associated nrf2 activation/stabilisation is consistent with previous study in human microvascular 
endothelial cells (HMEC-1) (Godman et al 2010). Profoundly, this study has revealed nrf2 stabilisation 
post HBO, hyperbaric pressure and hyperoxia in HDMEC.  
During homeostasis (e.g. control condition), the majority of nrf2 are rapidly (t1/2 = 20 mins) are 
degraded in the cytoplasm (Canning et al 2015), which might explain the basal levels of nrf2 in the 
control sample. In response to oxidative stress, nrf2 dissociates from Keap 1 complex, translocates 
and activates the expression of cytoprotective proteins in the nucleus and restores redox equilibrium 
(Katsuoka et al 2005, reviewed in Hayes and Dinkova-Kostova 2014). Thus, the treatments; HBO, 
hyperbaric pressure and hyperoxia, but more so HBO and hyperbaric pressure are expected to be 
associated with increased expression of cytoprotective genes/proteins.   
Nrf2 activity is tightly regulated with three subcellular populations of nrf2 identified; cytoplasmic, 
transcriptionally active population in the nucleus and a third population that localises to the outer 
mitochondrial membrane (reviewed in Plafker and Plafker 2015). A fourth redox protective plasma 
membrane distribution is hypothesised (HPA 2018, Hyun et al 2006). Keap 1 system serves to isolate 
nrf2 in the cytoplasm, whilst Gsk-3β promotes nuclear nrf2 extrusion and degradation (Biswas et al 
2014). Emerging evidence suggests the Ub-conjugating enzyme (UBE2E3) and its nuclear import 
receptor importin 11 (Imp-11) regulates (promotes) nrf2 activity by restricting nrf2 partitioning into 
the mitochondria as well as limiting nuclear Keap 1 mediated repression of nrf2 (Plafker and Plafker 
2015).  
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In this study, distinct patterns of nrf2 distribution post treatments in comparison to control were 
observed. Post HBO and to a lesser extent hyperbaric pressure, nrf2 accumulation showed 
predominant nuclear and plasma membrane association relative to control which suggests nuclear 
nrf2 activation and plasma redox system (PMRS) activity. Therefore, the prospect of nuclear nrf2 
activation and PMRS activity post HBO and hyperbaric pressure represents a more efficient cell 
protective mechanism which may have been less functional in hyperoxia and possibly inactivated in 
the control sample. On the other hand, nrf2 distribution showed predominant perinuclear 
association post hyperoxia relative to the control. Perinuclear nrf2 partitioning in oxidatively stressed 
human choriocarcinoma cells is due to mitochondrial dysfunction and precedes cell membrane 
disruption and cell death (Hallmann et al 2004, Plafker and Plafker 2015). Likewise, here, the 
prospect of mitochondrial dysfunction in HDMEC post hyperoxia, and to a smaller extent hyperbaric 
pressure is inferred based on the observed nrf2 perinuclear partitioning. Owing to these differences 
in nrf2 distribution post treatments, further studies are required to accurately pin-point the effects 
of HBO, hyperoxia and hyperbaric pressure on nrf2 distribution in HDMEC. In addition, due to the 
limitations of using an ordinary fluorescent microscope such as the possibility of overlapped cellular 
structures, these preliminary cellular distribution data require further studies with confocal imaging 
to accurately pin-point nrf2 distribution. 
HO-1 possesses a complex role in angiogenesis, in addition to exhibiting antioxidant, antiapoptotic, 
and anti-inflammatory roles (Bussolati et al 2006). Based on preliminary WB data, HO-1 appeared 
elevated in response to treatments; HBO, hyperoxia and hyperbaric pressure relative to control, 
which may have been nrf2 mediated. In addition, HO-1 protein appeared elevated in control 
condition and HBO in response to high glucose versus low glucose which suggests HO-1 induction to 
arrest high glucose associated cellular insult. In hyperoxia, HO-1 level seemed consistent in low and 
high glucose, suggesting a hyperoxia alone associated effect. Fundamentally, HO-1 exerts a positive 
feedback control on the synthesis and activity of VEGF, thus highlighting an essential role for HO-1 in 
VEGF mediated angiogenesis (Bussolati et al 2006). Therefore, it is likely HO-1 induction in response 
to these treatments might result in HO-1 mediated mechanisms e.g. angiogenesis, anti-oxidation, 
anti-apoptosis and anti-inflammation but further studies are required to qualify this. Due to 
variabilities in HO-1 expression between replicates and actin loading controls, these results are 
preliminary and warrant further studies to obtain robust results and to further piece together the 
relevant mechanisms. 
 
 
 
  
165 
 
IL-6 mRNA levels in HDMEC post HBO, hyperoxia and hyperbaric pressure but more so HBO were 
significantly suppressed relative to control. In addition, IL-6 mRNA downregulation showed glucose 
dependency post HBO and hyperoxia. IL-6 mRNA downregulation in HBO is consistent with previous 
studies (Benson et al 2003, Al-Waili 2006). In addition, the glucose dependent raise in IL-6 mRNA (i.e. 
less suppression) in response to high glucose is consistent with a previous study (Piconi et al 2004). 
Incidentally, unlike HBO, hyperoxia was associated with further suppression of IL-6 mRNA in 
response to high glucose. Enhanced IL-6 levels is protective in hyperoxic lung injury, hyperoxia-
induced cell death, and DNA fragmentation via IL-6 induced expression of the B-lymphoma 2 (Bcl-2) 
apoptotic regulator gene (Waxman and Kolliputi 2009). Therefore, these glucose-associated 
responses in IL-6 mRNA post HBO or hyperoxia are likely to have pertinent and distinct cellular 
effects.   
Since IL-6 is regulated mainly at the mRNA level, these changes represent specific regulatory 
response(s)/mechanisms. It is possible the treatments were associated with decreased synthesis of 
IL-6 mRNA reflected as a downregulation in IL-6 mRNA levels, which would be in agreement with 
Benson et al 2003 and Al-Waili 2006. In addition, the likelihood of IL-6 mRNA destabilisation post 
treatment is not excluded. Possibly, the treatments may have been associated with activation of 
non-coding micro-RNA (miRNA) mediated destabilisation of IL-6 mRNA (Chen et al 2012, Zilahi et al 
2012). Alternatively, the treatments may have been associated with increased IL-6 mRNA translation 
to IL-6 protein (resulting in the lower levels of IL-6 mRNA) relative to controls. Therefore, more 
studies are still needed to rightly pin-point the mechanism(s) behind the significant changes in IL-6 
mRNA levels post treatments.  
HBO is not expected to affect circulating levels of IL-6 in normal individuals (i.e. in unstressed 
condition) (Thom 2009). But links between high altitude environment (a condition associated with 
increased cellular stress and adaptation) and increased serum IL-6 exist (Kubo et al 1996, reviewed in 
Grocott et al 2007). Thus, owing to the observed changes in IL-6 mRNA in response to treatments, 
the likelihood of cellular stress and adaptation responses post treatments are predicted. Essentially, 
this suggests the glycemic status of patients undergoing HBO might influence their immunological 
(IL-6) responses and vice versa.  
 
 
 
 
 
 
  
166 
 
The probable (preliminary WB) elevation of NFᴋB post hyperoxia and hyperbaric pressure may be 
indicative of an acute endothelial cell activation and pro-inflammatory response relative to control 
(Kobayashi et al 2003). Ironically, NFᴋB levels post HBO appeared consistently low relative to control 
which may be indicate of a basal NFᴋB level that is necessary for normal endothelial cell function 
such as cell growth and the regulation of inflammatory gene targets (Barkett and Gilmore 1999, 
Dolcet et al 2005). Since nrf2 distribution post HBO was predominantly nuclear, the possibility of an 
enhanced nuclear nrf2/ NFᴋB cross-talks leading to amelioration of NFᴋB accumulation/activation in 
HBO cannot be excluded (Grottelli et al 2016, Li et al 2008, Kim et al 2013, and Minelli et al 2012). In 
addition, elevated nuclear nrf2 levels post HBO might have resulted in an increase in nrf2 mediated 
anti-inflammatory target signalling which might have dampened any NFĸB activation and pro-
inflammatory responses (Bellezza et al 2018, Grottelli et al 2016, Li et al 2008, and Minelli et al 
2012). Exposure of human aortic endothelial cells (HAEC), high glucose (10 mM and 20 mM) resulted 
in increased activation of NFĸB leading to the inhibition of endothelial cell migration, a phenotype 
associated with impaired wound healing (Hamuro et al 2002). In this study, whilst NFĸB activation 
was observed post hyperoxia and hyperbaric pressure, the effect of glucose on NFĸB activation was 
not evident. However, it is likely variability in actin loading controls may have confounded the 
discernment of any glucose associated effect.  
To summarize this chapter, redox (nrf2) and pro-inflammatory responses in HDMEC were affected by 
varying glucose concentration, oxygen and pressure. Redox and pro- inflammatory are associated 
with cellular responses to high glucose (hyperglycaemia). In the following chapter, the role of HIF1α 
as a converging point is examined. In addition, the expression of vascular endothelial growth factor 
(VEGF) is examined. Lastly, an endothelial cell proliferation marker (PECAM-1) is used to examine the 
effect(s) of treatments on HDMEC. These studies are carried out using both single cell system 
(HDMECs) and a retinal explant model.  
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5.6 Limitations 
There were variabilities in NFĸB expression between replicates as well as their actin loading controls 
making it difficult to draw conclusions on the expression of nrf2, HO-1 and NFĸB based on WB assay 
alone. Due to these inconsistencies, the WB data are seen as initial preliminary data which require 
further experimental designs and optimisations for robust WB data. Throughout the study, HDMEC 
between passages P4-7 were used. So, it is likely the variabilities in target expressions are as a result 
of cells being in different cell cycle stages. In future design, prior validation experiments should be 
undertaken to identify optimal passage number(s) for the expression of targets of interest. Secondly, 
HDMEC is a mixture of HDLEC and BECs, and the variability may be a reflection of having two cell 
populations, albeit since HDLEC are in majority, it is possible they exhibited dominant characteristics. 
The use of an ordinary fluorescent microscope for ICC imaging ofnrf2 expression produced 
satisfactory results for ascertaining nrf2 accumulation as well as giving preliminary indication to nrf2 
cellular distribution. However, exact cellular distribution and association of nrf2 under the different 
conditions could not be confirmed. In future experimental design, confocal microscopy would be 
desirable.  
Lastly, measurement of Il-6 content of media was not undertaken in order to postulate any 
functional implication of IL-6 mRNA downregulation post treatments. In future, the experimental 
design would need to be adapted to include the measurement of IL-6 protein in the media using an 
ELISA technique in order to confirm a functional effect of IL-6 mRNA downregulation.  
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Chapter 6.0: HIF-1α, VEGF and PECAM-1 
expression 
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6.1 Hypothesis 
The changing concentration of glucose, oxygen tension and pressure has an effect on human dermal 
microvascular endothelial cell HIF-1α expression leading to angiogenesis and cell proliferation  
 
 
6.2 Introduction 
Endothelial cell phenotype, metabolic activity and key endothelial cell functions such as migration 
and angiogenesis are linked (Doddaballapur et al 2015). From the previous chapters, HDMEC sizes 
were significantly changed in response to hyperoxia relative to control. Based on ICC fluorescence 
intensity, nrf2 level was significantly decreased in response to high glucose in the control condition 
whilst HBO, hyperoxia and hyperbaric pressure were associated with nrf2 stabilisation and 
accumulation relative to control. In addition, nrf2 distribution was distinct post HBO and hyperbaric 
pressure, and hyperoxia relative to control. Consequently, based on preliminary WB, nrf2 
stabilisation and accumulation post treatments appeared to have resulted in HO-1 induction relative 
to control. Moreover, high glucose associated effect on HO-1 induction appeared imminent for 
HDMEC in control condition and HBO, but HO-1 induction post hyperoxia seemed independent of 
glucose concentration. Immunological response (IL-6) was significantly impacted following 
treatments and IL-6 mRNA levels showed pertinent glucose dependent response in HBO. More so, 
HDMEC activation and pro-inflammatory response appeared likely post hyperoxia and hyperbaric 
pressure, whilst remaining basal post HBO relative to control. Caution is to be exercised in the 
interpretation and conclusions of results from WB data since there were variabilities in targets (HO-1 
and NFĸB) expression between replicates and actin loading controls.  
In this chapter, the effects of high glucose in isolation or in combination with HBO, hyperoxia and 
hyperbaric pressure on HIF-1α, VEGF and PECAM-1 are examined. Acute or prolonged 
hyperglycaemia leads to increased ROS, AGEs and RAGE resulting in the activation of PKC and 
overstimulation of the hexosamine pathway (Brownlee 2005). These hyperglycaemia induced 
responses result in damaging oxidative stress which sets up damaging glucotoxicity pathways: PKC, 
hexosamine and polyol and AGE, in addition to NFᴋB driven expression of pro-inflammatory 
cytokines (Knott and Forrester 2003, Obrosova et al 2005, Brownlee 2001 and2005, Adamis 2002). In 
the diabetic endothelium, glucotoxicity associated insults impair endothelial function leading to 
macro and microvascular complications including DR and impaired wound healing (reviewed in Sena 
et al 2013).  
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Importantly, hyperglycaemia is the primary initiating factor in DR affecting all the three parts of 
retinal vessels (reviewed in Knott and Forrester 2003). Chronic hyperglycaemia complexly affects 
both HIF-1α stability and activation, resulting in the suppression of HIF-1 target genes that are 
essential for wound healing (Sunkari et al 2015). HIF-1α is regulated by oxygen-dependent and non-
oxygen dependent stimuli such as growth factors, ROS, and mechanical stress (Wang et al 1995, 
Semenza, 1998, Zhong et al 1998, Haddad et al 2001 and 2002). Several of the non-oxygen 
dependent activators of HIF-1α primarily trigger HIF-1 signalling through their action on HIF-1α 
translation, which is different from the classic hypoxic stimuli on HIF-1 because hypoxia classically 
exerts its effect on HIF-1α protein (reviewed in Ziello et al 2007).  
ROS increase during inflammation causes HIF-1α accumulation and activation (Haddad et al 2001 and 
2002). In addition, HIF-1α activation during inflammation and upregulation of classical target genes 
like VEGF, GLUT1 and metalloproteinase, as well as HIF-1 targeting of immune functions such as β2 
integrins and chemokines receptors activation are documented (reviewed in Ziello et al 2007). 
Hyperglycemia activates signalling pathways such as the PKC pathway and drives HIF-1 signalling 
even in normoxia. Moreover, the PKC pathway also stimulates the expression of the S6 ribosomal 
proteins which specifically recognizes and drives HIF-1α mRNA translation. Hence, in normoxia prolyl 
hydroxylases (PHD) driven proteasomal degradation of HIF-1α can be countered via high glucose 
associated PKC driven increased S6 phosphorylation which is associated with increased HIF-1α mRNA 
translation into HIF-1α protein, and consequently increased HIF-1 signalling (Ziello et al 2007).  
Arguments that support HIF-1α destabilisation, proteasomal degradation as well as inhibition of HIF-
1α transactivation in hyperglycaemia under normoxia exist which may reflect specific cell-type 
responses (reviewed in Xiao et al 2013). These cell-specific HIF-1α responses in hyperglycaemia 
under normoxia as reviewed in Xiao et al (2013) is summarised in the following paragraphs. In 
HDMEC and human dermal fibroblasts (HDF), hyperglycaemia induced osmolality results in HIF-1α 
destabilisation. In addition, hyperglycaemia promotes the formation of methylglyoxal (MGO) which 
covalently modifies HIF-1α and p300/CBP co-activator. Covalent modification of HIF-1α leads to 
decreased HIF-1α and HIF-1β dimerization, culminating in decreased HIF-1 and HRE binding. More 
so, HIF-1α modification by MGO increases its association with heat shock protein (HSP) 40/70, which 
recruits the carboxyl terminus of the Hsc70-interacting protein (CHIP) and promotes HIF-1α 
proteasomal degradation. Furthermore, covalent modification of p300 by MGO leads to a reduction 
in HIF-1α transactivational capacity because p300 modification inhibits the interaction of the C-
terminal transactivation domain (CTAD) of HIF-1α and p300.  
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In retinal epithelial (RPE) cells, MGO formed as a result of hyperglycaemia increases the sensitivity of 
the hydroxyl groups on HIF-1α to VHL machinery. Moreover, hyperglycaemia suppresses the N-
terminal (NTAD) and C-terminal (CTAD) transactivation domains on HIF-1α. Ironically, 
hyperglycaemia induced ROS can result in HIF-1α impairment although ROS is classically expected to 
increase HIF-1α (Brownlee 2005, Nishikawa et al 2000). In addition, ROS produce  O2- which reacts 
with NO leading to NO unavailability leading to decreased HIF-1α accumulation and activation 
because NO is required for HIF-1α activation. More so, ROS inhibits HIF-1α expression via ROS 
induced repression of Ras-related C3 botulinum toxin substrate 1 (Rac1) expression because Rac1 
contributes to HIF-1α transactivation. Moreover ROS impairs HIF-1α by activating PHD ubiquitin-
proteasome activity.    
Growth factors are oxygen independent mediators of HIF-1α regulation. Growth factors drive HIF-1 
signalling via the PI3K, a serine/threonine kinase AKT (protein kinase B), and FKBP-rapamycin 
associated protein signalling (FRAP) (Zhong et al 1998). The PI3K/AKT/mTOR pathway is involved in 
HIF-1 signalling and angiogenesis in endothelial cells and in normal or cancerous tissues, thus 
providing a link between HIF-1 signalling in physiological and diseased states (Karar and Maity 2011). 
Taken together, HIF-1α impairment/ destabilisation by hyperglycaemia is a cell-type 
specific/dependent response (Xiao et al 2013).  
Angiogenesis is under the control of HIF-1 activity via HIF-1 mediated regulation of VEGF, the primary 
cytokine in angiogenesis (Lin et al 2004). HO-1 is also involved in VEGF-induced endothelial activation 
and angiogenesis (Bussolati et al 2006). In addition, VEGF molecule is involved in migration and in 
the transduction of mechano-stimuli in endothelial cells (Fujiwara 2006, Tzima et al 2005). In diabetic 
wounds, HIF-1α and VEGF are suppressed, with decreased angiogenesis and wound healing, which is 
reversed with HBO (Sunkari et al 2014, Lin et al 2017). Incidentally, wound healing and clinical 
outcomes with HBO vary and a lack of tight glycemic control might play a role, since hyperglycaemia 
exerts suppresses HIF mediated VEGF expression in dermal endothelial cells. Contrarily, in diabetic 
retinopathy (DR), there is over-production of VEGF which causes the progression of proliferative DR 
and diabetic macular oedema (DME) even in the face of a hyperglycaemic milieu (Simo and 
Hernandez 2009, Antonetti et al 1999). This again illustrates a cell/tissue-type specific and 
dependent response to hyperglycaemia.  
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The platelet endothelial cell adhesion marker (PECAM-1) is expressed by endothelial cells of all 
vascular beds and it plays a critical role in the maintenance of endothelial cell to cell contact and 
junctional integrity needed for normal endothelial cell growth (Podgrabinska et al 2010, Privratsky 
and Newman 2014). In addition, PECAM-1 presence in endothelial cells is associated with absence of 
endothelial-mesenchymal transition (EMT) and MMP-2 expression (Enciso et al 2003). Thus, the 
absence/downregulation of PECAM-1 may be indicative of endothelial cell activation. PECAM-1 
undergoes phosphorylation on tyrosine residues (activation) in response to mechanical and 
biochemical stimuli such as shear/stretch stress and high glucose respectively (reviewed in Ilan et al 
2000, Fleming et al 2005, Fujiwara 2006, and Tzima et al 2005). Moreover, high glucose is associated 
with the downregulation of junctional proteins in endothelial cells (Yan et al 2012). Hence, 
mechanical stimuli and high glucose are expected to influence PECAM-1 expression in HDMEC.  
HBOT is a treatment modality involving the use of hyperbaric oxygen (HBO). Its exact mechanisms 
are still being studied and there are questions about the contribution of its components (HBOT Trust 
2018, Thom 2011, Godman et al 2010, Löndahl et al 2013, and Akgu¨et al 2014). HBO is known to 
elicit beneficial ROS response (Thom 2011, Zhao et al 2017). Hyperoxia when used as a single 
component is associated with cell death, inflammation, induction of stress responses, and 
modulation of cell growth. In addition, hyperoxia elicits its mechanisms majorly via the mitogen-
activated protein kinases (MAPK; ERK, JNK and p38), activator protein -1 (AP-1) and NFĸB and these 
pathways converge, in the expression of a range of stress response genes, cytokines, and growth 
factors (Lee and Choi 2003).  
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HBO has a complex effect on HIF-1α stability and transactivation (Sunkari et al 2015). HBO-mediated 
HIF-1α stabilisation is not a direct consequence of high oxygen levels but HBO-induced mechanisms 
including ROS increase (Thom 2009). Paradoxically, ROS is not the direct effector of HIF-1α stability 
post HBO because ROS stabilises HIF-1α through VHL mediated prolyl hydroxylase (PHD) inhibition, 
whilst HBO-mediated HIF-1α stability is VHL/PHD-independent (Sunkari et al 2015). Likely 
mechanisms for HBO mediated HIF-1α stabilisation have been proposed. ROS mediated increases in 
heat shock protein (HSP90) post HBO is proposed to result in HIF-1α stabilisation (Isaacs et al 2002, 
Cabigas et al 2006). Other HBO induced mechanisms are suggested to occur via; the receptor for 
activated C kinase 1 (RACK1), mouse double minute 2 Mdm2, fork head box O4 (FOXO4), Jun 
activation domain-binding protein-1 (Jab1) and glycogen synthase kinase 3 (GSK3) (Liu et al 2007, 
Carroll and Ashcroft 2008, Tang and Lasky 2003, and Flugel et al 2007).  
There is on-going debate on the safety of HBO in DR based on a theoretical risk of increased 
neovascularisation, but available data have so far suggested otherwise. For instance, based on a 
recent report, HBO administration caused increased oxygenation and choroidal blood supply as well 
as decreased fluid retention (oedema) in the retina (Murphy-Lavoie et al 2017). As a caution, more 
studies are still required to understand HBO and its long-term effects in retinal complications in 
diabetes for safer clinical use as a treatment option.  
The aim of this chapter is to understand the role of varying glucose concentration, oxygen and 
pressure on the expression of HIF-1α and VEGF. In addition, the effect (s) of treatment on PECAM-1 
expression is examined. The understanding of this concept will help inform further on the 
mechanisms of HBO in the context of high glucose, as well as decipher the contribution of the single 
components of HBO.  
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6.3 Materials and Method 
Sample when used in this section may refer to cells (HDMECs), or retinal explants. Where needed, 
the sample is mentioned specifically. Non-confluent HDMECs cells grown in HDMEC growth media 
(MV) (PromoCell) at a density of 35,000-38,000 cells/well in 24-well plates in low (5.5 mM). For high 
glucose treatment, HDMEC growth media (containing 5.5 mM glucose) was supplemented with 14.5 
mM D-glucose to give a final concentration of 20mM. Samples were set up in duplicates 
(immunocytochemistry) or sixplicates (western blot, WB). Retinal tissues from adult pigs weighing 
70-80kg of both sexes were derived under aseptic conditions. Retinal tissues were cultured in low 
(1g/L i.e. 5.5 mM) or high (4.5g/L i.e. 25 mM) glucose within a three-dimension (3D) bilayer matrix 
with retinal tissue sandwiched (explants) in duplicates. Full details of HDMEC and retinal explant 
culture are reported in chapter 2 sections 2.2 and 2.3 respectively. Samples were exposed to; HBO, 
hyperoxia, or hyperbaric pressure alone with equivalent samples in control condition (controls). Post 
treatment, samples were incubated for 2 h (explants) or 4 h (HDMECs) and 24 h, and harvested for 
assays.  
HDMEC were stained for immunocytochemical analysis by incubating overnight at 4oC with primary 
antibodies (1:50); anti-HIF-1α (ThermoFisher Scientific), anti-VEGF (Santa Cruz), and anti-CD31 
(Sigma-Aldrich), followed by incubation with goat anti-mouse IgG, DyLight 488 conjugated highly 
cross-adsorbed secondary antibodies (1:500) (see table 2.1 for full list of antibodies and supplier 
details). HDMEC were counterstained with DAPI (1µg/ml) and images were visualised with a 
fluorescent microscope; Leica DMIL microscope with attached camera (Leica DC200) at 400X 
magnification. Serial retinal explant sections (20 µm) on Superfrost Plus slides were stained 
according to standard Immunohistochemical protocol with validated primary monoclonal mouse 
anti-Hif1α (1:20), and anti-cd31 (1:20) diluted in 1x TBS. Antigen detection was completed with 
fluorescently labelled DyLight 488 Goat anti-mouse IgG (H+L) Highly crossed adsorbed secondary 
antibody (1:200) (ThermoFisher Scientific) according to the manufacturer’s instructions. Sections 
were counterstained with 1 µg/ml of DAPI for nuclear delineation and visualized with an inverted 
fluorescent microscope at 200X magnification and documented as micrographs. Blotted PVDF 
membranes were incubated with primary targets (1:100); anti-HIF-1α (ThermoFisher Scientific), anti-
VEGF (Santa Cruz) overnight with anti-β-actin (St John’s Labs, UK) as loading control. Blotted targets 
were detected with Goat anti-mouse IgG_ Horseradish peroxidase (HRP) conjugated secondary 
antibody diluted in 1.5% BSA/TBS and visualised by chemiluminescence. WB results are presented as 
sample blots in the relevant sections. WB results are preliminary results due to variabilities in the 
target (HIF-1α and VEGF) expression and actin loading controls.  
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6.4 Results 
 
 
6.4.1 Effect of glucose concentration, oxygen tension and 
pressure on HIF-1α, VEGF and PECAM-1 protein 
expression 
The expressions of HIF-1α and VEGF between replicates and their actin loading controls were 
variable and the presented WB blots are preliminary. Variability of HIF-1α expression may be 
indicative of HIF-1α destabilisation via PHDs in normoxia post treatment, which highlights a potential 
need for PHD blockade in future studies. Although, HBO-mediated HIF-1α stabilisation is VHL/PHD 
independent (Sunkari et al 2015), the likelihood of HIF-1α destabilisation during incubation under 
control condition post treatment cannot be excluded.   
Based on preliminary representative WB data, nuclear HIF-1α appeared elevated at 4 h post HBO, 
hyperoxia and hyperbaric pressure in comparison to control (fig 6.1, A). Cytosolic HIF-1α levels 
appeared consistent in all samples which may be indicative of basal HIF-1α level (fig 6.1, B). In both 
nuclear and cytosolic fraction, glucose associated effects on HIF-1α expression did not appear 
evident. 
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Figure 6. 1 Western blots of HIF-1αat 4 h 
Representative nuclear blot may indicate increased HIF-1α protein following HBO, hyperoxia and hyperbaric pressure in 
comparison to control. Cytosolic HIF-1α levels appeared unchanged in all the conditions relative to control which may be 
indicative of basal cytosolic levels. WB data of nuclear and cytosolic expression of HIF-1α at 4 h and the actin loading were 
variable. Therefore, the presented blots are preliminary. WB analysis of nuclear HIF-1α was performed in more than three 
independent experiments which were variable and only result of one replicate is presented. Lysates were harvested from 
HDMEC pooled from six identical wells per sample at 4 h post treatment. 
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Based on preliminary results, nuclear HIF-1α appeared elevated post HBO (low glucose) when 
compared to control, which might be indicative of HBO associated nuclear HIF-1α increase (fig 6.2, 
A). HIF-1α levels in high glucose post HBO appeared diminished relative to low glucose sample, which 
may be suggestive of high glucose mediated HIF-1α suppression in HDMEC. Cytosolic HIF-1α protein 
appeared elevated post hyperoxia relative to control (fig 6.2, B).  
 
 
 
 
 
Figure 6. 2 Western blots of HIF-1α at 24 h 
Representative nuclear blots may indicate increased nuclear HIF-1α post HBO (low glucose) relative to control (A). In 
addition, nuclear HIF-1α post HBO appeared diminished in high glucose relative to low glucose. Cytosolic HIF-1α appeared 
elevated in hyperoxia relative to control. Blots are representative of n = 2 independent experiments. WB results and actin 
loading were variable and would need to be repeated further for a more reproducible result. Lysates were harvested from 
HDMEC pooled from six identical wells per sample at 24 h post treatment. 
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Preliminary WB data of VEGF expression appeared to indicate increased VEGF levels post hyperoxia 
(high glucose) in comparison to control. VEGF accumulation may coincide with an earlier observed 
increase in HO-1 following hyperoxia which may suggest a VEGF mediated HO-1 induction in 
hyperoxia but further studies are needed. 
 
 
 
 
 
 
 
Figure 6. 3 Western blots of VEGF at 24 h 
VEGF level appeared elevated in response to concomitant hyperoxia and high glucose relative to control. Blots are 
representative of n = 2 Independent experiments. Owing to the variability in WB results and corresponding variation of 
actin loading control, these preliminary data would need to be further examined to obtain more reliable data.  
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Immunocytochemical (ICC) staining was used to ascertain HIF-1α, VEGF, and PECAM-1 expression in 
HDMEC at 4 h and 24 h post treatments. But HIF-1 and VEGF detection with ICC were not satisfactory 
(results not included). Representative ICC micrographs of PECAM-1 of n ≥ 4 independent 
experimental replicates are presented.  
In control samples, high glucose was associated with an acute (4 h) downregulation of PECAM-1 in 
comparison to low glucose (fig 6.4A vs B). High glucose associated downregulation of PECAM-1 may 
not have been sustained as the effect was no longer apparent after 24 h (fig 6.4D vs B). Increased 
deposition of PECAM-1 within likely endothelial junctions with stress fibres visible seemed apparent 
(fig 6.4D, white arrowheads). HBO was not associated with PECAM-1 downregulation in response to 
high glucose and PECAM-1 appeared unchanged irrespective of time in culture relative to control (fig 
6.5). Hyperoxia alone (fig 6.6) was associated with PECAM-1 upregulation (increase) relative to 
control. Concomitant hyperoxia and high glucose further augmented PECAM-1 upregulation 
(increase) relative to control, which may indicate an acute (4 h) PECAM-1 upregulation to counter 
concomitant hyperoxic and high glucose insult. Within 24 h, PECAM-1 expression post hyperoxia 
appeared suppressed and seemed worsened in concomitant hyperoxia and high glucose relative to 
control (fig 6.6 C and D). HDMEC exposure to hyperbaric pressure was associated with PECAM-1 
upregulation relative to control. PECAM-1 expression in hyperbaric pressure did not change in 
response to glucose concentration or time in culture relative to control (fig 6.7). 
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Figure 6.4 ICC detection of PECAM-1 in HDMEC at 4 h and 24 h in control condition  
HIF-1α and VEGF protein were not at a level detectable with ICC for HDMEC in control condition. Acute (4 h) high glucose 
associated downregulation of PECAM-1 appeared imminent, but the effect was no longer apparent at 24 h. Increased 
deposition of PECAM-1 within likely endothelial junctions with stress fibres visible appeared imminent (white arrowheads). 
Selected micrographs are representative of n ≥ 4 independent experiments. Magnification = 400X, scale bar = 500 µm. 
 
 
 
 
Figure 6. 5 ICC detection of PECAM-1 in HDMEC at 4 h and 24 h in HBO 
HIF-1α and VEGF protein were not at a level detectable with ICC for HDMEC in HBO. HBO was not associated with PECAM-1 
downregulation/change irrespective of glucose concentration or time in incubation. Selected micrographs are 
representative of n ≥ 4 independent experiments. Magnification = 400X, scale bar = 500 µm.  
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Figure 6. 6 ICC detection of PECAM-1 in HDMEC at 4 h and 24 h in hyperoxia  
HIF-1α and VEGF protein were not at a level detectable with ICC for HDMEC in hyperoxia. Acute (4 h) PECAM-1 
upregulation in hyperoxia appeared to be present relative to control. Concomitant hyperoxia and high glucose appeared to 
further augment PECAM-1 expression at 4 h relative to control with increased PECAM-1 deposition along endothelial 
junctions seen (white arrow). PECAM-1 levels at 24 h was decreased in hyperoxia and further suppressed in concomitant 
hyperoxia and high glucose relative to control. Selected micrographs are representative of n ≥ 4 independent experiments. 
Magnification = 400X, scale bar = 500 µm.  
 
 
 
Figure 6. 7 ICC detection of PECAM-1 in HDMEC at 4 h and 24 h in hyperbaric pressure  
HIF-1α and VEGF protein were not at a level detectable with ICC for HDMEC in hyperbaric pressure. Hyperbaric pressure 
appeared to be associated with increased PECAM-1 deposition relative to control. PECAM-1 accumulation post hyperbaric 
pressure did not appear to be affected by glucose concentration of time in culture. Selected micrographs are 
representative of n ≥ 4 independent experiments. Magnification = 400X, scale bar = 500 µm.  
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Owing to the lack of HIF-1α detection with WB or ICC in single endothelial cell model (HDMEC), HIF-
1α expression was studied using immunohistochemistry (IHC) methods in a retinal explant model, 
which represents a higher complex model with the added benefit of intra- and intercellular cross-talk 
which might enhance HIF-1α detection (Matteucci et al 2015). Serial sections were blotted with anti-
HIF1α and anti-PECAM-1. Co-localisation of HIF-1α and PECAM-1 immunoreactivity served as guide 
to pin-point endothelial cell associated/specific HIF-1α expression. HIF-1α immunoreactivity with 
punctate (strong and sharp) distribution were tentatively associated with endothelial or leukocyte 
specific nuclear expression, whilst diffused HIF-1α immunoreactivity within vessel-like structures 
which were PECAM-1 positive were associated with HIF-1α expression within microvessels of the 
retina. Due to limitations with the quality of the images, it was not possible to accurately pin-point 
cell-specific HIF-1α association and distinctions could not be made regarding endothelial or 
leukocyte specific HIF-1α associations. The results here therefore provide preliminary data that 
provide a basis for further investigations. Furthermore, although HIF-1α expression was linked with 
their expression in the different layers of the retina and vascular cells (endothelial cells or 
leukocytes), it is possible that non-vascular cells such as neuronal cells (rods and cones), Muller cells 
etc. might be expressing HIF-1α. Hence, the study was further limited in accurately delineating 
specific HIF-1α associated cells, and further clarification with confocal is necessary. 
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Retinal explants in control condition (control) at 2 h and 24 h post treatments showed increased HIF-
1α in high glucose relative to low glucose explants (fig 6.8). Based on the location of the HIF-1α 
immunoreactivity, HIF-1α reactivity appeared limited to the outer retinal layer (ONL) at 2 h (C and D). 
Remarkably, HIF-1α immunoreactivity was dampened at 24 h in the low glucose explants but HIF-1α 
immunoreactivity appeared elevated and invasive through retinal layers in high glucose explants. 
HIF-1α immunoreactivity may be endothelial specific since HIF-1α reactivity was localised within 
vessel-like structures which stained positive for PECAM-1 (G and H). This seemed to echo the 
previous ICC result of increased PECAM-1 expression in response to high glucose for HDMEC in 
control condition. In retrospect, HIF-1α upregulation in response to high glucose in the explants was 
in converse to the absence/lack of HIF-1α expression in HDMEC highlighting a potential cell-type 
difference between endothelial cells from retinal origin and dermal origin. In addition, it appears to 
highlight differences between single versus complex study models.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
184 
 
 
Figure 6. 8 IHC detection of HIF-1α in retinal explants at 2 h and 24 h in control condition 
HIF-1α reactivity appeared elevated in retinal explants in high glucose relative to low glucose at 2 h and 24 h. In addition, 
HIF-1α expression at 24 h in response to high glucose appeared to co-localise with PECAM-1 within vessel-like structures 
which is suggestive of a vessel associated and endothelial or leukocyte associated HIF-1α expression/activation. 
Micrographs are representative of n ≥ 4 independent experiments. Magnification = 400X, scale bar = 500 µm.  
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Explants in HBO exhibited HIF-1α immunoreactivity in all retinal layers going from the outer nuclear 
layer (ONL) (including the photoreceptors) to the inner nuclear layer (INL) and retinal vascular bed 
(fig 6.9). The majority of HIF-1α reactive cells appeared to be endothelial based on their elongated 
shape and co-localisation with PECAM-1. In addition, HIF-1α reactivity post HBO was both time and 
glucose concentration independent in comparison to control. More so, several of the HIF-1α labelled 
signals were punctate in nature suggesting nuclear associated HIF-1α expression. Furthermore, HBO 
was associated with HIF-1α immunoreactivity within large, moderate and small vessel-like structures 
identified as retinal vessels based on positive immunoreactivity to PECAM-1 (fig 6.9 G, white arrow 
(large vessel)). Curiously, large vessel associated HIF-1α immunoreactivity was not seen in the 
control explants, which may be indicative of superior oxygenation and HIF-1α stabilisation, and 
potentially higher HIF-1 signalling in retinal explant vessel post HBO relative to control. 
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Figure 6. 9 IHC detection of HIF-1α in retinal explants at 2 h and 24 h in HBO 
HIF-α expression was seen in all retinal layers. HIF-1α levels appeared elevated relative to control. In addition, HIF-1α 
immunoreactivity was independent of time and glucose concentration. Moreover, the majority of HIF-1α reactive cells 
were elongated and stained positive for PECAM-1 suggesting they were likely of endothelial lineage. More so, HIF-1α 
signals were punctate in nature which may be indicative of nuclear HIF-1α association. HIF-1α immunoreactivity in large 
retinal vessel was seen (white arrow) (G), in addition to moderate and smaller vessel-like structures which were PECAM-1 
positive. Micrographs are representative of n ≥ 4 independent experiments. Magnification = 400X, scale bar = 500 µm. 
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Explants in hyperoxia (fig 6.10) and hyperbaric pressure (fig 6.11) showed increased HIF-1α reactivity 
associated with all retinal layers in comparison to control. In addition, based on the 
compact/punctate nature of the HIF-1α labelled signals; hyperoxia and hyperbaric pressure were 
associated with more nuclear HIF-1α reactivity relative to control. Vessel associated HIF-1α 
immunoreactivity was not pronounced post hyperoxia but explants in hyperbaric pressure showed 
pronounced HIF-1α immunoreactivity in moderate sized vessel-like structures relative to control. 
Hyperoxia was associated with strong HIF-1α immunolabelling in the ganglion cell layer (GCL) at 2 h. 
In addition, similar to the pattern of hyperoxia associated PECAM-1 downregulation in HDMEC at 24 
h, retinal explants in hyperoxia exhibited dampened PECAM-1 immunoreactivity at 24 h, which was 
further suppressed in concomitant high glucose and hyperoxia. HIF-1α immunoreactivity in 
hyperbaric pressure treated explants was dampened at 24 h similar to control, and unlike HBO 
explants which highlight a difference in HIF-1α stabilisation between HBO and hyperbaric pressure.   
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Figure 6. 10 IHC detection of HIF-1α in retinal explants at 2 h and 24 h in hyperoxia 
HIF-1α was detected in explants following hyperoxia in both low glucose and high glucose explants. HIF-1α 
immunoreactivity was associated with the outer and inner retinal layer with sparse expression in the middle retinal layer. 
Strong HIF-1α labelling in retinal ganglion cell layer was evident in low glucose post hyperoxia. HIF-1α activation and 
PECAM-1 expression appeared lessened at 24 h. Micrographs are representative of n ≥ 4 independent experiments. 
Magnification = 400X, scale bar = 500 µm.  
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Figure 6. 11 IHC detection of HIF-1α in retinal explants at 2 h and 24 h in hyperbaric 
pressure 
HIF-1α immunoreactivity appeared elevated at 2h post hyperbaric pressure relative to control. HIF-1α immunoreactivity 
post hyperbaric pressure was associated with all retinal layers, moderate and small vessel-like structures (co-localised with 
PECAM-1). HIF-1α immunoreactivity was dampened (low glucose) at 24 h. Micrographs are representative of n ≥ 4 
independent experiments. Circled- highlights photoreceptor reactivity. Magnification = 400X, scale bar = 500 µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
190 
 
6.5 Discussion 
Western blot (blot) data of HIF-1α and VEGF expressions between replicates and their actin loading 
controls were variable. In addition, ICC study of HIF-1α and VEGF expressions was not successful. 
Based on preliminary WB data, HIF-1α was basal in control condition which may be reflective of low 
endogenous levels in HDMEC. Curiously, the treatments did not elicit modest HIF-1α elevation 
relative to control unlike other HIF-1α inducers such as dimethyloxalylglycine (DMOG) or cobalt 
(Ayrapetov et al 2011).  
Classically HIF-1α is degraded in normoxia (Wang et al 1995). Therefore, if normoxia (proline 
hydroxylation) was exclusively associated with HIF-1α degradation in this study, then PHD blockade 
could have been optimal in the experimental design (Wang et al 1995, Baek et al 2005).  
Hyperglycaemia impairs hypoxia-dependent HIF-1α protein stability and function (Botusan et al 
2008). Here, high glucose appeared to suppress HIF-1α relative to low glucose in HDMEC. 
Fundamentally, this demonstrates the impact of glycemic status on HBO outcome, in this instance on 
HIF-1α stabilisation. Since all samples were incubated in normoxia for 4 h and 24 h post treatment, it 
is hard to distinguish between normoxia associated (proline hydroxylation) and hyperglycaemia 
mediated HIF-1α degradation, although both can act in concert (Botusan et al 2004). In HDMEC, high 
glucose (hyperglycaemia) in normoxia causes increased HSP40/70 mediated HIF-1α ubiquitination 
and degradation (reviewed in Xiao et al 2013). Hence, HIF-1α degradation in HDMEC (high glucose) 
post HBO/treatments stabilisation due to HSP40/70 activity in normoxia is likely. In addition, high 
glucose induced ROS causes HIF-1α destabilisation via ROS mediated RAC1 suppression and PHD 
activation (reviewed in Xiao et al 2013). Thus, ROS mediated PHD activation leading to augmented 
HIF-1α degradation in normoxia is expected. This possibility is made more conceivable because nrf2, 
a ROS regulator, as seen from previous result chapter was induced in response to HBO/treatments.  
Therefore, low/basal levels of HIF-1α in HDMEC in general and, in particular in high glucose poses a 
complex scenario and the exact mechanism(s) remains to be ascertained and these preliminary data 
warrant further studies. 
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A clearer picture of HIF-1α stabilisation/ expression was apparent using the retinal explant model. 
HIF-1α was notably increased in response to high glucose relative to low glucose for explants in 
control condition. Interestingly, explants in control condition did not evidence HIF-1α 
immunoreactivity in all retinal layers, although HIF-1α is expressed in all layers of the retina (Thiersch 
et al 2009). On the other hand, HBO/hyperoxia/hyperbaric pressure explants showed elevated HIF-
1α immunoreactivity in all retinal layers. In addition, HIF-1α immunoreactivity post HBO was 
associated with large, moderate and small retinal vessels (PECAM-1 positive), which appeared 
consistent with the concept of superior oxygenation and HIF-1α stabilisation with HBO (Murphy-
Lavoie et al 2012). HIF-1α is stabilised by HBO (Thom 2011, Sunkari et al 2015), in a PHD/VHL 
independent manner which may involve mechanisms such as increased HSP90 induction, RACK1, 
Mdm2, FOXO4, Jab1 and GSK3 (Liu et al 2007, Carroll and Ashcroft 2008, Tang and Lasky 2003, and 
Flugel et al 2007). Therefore, the elevation of HIF-1α in retinal explants which is indicative of its 
stabilisation relative to control is expected to have come about via several of these mechanism but 
further studies are necessary to pin-point the exact mechanism(s). 
VEGF exhibits intertwined functions with HO-1 in angiogenesis (Bussolati et al 2004). In human 
endothelial cells, VEGF induced prolonged HO-1 expression and activity, and inhibition of HO-1 
abrogated VEGF-driven angiogenesis (Bussolati et al 2004). Here, preliminary WB suggested VEGF 
accumulation post hyperoxia relative to control, which may have been oxidant mediated (Sheikh et 
al 2010). In addition, it is likely the effect (VEGF elevation) accrued from concomitant high glucose 
and hyperoxia which may be indicative of a hyperglycaemia (PKC mediated) and oxidant mediated 
VEGF accumulation. Consequently, the likelihood of VEGF mediated HO-1 induction post hyperoxia 
(high glucose) is a strong possibility since HO-1 levels appeared consistent relative to VEGF. On the 
other hand, although HO-1 appeared elevated in response to other treatments/high glucose (e.g. in 
HBO), no corresponding elevation in VEGF levels was seen.  
Paradoxically, VEGF expression is also induced via HIF-1 mediated signalling (Botusan et al 2008). 
Therefore, the low levels of HIF-1α and consequently decreased HIF-1 signalling as seen with HDMEC 
samples may be connected to the absence of distinct VEGF upregulation post treatments, the 
exception being hyperoxia sample (high glucose) where the prevalent mechanisms could not have 
been HIF-1α mediated. Interestingly, although HDMEC samples in HBO for instance did not display 
discernible VEGF upregulation, glucose dependent response in HO-1 induction seemed apparent. 
Perhaps, the glucose associated HO-1 inductions in these conditions were due to the predominant 
nuclear nrf2 elevation in HBO and hyperbaric pressure. Based on the variability in VEGF and HO-1 
expression, caution is exercised in the over interpretation of these data because further studies are 
still required to accurately pin-point the exact mechanism. 
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Long-term (14 days) culture of HUVEC in 30 mM glucose was associated with significant 
downregulation of PECAM-1 expression in HUVEC cells (Baumgartner-Parzer et al 1995). Likewise 
here, PECAM-1 expression in HDMEC and retinal explants changed in response to treatment and high 
glucose was associated with acute (4 h) PECAM-1 downregulation in control condition. In addition, 
hyperoxia and/or high glucose were associated with PECAM-1 downregulation at 24 h. High glucose 
phosphorylates VE-cad in endothelial adherens junction causing junctional disruptions in endothelial 
cells (Haidari et al 2014). Therefore, it is conceivable that high glucose and/or hyperoxia associated 
downregulation of PECAM-1 in HDMEC might result in disruption of endothelial adherens junctions 
and consequently loss of endothelial barrier integrity. PECAM-1 downregulation is associated with 
endothelial cell activation and loss of PECAM-1 protective effect. Thus, hyperoxia and/or high 
glucose might impact negatively on HDMEC barrier integrity or functions, whilst HBO and hyperbaric 
pressure are likely to be associated with maintenance of endothelial integrity and PECAM-1 cell-
mediated activities (Wang et al 2009, Podgrabinska et al 2010, Privratsky and Newman 2014, Enciso 
et al 2003, Yan et al 2012).  
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6.6 Limitation 
Targets (VEGF and HIF-1α) expressions in HDMEC (P4-7) and actin loading control were variable due 
to differences in passages of HDMEC used. Prior validation of target expression to establish an 
optimal passage number would have been optimal.  In addition, the loading control may not have 
been optimal. Although, the study deciphered HIF-1α stabilisation and increased expression in the 
explants, the mechanisms behind HIF-1α stabilisation were not determined. In addition, the 
possibility of HIF-1α transactivation was not explored, which could have been addressed with HRE 
reporter gene assay. Instead, efforts were made to answer this question by examining VEGF in 
HDMEC, a known target of HIF-1. However, HIF-1α associated VEGF up-regulation was not identified 
possibly due to HIF-1α destabilisation in normoxia/hyperglycaemia in HDMEC. Based on preliminary 
results, the possibility of oxidant and hyperglycaemia associated VEGF elevation appeared likely but 
the exact mechanisms were not clearly ascertained. Moreover, the variability in VEGF and HO-1 WB 
expressions further complicated the observations made. More so, corresponding ICC examinations 
for HIF and VEGF did not give any meaningful results which opens up more questions to address HIF-
1α, VEGF and HO-1 regulations in future studies. 
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Chapter 7.0: Limitations, overall discussion 
and future work 
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7.1 Over all study limitations 
Several limitations were encountered in the course of this study. In the western blot (WB) assay, 
target expressions were varied. In biological experimental systems, the exact same cell (sample) 
cannot be collected between replicates since protein synthesis, cell size/cycle, or apoptotic ability 
may be changed at each stage. Thus, it is likely some of the variabilities in target expressions arose 
from the use of HDMEC at different passage numbers (P4-7), in addition to HDMEC being a mixture 
of two cell populations (HDLEC and BEC). Actin (loading control) expressions were also highly 
variable. Being a house-keeping protein (HKP), actin is constitutively expressed and performs 
essential tasks in cytoskeleton microfilaments in all cellular compartments making it an ideal loading 
control (Moritz 2017). However, actin exhibits loading and biological variation leading to inaccuracies 
in loading control, and consequently in accurate determination of target expression. In retrospect, 
an initial study could have been conducted to determine an optimal loading control well-suited for 
the experimental conditions in this study. In addition, total protein loading staining (TPS) which are 
superior to HKP could have been more optimal in comparison to actin (Moritz 2017). Based on these 
variabilities, WB data of target expressions were preliminary, necessitating further experiments.  
Another limitation encountered was image acquisition. Throughout the study, light/fluorescent 
microscopes were used. Whilst, these forms of microscopy serve well certain purposes, some of the 
readouts; HDMEC size measurement, the role of glucose on HDMEC, confirmation of nrf2 sub-
cellular localisation, and identification of cell-specific HIF-1α expressions in explants for instance 
were not sufficiently addressed with light/fluorescent microscopes. In hind-sight, the combinations 
of light/fluorescent and confocal microscopy could have been optimal. 
In terms of experimental design, the durations (4/24 h) of high glucose incubation were too short for 
discerning glucose- related effects on HDMEC morphology. In addition, studies were not undertaken 
to address pertinent questions that had arisen from some of the results. This includes establishing 
the involvement of ROS in nrf2 activation and stabilisation, the functional implication of IL-6 mRNA 
downregulation including assessment of IL-6 protein, confirmation of HIF-1 signalling post HIF-1α 
stabilisation in explants. These aspects have been discussed in all relevant result sections and further 
studies (section 7.3). 
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7.2 Result summary 
A summary of relevant results is presented and illustrated with a simplified diagram (fig 7.1), with 
detailed discussion and conclusion in section 7.3. Early degeneration of retinal tissue is apparent 
within minutes in free floating retinal culture, stemming from gliosis in the absence of anchorage. In 
3.0, retinal tissues and vessels cultured as explants based on a novel retinal explant model developed 
in this study were maintained intact and viable for more than 24 h. In addition, a hyperbaric model 
closely aligned to UK clinical protocol for HBOT was successfully validated.   
In chapter 4.0, mean sizes of HDMEC (n = 40) were changed significantly post treatments (***p < 
0.0001, n = 8). HDMEC in hyperoxia (low glucose) were significantly bigger in comparison to control 
and HBO (*p < 0.05), or hyperbaric pressure (**p < 0.01) based on Tukey’s post hoc analysis. In 
addition, the metabolic activity of HDMEC post treatment was changed (*p < 0.05, n = 8) with 
HDMEC in hyperoxia exhibiting a pattern of decreased metabolic activity relative to control but the 
effect did not reach statistical significance (p > 0.05). HBO was not associated with significant 
changes in HDMEC size, shape or metabolic activity relative to control (p > 0.05).  
In chapter 5.0, nrf2 was basal (control) but showed an acute (4 h) glucose associated suppression in 
redox response (nrf2) (p < 0.05) in high glucose relative to low glucose. Nrf2 stabilisation and 
accumulation at 4 h and 24 h post treatments (HBO, hyperoxia and hyperbaric pressure) relative to 
control was determined. In addition, the cellular distributions of nrf2 were distinct post treatments 
relative to control. The distribution of nrf2 in the control sample was predominantly cytoplasmic as 
expected under basal homeostatic conditions. On the other hand, post HBO and hyperbaric pressure, 
nrf2 protein was accumulated in areas associated with nuclear and plasma membrane relative to 
control. Curiously, nrf2 distribution in hyperoxia and to a lesser extent hyperbaric pressure appeared 
predominantly perinuclear associated. Nrf2 stabilisation and accumulation is consistent with nrf2 
activation and nuclear expression of targets including heme-oxygenase -1 (HO-1). Therefore, it is 
conceivable that nrf2 stabilisation/accumulation may have resulted in HO-1 induction since HO-1 
protein appeared raised post treatments relative to control. Moreover, HO-1 appeared raised in 
response to high glucose relative to low glucose for HDMEC in control condition and HBO but HO-1 
levels post hyperoxia appeared to be glucose-independent.  
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Immunological responses were varied depending on glucose concentration, oxygen and pressure 
levels. IL-6 mRNA levels were significantly downregulated (suppressed) at 4 h post treatments (p < 
0.0001, n = 8); HBO, hyperoxia and hyperbaric pressure, but more so post HBO relative to 
β2m/calibrator. IL-6 mRNA was significantly less suppressed in high glucose post HBO (p < 0.01), 
whilst more suppressed following hyperoxia (p < 0.0001) relative to β2m/calibrator in comparison to 
low glucose. Based on preliminary WB data, activated NFᴋB (p65) protein at 4 h appeared elevated 
post hyperoxia and hyperbaric pressure, whilst basal post HBO relative to control. 
In chapter 6.0, preliminary WB data of nuclear HIF-1α protein in HDMEC at 4 h appeared raised post 
treatments in comparison to control. In addition, HIF-1α appeared suppressed in high glucose 
relative to low glucose post HBO at 24 h. Hyperoxia may have resulted in increased cytosolic HIF-1α 
protein at 24 h relative to control. Furthermore, it is likely hyperoxia was associated with increased 
VEGF levels relative to control which may be suggestive of an oxidant mediated VEGF increase in 
HDMEC. Moreover, it is plausible hyperoxia associated VEGF increase and HO-1 induction post 
hyperoxia are connected, i.e. VEGF increase may have resulted in HO-1 induction (Bussolati et al 
2004), although other mechanisms could be at play. PECAM-1 expression showed an acute (4 h) 
downregulation (in high glucose) in the control sample. Likewise, PECAM-1 expression post 
hyperoxia showed a hyperoxia associated downregulation, which was further exaggerated in 
concomitant hyperoxia and high glucose. Interestingly, PECAM-1 expression post HBO and 
hyperbaric pressure appeared unaffected by glucose concentration relative to control. Whilst HIF-1α 
inductions post treatments in HDMEC were hardly pronounced, HIF-1α inductions was distinctly 
evoked post treatments, and particularly post HBO relative to control. In addition, although HDMEC 
based study of HIF-1α (all conditions) and PECAM-1 (control and hyperoxia) showed high glucose 
associated variations (decrease), glucose treatment was associated with heightened HIF-1α with 
corresponding elevated PECAM-1 expression in retinal explants. This might be reflective of cell-origin 
differences (dermal versus retinal). In addition, it may be indicative of inter-cellular cross-talk 
obtainable in complex systems such as retinal tissue in comparison to a single cell type (HDMEC) 
(Matteucci et al 2015).  
In general WB expression and actin loading for the study of targets; HO-1, NFᴋB, HIF-1α and VEGF 
were highly variable. Hence, caution is exercised in the interpretation of preliminary WB data which 
requires future studies for further clarification.   
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Glucose effect was a key aim in this study because HBO is utilised in diabetic settings in the 
treatment of recalcitrant diabetic ulcers. HBO is also utilised for non-diabetic conditions such as 
autism, gas poisoning, decompression illness etc. The role of glycemic status on HBO outcome in 
these diabetic/non–diabetic indications is not yet well understood.  
In general, glucose dependent effects in HDMEC were not ubiquitous in this study as expected.  The 
incubation period (4 /24 h) were perhaps too short for significant glucose dependent effect 
particularly on morphology in HDMEC as discussed in section 7.1 (Overall study limitation). On the 
other hand, the absence of robust HIF-1α induction is conceivably a cell-dependent response in 
HDMEC since HIF-1α reactivity was pronounced in retinal explants at shorter incubation periods (2 
h). In the control condition, nrf2 showed an acute (4 h) glucose associated impairment in high 
glucose relative to low glucose (p < 0.05). High glucose associated impairment of nrf2 expression was 
not present in HBO or its components (p > 0.05). Based on preliminary WB results, HO-1 appeared 
raised in response to high glucose relative to low glucose and may have been a cell-mediated 
response to override high glucose associated effect, which is consistent with previous studies 
(Castilho et al 2012, He et al 2015). Curiously, HO-1 appeared raised to a similar extent in low and 
high glucose relative to control in hyperoxia, which may be suggestive of a hyperoxia alone effect.  
Immunological responses showed glucose dependence. IL-6 mRNA in HBO was significantly less 
suppressed (p < 0.01), whilst more suppressed post hyperoxia (p < 0.0001) in high glucose relative to 
low glucose in HDMEC. This highlights a potential role of glycemic status on HBO associated 
immunological (IL-6) responses. Similarly, glycemic status might have a role on HBO associated 
benefit in HIF-1α stabilisation because nuclear HIF-1α in HDMEC was suppressed at 24 h in high 
glucose relative to low glucose. Ironically, VEGF appeared elevated post hyperoxia in high glucose 
relative to low glucose although HIF-1α induction was not evident which may highlight a HIF-1 
independent VEGF upregulation, possibly oxidant mediated (Sheikh et al 2000). As mentioned 
previously, whilst HIF-1α (all samples) and PECAM-1 (control and hyperoxia) were downregulated in 
HDMEC, high glucose was associated with heightened HIF-1α/PECAM-1 immunoreactivity in all 
samples relative to control in retinal explants. These HIF-1α specific differences between HDMEC and 
retinal explants may highlight differences in endothelial cells of different origin (retinal versus 
dermal) (Yuen et al 2009). It may also reflect differences between a single cell type response and 
complex intercellular cross-talk and responses in the retina (Matteucci et al 2015).   
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Figure 7.1 Summary of relevant study results  
The diagram above shows a summary of study result which may be a preliminary mechanism (s) in the investigation of the 
molecular mechanisms in HDMEC (*) and a novel retinal explant model of endothelial cell responses to varying glucose 
concentration, oxygen and pressure (HBO) using a bespoke hyperbaric unit simulated according to HBOT procedures. 1. 
HDMEC size was significantly increased following exposure to hyperoxia (HYP) relative to control. 2. HIF-1α expression in 
retinal explants in control condition (control) was increased in response to high glucose (HG). HIF-1α expression was 
exaggerated in response to treatments; hyperbaric oxygen (HBO), hyperoxia (HYP), and hyperbaric pressure (HYB), which 
showed further increase in the presence of HG and associated with a corresponding increase in PECAM-1 immunoreactivity 
in retinal explants in response to HG. In HDMEC high glucose (+ HG*) was associated with decreased HIF-1α protein relative 
to low glucose (LG) in HBO. In addition, in HDMEC (*), VEGF appeared elevated in response to HYP (HG). Moreover, in 
HDMEC, PECAM-1 appeared downregulated in response to HG in HYP and control (Ctrl). 3. In HDMEC, nrf2 was significantly 
increased in response to treatments; HBO, HYP and HYB relative to control. Nrf2 showed a statistically significant acute (4 
h) impairment in nrf2 induction in HG relative to LG for HDMEC in control condition. HO-1 protein appeared raised in HG 
relative to LG for HDMEC (control condition and HBO), and in response to treatments; HBO and HYP relative to control. IL-6 
mRNA was significantly suppressed in response to treatments; HBO, HYP and HYB relative to control. IL-6 mRNA 
suppression was lessened (i.e. higher IL-6 mRNA) in HG relative to LG in HBO, but more suppressed in HYP (i.e. lower IL-6 
mRNA) in HG relative to LG.  
Key: HBO (hyperbaric oxygen), HYP (hyperoxia), HYB (hyperbaric pressure), HG (high glucose), LG (low glucose), Ctrl 
(control), arrowhead up (increase), arrowhead down (decrease). The number of arrows is used as an indication of the level 
of expression and three arrows are used for results with statistical significance or obvious predominant expression was 
seen. Red labels indicate results based on western blots (WB) which are subject to further examination for more robust 
results. Results relating to HDMEC are indicated with (*). 
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7.3 Overall Discussion and Conclusion 
In the following paragraphs, study findings are discussed in the context current literature, in addition 
to discussions in the relevant result chapters. Firstly, the role of high glucose is discussed.  In normal, 
physiological condition, endothelial cells (ECs) are exposed to tightly regulated circulating blood 
glucose range of approximately 3.6–5.8 mM (physiological basal levels). When exposed to high 
glucose, defined as exposure of vascular ECs to glucose levels over 10 mM (in vitro or in vivo), 
cellular homeostasis and biochemistry are perturbed. As a consequence, EC lose their typical 
quiescent phenotypes and endothelial dysfunction ensues. Physiologically, EC dysfunction is 
characterised by deficiency in NO availability, reduction in endothelial-derived vasorelaxation, 
impaired fibrinolytic ability, altered expression of growth factors, adhesion molecules and 
inflammatory genes leading to oxidative stress and enhanced permeability of cell layer (reviewed in 
Popov 2010). In addition to these direct effects of high glucose, high glucose can also lead to 
accelerated formation of diacylglycerol (DAG), methylglyoxal (MGO), AGEs, ROS and nitrosylated 
species which further amplify the imbalance. Fundamentally, it is well agreed that endothelial 
dysfunction precedes the development of vascular structural changes in diabetes, which underlines 
the importance of examining high glucose effects in HDMEC.  
Upregulation of aryl hydrocarbon receptor transcription factor, p300 and the chicken ovalbumin 
upstream promoter-transcription factor II (COUP-TFII) is associated with enhanced glucose 
metabolism (Dabir et al 2008, Chen et al 2010).  In HUVEC, high glucose increased p300 upregulation 
short term (60-240 min), whilst decreased longer term (48 h) (Chen et al 2010). However, in this 
study, based on Resazurin assay, incubations of HDMEC in high glucose for 4 h post treatments were 
associated with significant change (increase/decrease) in HDMEC metabolic activity, although a 
pattern of high glucose associated increase was seen for HDMEC in control and HBO conditions (p > 
0.05). This suggests a distinctive cell dependent response and it is likely HDMEC have a slow 
metabolic phenotype (Ahmed et al, 1994, Nakayama et al 1997, Zalata et al 1998, Perrot et al 2003, 
De Bock et al 2013 and Doddaballapur et al 2015). As regards morphological changes, high glucose 
did not elicit evident structural/significant size changes in HDMEC (p > 0.05). High glucose is 
associated with disorganisation of tight junction structures in diabetic retina and cerebral 
microvessels as a result of diabetic hyperpermeability (Antonetti et al 1999). In addition, high 
glucose induced actin stress fibre formation in endothelial cells (Salameh et al 1997). More so 
microvascular leakage in the retinal microvasculature is enhanced in STZ‐induced diabetic rats due to 
high glucose dependent modulation of cytoskeletal contraction (Yu et al 2005).  
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Furthermore, in human vascular endothelial cell, hyperglycaemia induced AGE and RAGE/Rho 
signalling was associated with cell contraction (Hirose et al 2009). Incidentally, it takes up to 2 weeks 
of high glucose exposure for AGE formation to occur in endothelial cells (Catrina et al 2004, reviewed 
in Cheng et al 2011). Thus, the absence of evident high glucose associated structural or significant 
size alterations in HDMEC might be alluded to a non-optimal incubation period because glucose 
mediated changes in phenotype require durations longer than 4 h (De Nigris et al 2015). Moreover, 
the use of an ordinary microscope rather than confocal imaging may have contributed to the lack of 
identification of early structural/micro-level deregulations.  
Nrf2 is not essential for survival but, activation of nrf2-ARE pathway is fundamental for the 
maintenance of the intracellular glutathione (GSH) and the induction of antioxidant defense 
k2enzymes. Nrf2 counteracts high-glucose induced damage and downstream inflammatory 
responses in diabetes. High glucose induced ROS and AGE rather than a direct high glucose effect is 
the mechanism for nrf2 activation/accumulation in high glucose (He et al 2010). In human 
endothelial cells, high glucose concentration of 30 mM (6 h) did not elicit nrf2-pathway (Xue et al 
2008). However, nrf2 activators increase hyperglycaemia-induced ROS generation leading to nrf2 
activation (Xue et al 2008). So, although high glucose does not directly evoke nrf2 activation, high 
glucose associated increase in ROS production can precipitate nrf2 and nrf2-dependent HO-1 
expression (He et al 2010). In this study, high glucose (20 mM, 4 h) was associated with acutely lower 
levels of nrf2 relative to low glucose for HDMEC in control condition (p < 0.05), which suggested a 
lack of acute high glucose associated ROS dependent induction of nrf2. Interestingly, this 
phenomenon appeared lacking for HDMEC in HBO and hyperbaric pressure. Evidently, increased ROS 
(as a result of increased partial pressures of oxygen and associated stress) post HBO, hyperoxia and 
hyperbaric pressure would have augmented nrf2 activation in concert (or in the absence) of high 
glucose associated ROS dependent nrf2 induction.  
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Remarkably high glucose associated impairment in nrf2 induction for HDMEC in control condition 
was no longer evident at 24 h, suggesting a cell mediated response. On the other hand, HDMEC in 
hyperoxia demonstrated a delayed (24 h) high glucose associated trend of nrf2 decline (p > 0.05). In 
diabetic condition, nrf2 activation and HO-1 accumulation is an adaptive response against oxidative 
stress (Jiang et al 2010). So it is notable that total protein HO-1 levels as determined with preliminary 
WB data appeared elevated in response to high glucose relative to low for HDMEC in control and 
HBO conditions at 24 h. Ironically, HDMEC in hyperoxia did not appear to show the same glucose 
associated response, which may further strengthen the previous observation of nrf2 decline at 24 h 
in concomitant hyperoxia and high glucose.  In addition, it suggests the apparent elevation in HO-1 
protein elevation may have been due to hyperoxia effect alone. Since diminished nrf2 activity may 
render endothelial cells vulnerable to oxidative stress (reviewed in Cheng et al 2011), the 
consequence of continued concomitant hyperoxia and high glucose on nrf2 and consequently 
adaptive responses is worth examining in further studies because of the likely implications on 
cellular oxidative stress.  
High glucose is associated with pro-inflammatory changes in vascular endothelial cells (reviewed in 
Popov 2010). Likewise in this study, IL-6 mRNA level was significantly higher in high glucose post HBO 
(p < 0.01), whilst decreased post hyperoxia (p < 0.0001). A high glucose effect on NFĸB expression 
was not evident (all samples) due to inconsistencies in actin loading control, although NFĸB elevation 
post hyperoxia and hyperbaric pressure but not HBO relative to control was apparent. This apparent 
NFĸB modulation post HBO may have subject to nrf2 mediated amelioration. Nrf2 is associated with 
shear stress response, inflammation resolution and suppression of endothelial dysfunction, which is 
consistent with the nrf2/ NFĸB cross-talk postulation (Zakkar et al 2009, Bellezza et al 2018). 
Therefore, the seeming abrogation of NFĸB activation judging from its basal levels in HBO relative to 
control suggests a likely functional nrf2/NFĸB cross-talk, a concept which is prospective and requires 
further investigation.  
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Based on preliminary WB results, nuclear HIF-1α protein appeared diminished in high glucose 
relative to low glucose in HDMEC, which seems consistent with previous reports (Catrina et al 2004, 
reviewed in Xiao et al 2013). In addition, high glucose associated decline in HIF-1α protein appeared 
imminent for HDMEC in HBO. Essentially, this appears to demonstrate the impact of glycaemic status 
on HBO outcome in regards to HIF-1α stabilisation. It is plausible HDMEC incubation in normoxia 
post HBO may have resulted in prolyl hydroxylases (PHD) mediated HIF-1α degradation of any HBO-
stabilised HIF-1α, which raises the question of how long HIF-1α can be stabilised post HBO. Another 
reasonable consideration is the role of cell-type (HDMEC) dependent response. This last rationale 
becomes more acceptable when considering the outcome of HIF-1α expression in retinal explants 
where HIF-1α expression was abundantly elicited in response to high glucose relative to low glucose, 
which fitted with the concept of high glucose mediated HIF-1α protein stabilisation and 
accumulation via PKC activation in retinal cells (Suzuma et al 2002, Geraldes et al 2009). Thus, HIF-1α 
regulation in high glucose and/or HBO is complex and intrinsic cell-type differences between dermal 
(HDMEC) and retinal (explants) endothelial cells might play a role in these complexities. Moreover, 
heightened HIF-1α expression in response to high glucose may also reflect cross-talks between 
different cell types in the retina which is otherwise absent in single cell systems such as HDMEC 
(Matteucci et al 2015). 
High glucose (20 mM, 4 h) was associated with PECAM-1 suppression in control condition, but 
concomitant high glucose and hyperoxia resulted in PECAM-1 upregulation. Acute PECAM-1 
upregulation in concomitant high glucose and hyperoxia may have been an early intervention to 
activate early inflammatory cascade which is crucial to forestall cellular damage (Piedboeufet al 
1998). Therefore, it seems congruent that NFĸB appeared elevated post concomitant high glucose 
and hyperoxia. Ironically, although early (4 h) PECAM-1 upregulation in concomitant high glucose 
and hyperoxia was seen, it was suppressed at 24 h. Thus, continued concomitant high glucose and 
hyperoxia would likely result in loss of endothelial cell integrity via PECAM-1 downregulation.  
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VEGF and HO-1 show complex inter-dependent functions in angiogenesis. In retinal endothelial cells, 
high glucose induced apoptosis stimulates recruitment of endothelial progenitor cells and VEGF 
(Bhatwadekar et al 2009). On the other hand, hyperglycaemia induced VEGF suppression via HIF-1 
inactivation impairs wound healing in diabetes. In this study, preliminary WB data suggested VEGF 
accumulation in HDMEC at 24 h in concomitant hyperoxia and high glucose. Incidentally, the same 
samples showed a likely HO-1 upregulation relative to control. Thus, more studies are required to 
examine further the role(s) of hyperoxia and high glucose on VEGF expression in HDMEC. 
The remaining section focuses on the roles of the treatment alone or in concert with high glucose.  
Nrf2 stabilisation/accumulation and cellular distributions in HDMEC post treatments were distinct 
relative to control. Post HBO and to a lesser extent hyperbaric pressure, nrf2 
stabilisation/accumulation was apparent for up to 24 h with nuclear and plasma membrane 
associated distributions relative to control. This distinct nrf2 distribution in HBO relative to control is 
likely a protective mechanism. Ironically, in hyperoxia nrf2 appeared diminished (24 h) and its 
distribution appeared predominantly perinuclear associated relative to control. HBO is associated 
with the activation of the PKC/JNK pathways (Hsieh et al 2010), and this occurs via PKC 
phosphorylation of the serine residue (Ser40) in Neh2 domain of nrf2, a Keap 1 interaction domain 
(Steinberg 2015). So, it is likely HBO promoted nrf2 dissociation from Keap 1 and consequently 
increased stabilisation via increased HBO associated PKC phosphorylation of ser40 residue of Keap 1 
(Neh2) interaction domain. In addition, HBO associated stimulation of the PI3K (Akt), MAPK, ERK and 
PKC signalling may have resulted in increased inhibition of GSK-3β mediated nrf2 nuclear export and 
proteasomal degradation (Biswas et al 2014).  
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Nrf2 stabilisation/activation is stimulated by increased NADPH bioavailability mediated via increased 
cellular glucose uptake and pentose phosphate pathway (PPP) activity (Heiss et al 2013). In patients, 
HBO administrations is consistent with increased glucose metabolism possibly via oxygen mediated 
increased oxidative phosphorylation (Löndahl et al 2013). HBO mediated increase in glucose 
metabolism would arguably be preceded by a corresponding increase in cellular glucose uptake and 
possibly increased PPP furnishing of NADPH. Hence, it is plausible nrf2 was stabilised post HBO (and 
to a lesser extent hyperbaric pressure) via mechanisms in these conditions that resulted in increased 
glucose uptake, PPP activity and NADPH bioavailability relative to control. Therefore, such HBO 
associated increase in NADPH might further relieve Keap 1 mediated suppression of nrf2 (Yates et al 
2009). In converse, hyperoxia mediated activation of nrf2 via ROS dependent means are immediate 
(acute) and short-lived (Nguyen et al 2009). Likewise in this study, nrf2 stabilisation in hyperoxia 
appeared potent acutely (4 h) (p < 0.0001) but seemed diminished at 24 h (p > 0.05) relative to 
control. In addition, hyperoxia causes the impairment of the glycolytic and mitochondrial oxidative 
metabolism, and inactivation of the ETC system (Das 2013). Essentially, hyperoxia shuts down 
glucose metabolism, consequently limiting NADPH bioavailability. Moreover, in concomitant high 
glucose and hyperoxia, these scenario might be exacerbated because of the build-up of metabolic 
intermediates which downregulates oxidative metabolism (Yates et al 2009). Whilst, no significant 
hyperoxia associated downregulation of metabolic activity was identified in this study, HDMEC in 
hyperoxia appeared consistent with a lower metabolic profile relative to control (p > 0.05). Taken 
together, nrf2 appears to exhibit peculiar characteristics in hyperoxia distinct from compounded 
hyperoxia and pressure (HBO). Therefore, more studies are needed to rightly discern these 
mechanistic details to further inform on the anti-oxidant contributions of HBO which can make a 
difference in patient outcome. 
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Immunological responses in HDMEC were different under the conditions tested, consistent with 
previous reports (Thom 2011). Fundamentally, the glucose dependent changes in IL-6 mRNA levels 
post HBO (increased IL-6 mRNA) relative to control might be of clinical relevance. It is worth 
weighing the differences in IL-6 mRNA regulation/response in high glucose post HBO and hyperoxia. 
IL-6 release triggers the activation of the Janus kinase / signal transducer and activator of 
transcription (JAK/STAT) and MAPK cascades (Heinrich et al 2003). In cells, JAK/STAT signalling is 
mediated primarily by NFᴋB and regulates apoptotic, proliferation, immune and inflammatory 
responses (O’Shea and Plenge 2012, Tanaka et al 2014). Thus, the apparent elevation of NFᴋB post 
hyperoxia may be demonstrating a hyperoxia associated JAK/STAT NFᴋB activation in HDMEC. On the 
other, since NFᴋB remained basal relative to control post HBO, it is probable HBO is not associated 
with IL-6 mediated activation of JAK/STAT mediated NFᴋB activation. Fundamentally, judging from 
the sustained profile of nrf2 post HBO, it is plausible HBO resulted in the activation of the nrf2/NFᴋB 
cross-talk and this may have played a key role in the abrogation of the IL-6 associated NFᴋB 
activation in HDMEC. 
As mentioned previously, HIF-1α induction in the retinal explants, is indicative of a distinct retinal cell 
response as well as demonstrates the importance of intercellular-cross-talks in complex systems 
(retinal tissue) which is absent in single cell systems. Essentially, HIF-1α induction and stabilisation in 
retinal explants post treatments and in particular post HBO is critical and might be of clinical 
relevance when considering the role of some HIF-1α target genes such as EPO, HO-1, and Glut-1 
which promote neurogenesis, in addition to being neuroprotective. This prospect of HIF-1α 
stabilisation and retinal neurogenesis presents another insight into the role of HIF-1α and HBO in 
ocular diseases, and warrants further studies. In retrospect, judging from the low and variable 
expression of HIF-1α in HDMEC which is suggestive of low endogenous levels, the incorporation of 2-
oxoglutarate analogue dimethyloxalylglycine (DMOG), a PHD blocker might have contributed to 
greater HIF-1α stabilisation (Hirota and Semenza 2005). It is reasoned, this might have given a better 
insight into the effect of treatments on HIF-1α induction. 
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Oxidants stimulate VEGF accumulation in endothelial cells (Sheikh et al 2000, Terraneo et al 2014). In 
addition, hyperoxia induces VEGF accumulation in a redox dependent manner (Terraneo et al 2014). 
Likewise in this study, hyperoxia (high glucose) was associated with an apparent increase in VEGF in 
concert with elevated HO-1 and nrf2, which appear consistent with Terraneo et al. Both HBO and 
hyperoxia lead to the generation of oxidants (ROS), which are known to stabilise HIF-1α (Thom 2011, 
Lee and Choi 2003). Paradoxically, high glucose induced ROS results in HIF-1α impairment via 
increased ROS impairment of NO and ROS repression of Rac1, in addition to ROS induction of PHD 
activities (reviewed in Xiao et al 2013). Thus, ROS mediated HIF-1α impairment and degradation 
might represent another avenue for increased HIF-1α degradation and low levels in HDMEC. In 
essence, it is plausible that hyperoxia associated VEGF elevation was independent of HIF-1α since 
nuclear HIF-1α was low and variable in hyperoxia and in all HDMEC as a whole. Fundamentally, 
hyperoxia associated VEGF elevation appears more consistent with an oxidant mediated mechanism 
rather than a HIF-1α mediated mechanism. VEGF upregulation in diabetic wounds is mediated via 
HIF-1 mediated mechanism (Thom 2009, Sunkari et al 2015). Ironically HBO mediated HIF-1α 
stabilisation and consequently HIF-1 signalling activities are not a direct result of increased oxygen 
levels or ROS. This is because ROS stabilises HIF-1α through VHL mediated prolyl hydroxylase (PHD) 
inhibition, whilst HBO-mediated HIF-1α stability is VHL/PHD-independent (Sunkari et al 2015). 
Therefore, the absence of modest HIF-1α induction post HBO beggars the question of what factors 
might have contributed to low HIF-1α and consequently decreased HIF-1 signalling mediated VEGF 
upregulation. As previously noted, it is possible HDMEC in general exhibit low endogenous HIF-1α 
levels. Secondly, although HBO mediated HIF-1α stabilisation is PHD/VHL independent, the likelihood 
of PHD mediated HIF-1α degradation, and consequently low HIF-1 signalling mediated VGEF 
induction in normoxia during incubation cannot be excluded.  
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Antioxidants and oxidant scavengers are associated with mitigation of oxidant induced VEGF 
production. Therefore, sustained levels of antioxidants or oxidant scavengers would result in the 
amelioration/abrogation of oxidant mediated VEGF accumulation. The implication of this is that 
sustained nrf2 or other oxidant scavengers mitigates VEGF elevation, which appears consistent with 
a possible nrf2 mitigation of hyperoxia associated VEGF accumulation in HBO since nrf2 was 
sustained in HBO. On the other hand, nrf2 reduction in hyperoxia after the initial surge possibly 
resulted in the enhancement of VEGF elevation. Interestingly, hyperoxia induced VEGF fraction is 
biologically active, which presents a prospective beneficial role for hyperoxia mediated VEGF 
upregulation (Sheikh et al 2010). Hyperoxia induced VEGF upregulation may come at a cost to cells 
because of hyperoxia associated signalling in cell death, stress, inflammation, JAK/ STAT, MAPK, 
NFĸB and the AP-1 pathways, which orchestrate the expression of a range of stress response genes, 
cytokines, and growth factors (O’ Shea and Plenge 2012), therefore further studies are needed to 
rightly discern key mechanistic details. Caution is to be exercised in the interpretation of VEGF 
upregulation based on WB data alone due to inconsistencies VEGF expression in this study and 
further studies are needed for more robust data. 
Endothelial cells respond to extracellular forces by modulating tension across junctional proteins and 
PECAM-1 is the primary e-cadherin utilised by endothelial cells to bear mechanical tension. PECAM-1 
induction in response to mechanical stress causes increased expression of weight bearing 
intermediate cytoskeletal filament such as vimentin (Conway and Schwartz 2014). Therefore, 
increased expression of PECAM-1 post hyperbaric pressure may have facilitated HDMEC retraction 
from increased extracellular pressure acting on its surface (Woodfin et al 2007). As previously noted, 
PECAM-1 expression is critical for the maintenance of endothelial cell phenotype and integrity. 
Therefore, it is conceivable that acute (4 h) PECAM-1 upregulation in concomitant hyperoxia and 
high glucose is an initial HDMEC specific response for cell survival and maintenance of cellular 
integrity (Newman and Newman 2013). Fundamentally, the downregulation of PECAM-1 
downregulation at a later time point (24 h) in concomitant hyperoxia and high glucose suggests the 
absence of appropriate cell response for maintenance of HDMEC integrity and survival. Interestingly, 
HDMEC in HBO showed no apparent changes in PECAM-1 which suggests a likely favourable 
modulation of homeostasis for HDMEC in HBO, but these would need to be ascertained in further 
experiments.  
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7.3 Further studies 
Firstly, hyperoxia associated VEGF accumulation in a HIF-1α independent manner warrants further 
studies to clarify the key pathways including the role(s) of HIF-1 isoforms owing to its potential 
implication in diabetic wounds. The possibility of HIF-1α in retinal explants in high glucose via a likely 
ROS/PKC mediated mechanism ought to be addressed in future studies. HBO associated nrf2 
activation/stabilisation in HDMEC is predicted to have had an effect on amelioration of NFᴋB 
activation possibly via a cross-talk between NFᴋB and the ROS/JNK pathway HDMEC and this 
warrants further examination. In addition, cellular distribution of nrf2 post HBO which may be 
associated with greater cellular protection against cellular oxidative stress requires further 
examination. Furthermore, it is needful to explore the possibility of HBO-induced nrf2 stabilisation 
and accumulation on endothelial progenitor cells (EPCs). In these studies, in-vitro approaches with 
HDMEC primary culture/retinal explants in conjunction with animal models of oxidative stress will be 
essential. The investigation might also include a clinical approach involving the analysis of blood 
samples of patients that are undergoing HBO, as well as those that have undergone HBO, after a 
significant time interval to verify any immediate and sustained nrf2 stabilization and activation. 
Moreover, PECAM-1 downregulation in high glucose, and hyperoxia and upregulation post 
hyperbaric pressure require further attention, to delineate the difference in mechanistic pathways 
post HBO, hyperoxia and hyperbaric pressure. The role of hyperbaric pressure on PECAM-1 
upregulation in HDMEC is very critical because of the correlation between elevated pressure and 
increased haemodynamic pressure on endothelial expression of PECAM-1 and the likely 
consequence of PECAM-1 upregulation in the vasculature. To do this, in-vitro studies can be 
designed with the same HDMEC model as well as in-vivo animal model to correlate findings.  
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